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Something Pooh said to Rabbit that reminded me of Science: 
'We might find something that we weren't looking for, which might be just what we were 
looking for, really!' 'I don't see much sense in that,' said Rabbit. 'No,' said Pooh humbly, 
'there isn't. But there was going to be when 1 began it.' 
. Taken from THE HOUSE AT POOH CORNER by A. A. Milne 
ii 
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To Mum and Dad 
ABSTRACT 
A new variant of human apolipoprotein B has been identified in a subject with decreased low 
density lipoprotein cholesterol and apolipoprotein B concentrations. Although no clinical 
signs of fat malabsorption were observed the subject was diagnosed, on the basis of his low 
cholesterol and apolipoprotein B level, as having hypobetalipoproteinaemia. 
iv 
The variant of apolipoprotein B was first identified by Western blot analysis. The analysis 
revealed an abnormal low molecular weight form of apolipoprotein B as well as normal 
apolipoprotein B-1 00 indicating that the subject was heterozygous for a truncated form of 
apolipoprotein B. The new variant (apo B-32) was a result ofa C--+-T transition at nucleotide 
4548 in exon 26 of the apolipoprotein B gene. This mutation changes a CAG codon which 
codes for glutamine into a TAG stop codon resulting in translation of a truncated 
apolipoprotein B protein approximately 32% the length of normal apolipoprotein B-1 00. 
Although only 32% of the length ofapolipoprotein B-IOO, apo B-32 was still capable of 
forming lipoprotein particles as indicated by its presence in both the low density and high 
density lipoprotein fractions. This density distribution is unique since apo B-32 is the shortest 
known truncated apolipoprotein B to be found in the low density lipoprotein fraction. This 
finding clearly indicates that the region of apo B-32 is important in the lipid binding 
characteristics of apolipoprotein B-100. The binding of apo B-32 to heparin confirmed three 
heparin binding sites previously predicted to be in the amino-terminal 30% of apolipoprotein 
B-100. 
Isolated lipoproteins formed from apo B-32 appeared to be similar to high density lipoproteins 
in size and composition. However, unlike high density lipoproteins, the apo B-32 lipoproteins 
in plasma were partially precipitated by polyanionlcation reagents normally used to precipitate 
very low density and low density lipoproteins. The presence of both apolipoproteins Al and 
E on the apo B-32 lipoproteins suggested that apolipoprotein Al or E may mediate the 
metabolism of apo B-32 since apo B-32 does not posses the receptor binding region for the 
low density lipoprotein receptor. 
v 
Four further subjects were identified as having reduced low density lipoprotein and 
apolipoprotein B concentrations. However a lack of any truncated apolipoprotein B in their 
plasma made it difficult to link their hypobetalipoproteinaemia with the apolipoprotein B gene. 
The cause of the hypobetalipoproteinaemia in these subjects remains uncharacterised although 
future linkage analysis studies in these individuals and family members will at least establish 
whether their hypobetalipoproteinaemia is related to the apo B gene. 
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CHAPTER 1 INTRODUCTION 
Lipoproteins are complex particles of lipid and protein (known as apolipoprotein) in the 
bloodstream that deliver cholesterol and triglyceride to tissues for metabolism and storage. 
Increasing awareness of the role of lipoproteins in controlling lipid levels within a population 
has prompted a number of structural studies on the major apolipoproteins. The majority of 
these studies have demonstrated the existence of biochemically defective apolipoproteins 
which contribute to the variation in lipid levels. In many cases the defective apolipoprotein is 
associated with the development of disease usually in the form of a specific hyper- or 
hypolipidaemia. Apolipoprotein (apo) B is a good example of this since molecular defects in 
this protein have a major effect on triglycerides and cholesterol levels. 
Hypobetalipoproteinaemia is a disease in which the plasma concentrations of low density 
lipoprotein (LDL) cholesterol and apo B are abnormally low. Recently, this has been shown 
to be due to mutations in the apo B gene that prevent full length translation of the protein. 
Homozygotes have extremely l~w levels of apo Band LDL cholesterol and suffer a variety of 
clinical problems arising from malabsorption of dietary fat and fat soluble vitamins. 
Heterozygotes, who typically show apo B and LDL cholesterol levels of less than half the 
levels found in normal subjects, are usually clinically asymptomatic. Heterozygotes for 
hypobetalipoproteinaemia are actually protected from the development of coronary heart 
disease by their low LDL cholesterol levels. 
Family studies of patients with hypobetalipoproteinaemia have revealed a number of defects in 
the apo B gene that interfere with the translation of the full length apo B protein (4536 amino 
acids). The truncated variants range in size, the smallest being apo B-2, a protein 2% the 
normal length ofapo B-IOO, the largest being apo B-89. Variants less than 30% the full 
length of apo B are not detected in plasma presumably because they are too short to package 
lipids into lipoproteins for secretion into plasma. Variants greater than 30% are found in 
plasma and are big enough to form lipoproteins. The lipoproteins formed from these variants 
vary in size and density according to the size of the variant, in that the longer the truncated 
2 
apo B variant, the bigger and more buoyant the lipoprotein particles formed. Variants near 
full length appear to package lipoproteins normally. However their metabolism differs from 
that of the apo B-1 00 lipoproteins since they react with the LDL receptor with greater affinity 
and are cleared from plasma at a greater rate. This in part explains the association of the near 
full length truncated variants with low cholesterol levels. Variants intermediate in length do 
not react with the LDL receptor since they do not have the LDL receptor binding region. 
The metabolism of the lipoproteins formed from these variants and their association with low 
cholesterol levels remains elusive. 
The aim of this thesis was to focus on subjects with abnormal lipid profiles, in particular those 
pointing to a defect in the apo B protein. More specifically those subjects with lipid profiles 
indicative ofhypobetalipoproteinaemia (low LDL cholesterol and low apo B). Individuals 
having LDL cholesterol levels below the lower limit of the normal range for their sex and age 
were identified for more detailed investigation. 
A 65 year old male was identified as having low LDL cholesterol during a routine lipid level 
check at a diabetes outpatient clinic at the Christchurch Lipid Clinic in 1989. A repeat blood 
sample in 1990 showed an LDL cholesterol of31mg/dL, well below the lower limit of the 
normal range (105mg/dL) indicating possible hypobetalipoproteinaemia. Further analysis 
showed a new truncated apo B variant. The finding of this variant which had a unique density 
distribution, prompted an in depth study of its structure and function. 
The main objective then was to elucidate the defect behind, and the altered structure, of the 
truncated variant. Once this was established, existing protein chemistry and molecular 
biology techniques were employed to characterise as fully as possible the lipoprotein particles 
formed from the truncated variant both in vivo and in cell culture. This information along 
with that obtained from other naturally occurring truncated variants has increased existing 
knowledge on the critical regions, in particular the lipid binding regions, in the structure of 
apo B. These regions are important in determining the function of the major apolipoprotein 
involved in cholesterol metabolism. Characterisation of the lipoproteins formed with the 
3 
truncated apo B variant has also given insight as to their metabolism. 
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CHAPTER 2 LITERATURE REVIEW 
2.1 The plasma lipoproteins 
Lipoproteins are the complexes of lipids and proteins that carry triglycerides and cholesterol 
in the bloodstream. They are roughly spherical particles with a core of non-polar lipids 
(triglyceride and cholesterol) surrounded by a mono-layer of polar lipids (mainly 
phospholipids) and apolipoproteins. The apolipoproteins, with the exception of the large 
apolipoprotein B, are water soluble and have the ability to exchange between particles (Havel 
and Kane, 1989a). 
Table 2.1 Physical Properties of Human Plasma Lipoproteinsa 
Lipoprotein Electrophoretic Particle size Molecular Density. 
class position (run) weight (Da) (g/mL) 
Chylomicrons ongm 75-1200 400000000 0.93 
VLDL pre-~ 30-80 10-80 000 000 0.93-1.006 
LDL ~ 18-25 2300000 1.006-1.063 
HDL a. 5-12 175-360000 1.063-1.21 
aadapted from Gotto et al (1986). 
There are four main classes of plasma lipoproteins the physical properties of which are given 
in table 2.1. Several methods exist for the isolation of the different classes (Mills et ai, 1984) 
however the most widely used is that of ultracentrifugation where the particles are separated 
on the basis of their density. The plasma lipoproteins differ in chemical composition. Table 
2.2 shows the chemical composition of the major lipoproteins found in man. The major lipid 
in chylomicrons and very low density lipoproteins (VLDL) is triglyceride. LDL are rich in 
cholesterol while the high density lipoproteins (HDL) contain more phospholipid and protein. 
Table 2.2 Chemical Composition of Human Plasma Lipoproteins 
Lipoprotein Class Cholesterol 
Chylomicronsa 2.5 
VLDLb 21.6 
LDLb 47.0 
HDLb 17.9 
aadapted from Skipski (1972) 
badapted from Chapman (1986) 
Triglyceride Phospholipid 
(% weight) 
84.0 9.0 
49.9 18.6 
11.2 22.1 
8.0 22.7 
5 
Protein 
2.5 (A,B,C) 
7.7 (B,C,E) 
20.9 (B) 
51.9 (A) 
The major apolipoproteins involved with each lipoprotein class are placed in brackets 
2.2 Lipoprotein assembly and secretion 
Evidence suggests there are only two types of cells that assemble and secrete lipoprotein 
particles, namely the absorptive cells of the intestine and hepatocytes (Gotto et ai, 1986). 
Lipoprotein assembly and secretion appears to follow the same route as other secretory 
proteins. This has been demonstrated by electron microscopy studies using radio- and 
immuno-Iabelled precursors (Glaumann et ai, 1975~ Alexander et ai, 1976) and more recently 
by pulse-chase and cell fractionation (Bamberger and Lanes, 1988~ Borchardt and Davis, 
1987). Figure 2.1 shows the general scheme of lipoprotein assembly and secretion using 
VLDL as an example. The apolipoproteins, with a signal peptide (Protter et ai, 1986) which 
is co-translationally cleaved, are synthesised on the ribosomes of the rough endoplasmic 
reticulum (RER). The apolipoprotein is then associated with lipid from the smooth 
endoplasmic reticulum (SER) to form a nascent lipoprotein particle. Transport to the Golgi 
apparatus then occurs and further lipid, mainly phospholipid (Higgins and Fieldsend, 1987), is 
added and the "apolipoproteins undergo glycosylation. Finally the particles are concentrated 
within the secretory vesicles of the Golgi and transported to the plasma membrane to which 
they fuse releasing the lipoprotein into the extracellular space. Chylomicrons enter the blood 
via the intestinal villi and VLDL through the sieve plate fenestrae of the liver. Once in the 
circulation the lipoprotein particles undergo extensive metabolism and modification. 
Nascent 
VLDL 
SER 
Lipids 
0. 
I Secretory 
• Vesicles 
Space of Disse 
5 c::: ~~ 
Figure 2.1 General scheme for the assembly and secretion of VLDL from hepatocytes 
(from Gotto et ai, 1986). 
2.2.1 The crucial role ofapo B 
The importance of apo B in lipoprotein assembly and secretion is emphasised in the rare 
disease abetalipoproteinaemia (Havel and Kane, 1989b). Patients with this recessive disorder 
have no detectable plasma apo B and as a consequence are unable to form the apo B-
6 
containing particles (chylomicrons, VLDL, LDL). Plasma cholesterol levels in these patients 
are very low «50mg/dL total cholesterol) as are plasma triglyceride levels «18mgldL total 
triglyceride). Subjects with abetalipoproteinaemia suffer an array of symptoms associated 
with severe fat malabsorption (Salt et ai, 1960; Malloy and Kane, 1982). Genetic studies 
have shown that the primary defect is not in the apo B gene (Talmud et ai, 1988). 
Identification of apo B mRNA and protein in the hepatocytes of affected patients (Lackner et 
ai, 1986) suggest that the defect is in the assembly and secretion of apo B containing 
particles. Recent work by Wetterau et al (1992) has shown the lack ofa microsomal 
triglyceride transfer protein, thought to be important in lipoprotein assembly, in subjects with 
abetalipoproteinaemia. This finding suggests that it is a defect in the microsomal transfer 
protein that is the basis for abetalipoproteinaemia. 
2.3 Metabolism of apo B-containing lipoproteins 
2.3.1 Chylomicron metabolism 
7 
The pathway of chylomicron metabolism is shown in figure 2.2. Chylomicrons are formed in 
the intestine from absorbed dietary cholesterol and triglycerides. After secretion from 
enterocytes, the triglyceride-rich chylomicrons containing apo B-48 and apo A are delivered 
to the bloodstream via the thoracic duct. Chylomicrons are rapidly metabolised in the 
circulation by lipoprotein lipase (LPL) which hydrolyses 80-90% of the triglyceride in the 
particle's mass (Young, 1990). LPL resides on the endothelial surface of capillaries and is 
activated by apo C-II (Gotto et ai, 1986) which is acquired by chylomicron particles along 
with apo E from circulating HDL. Triglycerides are utilised by extrahepatic tissues as a 
source of energy (skeletal muscle) or stored (adipose tissue). The particle at this stage with 
its shrunken core is termed a chylomicron remnant. Apo E on the surface of the remnant 
particle binds to receptors on the surface of liver cells that recognise apo E. There is now 
increasing evidence that the receptor involved in chylomicron remnant metabolism is the 
LDL-like receptor related protein (LRP) described by Beisiegel et al (1989). It has been well 
8 
demonstrated that LRP recognises the apo E on chylomicron remnants (Biesiegel et ai, 1989; 
Kowal et ai, .1989) and that this interaction is greatly enhanced by the presence of LPL 
(Beisigel et ai, 1991). 
HDl 
REMNANT 
lipoprotein 
Lipase 
Figure 2.2 Pathway of chylomicron metabolism (from Havel and Kane, 1989a). 
After receptor-mediated uptake and subsequent endocytosis the remnant particles are broken 
down to their constituents in lysosomes. The cholesterol component is generally esterified 
and either stored or used in the synthesis of bile acids and hepatic lipoproteins (Havel and 
Kane, 1989a). 
2.3.2 VLDL metabolism 
VLDL is formed in the liver from endogenously synthesised cholesterol and triglycerides. 
Figure 2.3 shows the pathway ofVLDL (and LDL) metabolism. VLDL particles enter the 
circulation via the hepatic vein. Initially VLDL is metabolised in a similar way to 
chylomicrons. The particle's triglyceride core is hydrolysed by LPL to form a VLDL 
remnant. VLDL is metabolised more slowly than chylomicrons having an average residence 
time of 15-60 minutes compared to 5-10 minutes for chylomicrons (Havel and Kane, 1989b). 
A fraction of the VLDL remnants (approximately one halt) are removed from the circulation 
almost entirely by hepatocytes (Havel and Kane, 1989a). It is thought that the LRP involved 
in chylomicron remnant metabolism is also the receptor responsible for the metabolism of 
VLDL remnants (Biesiegel et ai, 1991). 
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2.3.3 LDL metabolism 
Any VLDL remnants remaining in circulation are further hydrolysed by a hepatic lipase 
(Jones et ai, 1984) to form the denser cholesterol-rich LDL. independent secretion by the 
liver ofLDL particles has been implicated (Havel and Kane, 1989b) although most studies 
indicate that LDL arise solely from VLDL. The majority ofLDL (approximately 80%) is 
removed from the circulation by the interaction of the sole protein component, apo B-I00, 
with the LDL receptor on liver and peripheral cells (Brown and Goldstein, 1986). The 
remainder is removed by non-receptor pathways (Attie et ai, 1982~ Kesaniemi et ai, 1983). 
The residence time ofLDL (approximately 3 days) is much longer than that ofVLDL. LDL 
plays an important role in the delivery of cholesterol to tissues. In man approximately 60%-
70% of the total cholesterol is delivered to hepatic and extra-hepatic cells in the form ofLDL 
cholesterol (Scott, 1989). 
B-IOO:E 
Receptor 
lipoprotein 
Lipase 
Figure 2.3 Pathway of VLDL and LDL metabolism (from Havel and Kane, 1989a). 
A number of proteins are involved in the metabolism of the apo B-containing lipoproteins. 
Defects in anyone of these proteins can result in disease. 
2.4 Defects in lipid transport 
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Genetic defects have been identified in both the exogenous and endogenous pathways of lipid 
transport. These are summarised in tables 2.3 and 2.4. Defective chylomicron and VLDL 
secretion are characteristic of the two disorders, abetalipoproteinaemia and homozygous 
hypobetalipoproteinaemia (Havel and Kane, 1989b). Both disorders are rare and are inherited 
in an autosomal recessive fashion. In both conditions total cholesterol and triglyceride levels 
are very low (see section 2.2.1). A virtual absence ofapo Band apo B-containing lipoprotein 
particles is observed together with severe fat malabsorption. Some cases of homozygous 
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hypobetalipoproteinaemia are an exception to this since some apo B is present and clinical 
symptoms absent (see section 2.7). In the heterozygous state both abetalipoproteinaemia and 
hypobetalipoproteinaemia are asymptomatic. However, there is a difference in their effect on 
LDL cholesterol levels. In abetalipoproteinaemia, heterozygotes have relatively normal LDL 
cholesterol levels whereas in hypobetalipoproteinaemia, heterozygotes have LDL levels less 
than half that of normal (Farese et ai, 1992). Studies have shown that 
hypobetalipoproteinaemia is due to defects in the apo B gene (see table 2.5). The genetic 
defect in abetalipoproteinaemia is thought to be in a microsomal triglyceride transfer protein 
that is required for lipoprotein assembly (Wetterau et ai, 1992). 
Two disorders that interrupt the processing of chylomicrons and VLDL in plasma are LPL 
and apo C-II deficiency (Brunzell, 1989). Both conditions are characterised by elevated 
chylomicron and VLDL triglyceride levels, pancreatitis and eruptive xanthomas. The 
inheritance mode ofLPL and apo C-II deficiency is autosomal recessive and due to defects in 
the genes of both proteins (Fojo and Brewer, 1992). Both disorders are rare with a frequency 
of less than one in one million (Breslow, 1989). 
A more common disease is seen in type III hyperlipidaemia. Type III hyperlipidaemia is 
associated with genetic variation in apo E, the ligand responsible for the receptor-mediated 
clearance of chylomicrons and VLDL remnants. In this disorder there is an accumulation of 
remnant particles in the fasting plasma of affected individuals which greatly increases the risk 
of premature atherosclerosis (Mahley and Rail, 1989). The most common variant associated 
with type III hyperlipidaemia is apo E2 (Weisgraber et ai, 1982) in which a single amino acid 
substitution yields a protein with only 1 % normal receptor binding activity. Other apo E2 
variants with reduced receptor binding activity and associated with type III have been 
reported (Rall et ai, 1983; Wardell et ai, 1987; Wardell et ai, 1990). Homozygosity for E2 
seems to be a prerequisite for type III hyperlipidaemia, although it appears a further yet 
unknown defect is necessary for the development of the disease (Utermann, 1979). The 
frequency of type III hyperlipidaemia is estimated at one in five thousand (Breslow, 1989). 
Table 2.3 Defects in Exogenous Fat Transporta 
Defect 
Chylomicron secretion Apo B 
Chylomicron processing LPL 
Apo CII 
Chylomicron remnant clearance Apo E 
Disease 
Hypobetalipoproteinaemia 
Abetalipoproteinaemia 
LPL deficiency 
Apo CII deficiency 
Type III hyperlipidaemia 
Table 2.4 Defects in Endogenous Fat Transporta 
Defect Disease 
VLDL secretion ApoB Hypobetalipoproteinaemia 
Abetalipoproteinaemia 
VLDL processing LPL LPL deficiency 
Apo CII Apo ell deficiency 
VLDL remnant clearance ApoE Type III hyperlipidaemia 
LDL receptor Familial hypercholesterolaemia 
VLDL remnant processing HTGL HTGL deficiency 
LDL clearance ApoB Familial defective Apo B-1 00 
LDL receptor Familial hypercholesterolaemia 
a both tables were adapted from Breslow (1989) 
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The processing ofVLDL remnants to LDL is defective when there is a deficiency in hepatic 
lipase (Breckenridge et ai, 1982; Carlson et ai, 1986). Symptoms of this disorder include an 
increase in the triglyceride concentration of VLDL remnants and the presence of triglyceride-
enriched LDL particles. 
Lastly there are two diseases associated with the defective clearance ofLDL. The first of 
these diseases is familial defective apo B, a disorder characterised by elevated levels ofLDL 
cholesterol (Innerarity et ai, 1990) and an increased incidence of coronary heart disease. This 
disease is caused by a single base substitution (3 500Arg~Gln) in the apo B gene which 
produces a protein with only 2-4% the normal activity towards the LDL receptor (Innerarity, 
1987). The second disease involves a mirror-image defect where mutations in the LDL 
receptor (Brown and Goldstein, 1986) cause a similar rise in LDL cholesterol and a 
predisposition to coronary heart disease. This condition is known as familial 
hypercholesterolaemia. Both of these disorders are inherited in an autosomal dominant 
fashion and are reasonably common with a frequency of 1 in 500 (Breslow, 1989). 
2.5 Apo B structure 
The structure of the apo B-1 00 protein has been difficult to determine because of its large 
size and insolubility once delipidated. In 1986 four groups deduced the primary structure of 
apo B-I00 using apo B eDNA (Cladaras et ai, 1986; Knott et ai, 1986; Law et ai, 1986; 
Yang et ai, 1986). Human apo B mRNA consists of 14,121 nucleotides which code for a 
mature protein of 4536 amino acids and a 27 amino acid signal peptide which is co-
translationally cleaved (protter et ai, 1986). The predicted molecular weight of apo B, 
excluding glycosylation, is 512 kDA. It seems there is only one molecule of apo B per LDL 
particle since LDL only contains 500 kDA of protein (Scott, 1989). 
Amino acid sequence analysis has revealed that apo B is unique with there being only slight 
similarities to other apoproteins (De Loof et ai, 1987). Figure 2.4 shows some of the 
important structural features of apo B. There are 19 potential N-glycosylation sites in apo B, 
16 of which are known to be utilised (Yang et ai, 1989a). Analysis of secondary structure 
suggests that the amino-terminus of apo B is highly cross-linked (Yang et ai, 1989b) 
corresponding with a region rich in cysteines. 
2.5.1 Lipid binding potential 
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Numerous hydrophobic regions throughout the structure of apo B are thought to be 
important in lipid binding (Olofsson et ai, 1987). The amphipathic ex. helices in apo B (see 
figure 2.4) which are similar to those found in the putative lipid binding regions of other 
apolipoproteins (Knott et ai, 1986; De Loof et ai, 1987) are also thought to be important. 
Another structure with high lipid binding potential and which is unique to apo B is the 
amphipathic ~-sheet. It has been suggested that the many proline rich regions throughout apo 
B contribute to the ~-sheet arrangement (Young, 1990). Thus apo B has many potential lipid 
binding sites throughout its structure. This would help to explain its non-exchangeability 
betweeri lipoproteins and its absolute requirement for the formation of chylomicron and 
VLDL particles. 
The lipid binding ability of apo B has been demonstrated by many investigators. Chen et al 
(1989) showed that many peptides throughout apo B had the ability to recombine into 
lipoprotein-like particles when exposed to lipid. Yang et al (1989a) demonstrated that the 
regions between amino acids 1701 and 3070, and 4101 and 4536 were the main regions of 
apo B that were associated with lipid. This was concluded when digestion of the apo B on 
LDL left these regions largely undigested or IInon-releasable ll by trypsin and hence thought to 
be lipid associated. These regions correspond to sequences in apo B structure which are 
highly hydrophobic. 
The above studies which suggest that apo B binds lipid throughout its entire length are 
consistent with observations from naturally occurring truncated forms of apo B. Young et al 
(1989) discovered a truncated form of apo B (apo B-46) which was located mainly in the 
VLDL and LDL density range. Another shorter apo B (apo B-37), although detected in 
VLDL and LDL, primarily floated in the HDL density range (Young et ai, 1987a) and an 
even shorter variant (apo 8-31) was found only in the denser HDL and d> 1.21 fractions 
(Y oung et ai, 1990). All these findings suggest that the shorter the apo B, the less lipid is 
bound and the denser the lipoprotein particle formed. 
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Figure 2.4. Structural features of apo B (from Scott, 1989). Thrombin cleavage fragments 
T2, T3 and T4 are shown. Amphipathic a-helical domains are designated a and proline-rich 
~-sheets~. Cysteine residues shown as filled circles are known to be cross-linked. N-
glycosylation sites shown as filled circles are known to be utilised. Three basic domains that 
- bind to the LDL receptor are shown as filled boxes. Monoclonal antibody epitopes for 
antibodies that block binding to the LDL receptor are shown as filled boxes. 
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2.5.2 Receptor binding 
The receptor binding region of apo B has been well defined mainly by using monoclonal 
antibodies to apo B to block the binding ofLDL to the receptor (Milne et ai, 1989). This 
technique showed that by blocking the region between amino acids 2980 and 3780 (see figure 
2.4) the receptor binding activity ofLDL was abolished. Part of this region (amino acids 
3357 to 3367) had sequence homology with the region of apo E known to react with the 
LDL receptor (Knott et ai, 1986). This area is known to be well conserved through 
evolution and rich in positive charges. Such positively charged amino acids on apo Bare 
thought to interact with the negatively charged amino acids of the ligand binding domain of 
the LDL receptor (Brown and Goldstein, 1986). Finally there is a mutation at amino acid 
3500 involving a single amino acid substitution (Arg--+Gln) which yields a protein defective in 
binding to the LDL receptor and which is associated with hypercholesterolaemia (Innerarity et 
ai, 1990). 
2.5.3 Heparin binding 
Apo B also has the property of binding to heparin. This was shown by Weisgraber and Rail 
(1987) who found seven distinct regions in the apo B molecule that bound heparin strongly. 
These regions correspond to sequences rich in positively charged amino acids. It is thought 
that heparin binding sites on apo B may facilitate the binding of the triglyceride-rich 
lipoproteins to the capillary endothelium while they are metabolised by LPL. The capillary 
endothelium contains surface proteoglycans which are structurally similar to heparin. 
2.5.4 Modified fonns of apo B 
Apo B is very susceptible to proteolytic cleavage. Immediately after a blood sample is taken 
apo B is cleaved by the serine protease kallikrein to generate the fragments apo B-26 and apo 
B-74 (Cardin et ai, 1984). Further breakdown of apo B occurs from the action of another 
serine protease, thrombin (Hirose, 1987). It is therefore very important to routinely add 
appropriate protease inhibitors when working with apo B-1 00. 
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Oxidised LDL has been detected in the human circulation (Scott, 1989). In vitro studies have 
shown that monocytes, macrophages, and endothelial cells, all cells prominent in the arterial 
wall, can induce oxidation ofLDL (Steinberg et ai, 1989). There is now evidence that 
oxidation ofLDL occurs in vivo (Palinski et ai, 1989). Oxidation causes lipid peroxidation 
and modification of the amino acids of apo B-1 00. In particular, lysine and arginine residues 
are destroyed and the apo B protein becomes fragmented to expose domains which bind to a 
scavenger receptor on the surface of macrophages (Scott, 1989). Macrophages accumulate 
the modified LDL to form fat laden cells known as foam cells, a process thought to be 
important in the formation of atherosclerotic plaques (Steinberg, 1991). 
2.6 The apo B gene 
The gene for apo B is located at the short arm of chromosome 2 (Law et ai, 1985; Huang et 
ai, 1986). Figure 2.5 is a schematic diagram of the human apo B gene showing restriction 
sites and intron-exon boundaries. The apo B gene spans approximately 43 kilobases (kb) and 
contains 29 exons and 28 introns (Blackhart et ai, 1986). Over half of the apo B mRNA is 
coded for by the extremely large exon 26 which is 7572 base pairs (bp) long, the longest exon 
ever reported for any mammalian gene. 
The apo B gene is only expressed in large amounts in the liver and intestine (Knott et ai, 
1985). The factors responsible for preventing expression of the apo B gene in other tissues 
are not fully understood. DNA methylation could be one of the factors since it has been 
reported that the promoter regions of the apo B gene in liver and intestinal cell lines are 
undermethylated compared with cells from other tissues (Levy-Wilson and Fortier, 1989). 
Das and co-workers (Das et ai, 1988) have reported that DNA sequences governing specific 
expression in the liver appear to be located within 300 bp of the transcriptional start site. 
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Figure 2.S. Restriction map of the human apo B-I00 gene (from Blackhart et ai, 1986). 
The scale is in kb, and the filled areas below the restriction map delineate the exon regions. 
The promoter region of the apo B gene has been reasonably well defined. Sequences have 
been located between -128 and -86 that contain a positive element which increases 
expression (Das et ai, 1988). Within this region is a 13 bp sequence which is perfectly 
conserved in the mouse and human gene (Levy-Wilson et ai, 1988). Metzger et al (1989) 
demonstrated that the binding of two nuclear proteins designated AFI and CEBP was 
important in the transcription of the apo B gene. Within 60 bp upstream of the apo B gene 
transcriptional initiation site is a TATA box and a CAT box, presumably part of the promoter 
region (Blackhart et ai, 1986). In the 3' region of the gene, there are two poly-A signals 131 
bp apart both of which are utilised in making apo B mRNA (Breslow, 1988). 
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Current evidence suggests that there is little regulation of hepatic apo B gene expression at 
the transcriptional stage. Modification of the diet seems to have little influence on the level of 
apo B mRNA. Sorci-Thomas et al (1989) found there was no change in hepatic apo B 
mRNA in African green monkeys fed a diet high in saturated fats and cholesterol although the 
diet reduced by 50% the LDL receptor mRNA. Pullinger et al (1989) reported that the apo 
B mRNA levels in human hepatoblastoma cell lines remained unchanged under a variety of 
metabolic conditions. They did however find that the secretion rate of apo B could be 
modulated by insulin and fatty acids. Several investigators have reported that some 
intracellular apo B is degraded and not secreted (Borchardt and Davis, 1987; Bostrom et ai, 
1988). From these results it has been suggested that metabolic conditions, such as lipid 
availability, determines the amount of intracellular apo B that is secreted. It appears that the 
secretion of apo B-containing particles is controlled largely by co and/or post-translational 
factors. Investigation of these factors is currently a major focus of apo B research. 
2.6.1 Apo B-48 
The intestinal form of apo B is named apo B-48 because it is 48% the size of apo B-1 00 as 
determined by Kane et al (1980). Analysis of intestinal cDNA clones and protein sequencing 
have shown that apo B-48 is co-linear with the amino-terminal 2152 amino acids of apo B-
100 (Chen et ai, 1987). Several investigators have shown that apo B-48 is a product of the 
apo B-lOO gene derived by novel editing ofmRNA in the intestine (Chen et ai, 1987; Powell 
et ai, 1987; Higuchi et al. 1988a). In the intestine nucleotide 6666 of the apo B mRNA is 
changed from C to U which changes the codon for amino acid 2153 from CAA (which 
normally codes for glutamine) to UAA which is a stop codon. The exact mechanism 
responsible for the editing process is unknown. It has been postulated that perhaps a tissue 
specific enzyme~ which recognises a specific sequence within the apo B mRNA, deaminates 
the cytosine so it is read as a uracil. The fact that the sequence around nucleotide 6666 is 
well conserved and highly homologous between species (Davis et ai, 1989) supports this 
hypothesis. 
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2.6.2 Apo B gene variation 
The apo B gene is a very polymorphic locus. This was first noticed in the 1960's when 
investigators observed that multiple transfused patients developed antibodies to LDL. These 
antibodies were used to define the loci of genetic variations in apo B (Berg et ai, 1986; 
Breslow, 1988). Additional variations in the apo B gene were revealed by an apo B specific 
monoclonal antibody (MB 19) which detected a two allele polymorphism in apo B (Young et 
ai, 1986). 
Cloning and sequencing of the apo B gene in 1986 demonstrated that there was considerable 
variation in the DNA sequence. Yang et al (1989a) listed 75 differences in the apo B DNA 
sequence, 53 of which gave amino acid substitutions. Although some of these substitutions 
probably resulted from sequencing errors, many have been verified by direct amino acid 
sequencing and many create restriction fragment length polymorphisms (RFLPs) in the apo B 
gene. Significant associations between some of the RFLPs and lipoprotein levels have been 
reported (Young, 1990). 
Many repetitive elements occur in the intron sequences of the apo B gene. Introns 4, 14, 15, 
20, 21 contain Alu repeats (Scott, 1989). An AT-rich hypervariable region within 200 bp of 
the poly-A site, which is composed of 11 to 16 bp tandem repeats of varying size, has been 
reported (Huang and Breslow, 1987; Ludwig et ai, 1989). Boerwinkle and co-workers 
through PCR amplification and sequencing, have shown that there are 12 distinguishable 
alleles in this hypervariable region (Boerwinkle et ai, 1989). Hypervariable regions in the apo . 
B gene are very useful in epidemiological and family studies. 
Further variation in the apo B gene is seen in the form of specific mutations that cause 
specific hyper- and hypolipidaemias such as the mutation at amino acid 3500 which causes 
hypercholesterolaemia (see section 2.4) and the truncated forms ofapo B which cause 
hypocholesterolaemia (see section 2.7) 
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2.7 Familial hypobetalipoproteinaemia 
Many investigators have shown that low levels ofLDL cholesterol and apo B can be inherited 
within families in a simple Mendelian fashion. In the past five years, various laboratories have 
shown that familial hypobetalipoproteinaemia is associated with specific mutations in the apo 
B gene (Farese et ai, 1992). All the mutations interfere with the translation of the full length 
apo B and as a consequence truncated apo B molecules of varying length are produced (see 
table 2.5). There has also been reports of subjects with familial hypobetalipoproteinaemia 
that possess an apo B allele which markedly reduces the level of the full length apo B (Berger 
et ai, 1983; Collins et ai, 1988). 
An individual rarely inherits two defective alleles and is homozygous or compound 
heterozygous for familial hypobetalipoproteinaemia. The homozygous state is often clinically 
severe since the individual is unable to make chylomicrons and cannot absorb fat and fat-
soluble vitamins from the intestine. This results in symptoms such as steatorrhea, 
acanthocytosis, bleeding from vitamin K deficiency and neurological disorder mainly from 
vitamin E deficiency (Havel and Kane, 1989b). However, homozygotes and compound 
heterozygotes have been described who have been completely asymptomatic (Hardman et ai, 
1991; Talmud et ai, 1989). The severity of disease probably depends on the length and 
amount of apo B formed from the mutant alleles. A recent review on truncated apo B 
variants (Gabelli, 1992) concludes that homozygotes or compound heterozygotes that have 
variants greater than apo B-48 will be protected from fat malabsorption since the dietary 
pathway for the transport of lipids is preserved. Subjects with variants shorter than apo B-48 
would therefore be expected to suffer some form of fat malabsorption. This conclusion is 
supported by the lack of any clinical symptoms in a subject homozygous for apo 8-50 
(Hardman et ai, 1991). This is in contrast with a homozygote for apo B-39 in which clinical 
signs offat malabsorption were present (Collins et ai, 1988). 
Heterozygotes for hypobetalipoproteinaemia are almost always asymptomatic, because such 
patients can make some chylomicrons from the normal allele and hence clinical symptoms 
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from fat malabsorption are absent. Furthermore, because of their low LDL cholesterol levels, 
it seems that heterozygotes should be protected from developing coronary heart disease. 
Data from several investigators support this hypothesis (Kahn and Glueck, 1978; Glueck et 
ai, 1977). LDL cholesterol levels in heterozygotes are usually less than half that of 
unaffected family members (Young, 1990). The metabolic basis for the 'less than half normal 
levels is not fully understood. Indeed, the majority of the lipoproteins formed from truncated 
apo B mutants lack the ability to bind to LDL receptors which should produce a higher rather 
than lower level ofLDL. Hypotheses forwarded to explain this disparity include: 
1. The LDL receptor is up-regulated which results in an increased clearance ofLDL particles 
formed with the normal apo B allele (Young, 1990). 
2. The VLDL formed with the normal allele contains a greater number of apo E molecules 
which results in an increased clearance of VLDL. This effectively reduces the number of 
precursors for the formation ofLDL (Young, 1990). 
Another consistent finding in heterozygotes is the extremely low concentration of the 
truncated apo B in plasma. Generally the truncated apo B is only 2-10% of the apo B-1 00 
concentration formed with the normal allele (Young, 1990). Impaired synthesis and 
secretion, andlor increased catabolism of the lipoproteins with the mutant apo B species are 
possible explanations for this phenomenon. 
Studies suggest that familial hypobetalipoproteinaemia may affect 0.1-0.8% of the population 
(Andersen et ai, 1979; Laskarzewski et ai, 1982) as estimated from the frequency of the 
familial 'low cholesterol' phenotype. It is possible that subjects with this phenotype have 
defects in a gene other than apo B that causes low cholesterol (Young, 1990). An additional 
problem with estimating the incidence of hypobetalipoproteinaemia is that some subjects, that 
have low LDL cholesterol, have total cholesterol levels within the normal range (Young et ai, 
1989). 
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2.8 Truncated forms of apo B 
Studies of patients with hypobetalipoproteinaemia have revealed a number of mutations in the 
apo B gene that prevent translation of the full length apo B (4536 amino acids). These 
mutations are summarised in table 2.5. The majority of these studies have included family 
members to demonstrate the inheritance of the truncated apo B species thus confirming the 
familial nature of the hypobetalipoproteinaemia. All of these mutations involve the 
introduction of a premature stop codon through either a single nucleotide substitution or 
deletion leading to a frameshift. All except two of the single nucleotide substitutions are 
C~T transitions, a common transition in causing human genetic disorders (Cooper and 
Youssoufian, 1988). Hence CGA and CAG codons provide potential sites for mutation to 
stop codons. Collins et al (1988) reported 12 CGA co dons in apo B mRNA. There are many 
more CAG co dons hence the potential for the production of truncated apo B variants from 
C~ T transitions is large. 
The first truncated apo B found in association with hypobetalipoproteinaemia was apo B-37 
reported by Young et al (1987a). Since then there has been a number of truncated apo B 
variants reported (see table 2.5). To date each of the reported mutations causing 
hypobetalipoproteinaemia have occurred only within a single family thus it seems no single 
mutation predominates. The majority have been found in heterozygotes where there is one 
normal apo B allele although a few compound heterozygote and homozygote cases have been 
reported. All of the truncated species confer very low levels ofLDL cholesterol and apo B. 
However the functional properties of the various truncated apo B species differs according to 
their size. 
Variants such as apo B-87 and apo B-89 (Gabelli et ai, 1989; Krul et ai, 1989) which 
terminate near the carboxy-terminus of the protein presumably package lipoprotein particles 
normally since they are found in VLDL and LDL. Both variants have the LDL receptor 
binding domain intact. However it was shown that both had increased affinity for the LDL 
receptor, partially explaining the association with low LDL cholesterol levels (Gabelli et ai, 
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Table 2.5 Mutations of the Apo B Gene Associated with Familial Hypobetalipoproteinaemia 
Mutation No. Amino ApoB LDL Cho!. Clinical features References 
acids in I2lasma (mmol/L) 
Apo B2: G~T at Absent 0.75-1.21 
first base of intron 5 Compound 
heterozygote with Huang et al 
Apo B9: C~T at 411 Absent 0.41 severe clinical (1991) 
nucleotide 1443 course 
Apo B25: 694 bp 1085 Absent NAa Homozygote with Huang et al 
deletion including all classical symptoms (1989) 
of ex on 21 
Apo B29: C~T at 1305 Absent NA Heterozygotes Collins et al 
nucleotide 4125 (1988) 
Apo B31: Deletion of 1425 HDL, d>1.21g/rnL 0.73 Heterozygotes Younget al 
nucleotide 4480 (1990) 
Apo B32: C~Tat 1449 LDL, HDL, 0.80 Heterozygote with McCormick et 
nucleotide 4557 d>1.21 g/rnL highHDL al (1992) 
Apo B37: deletion of 1728 VLDL,LDL, 1.09 Compound Young et al 
nucleotides 5391~ HDL heterozygote (1987a and b) 
5394 
Apo B39: deletion of 1799 VLDL,LDL NA Homozygote with Collins et al 
nucleotide 5591 fat malabsorption (1988) 
Apo B40: deletion of 1829 VLDL,LDL, 1.27 Compound Krul et al 
nucleotides 5693~ HDL heterozygotes (1989) 
5694 
Apo B46: C~T at 2057 VLDL,LDL, 1.91 Heterozygotes Young et al 
nucleotide 6381 HDL (1989) 
Apo B50: C~T at 2251 VLDL,LDL, NA Homozygote Hardman et al 
nucleotide 6963 HDL without symptoms (1991) 
Apo B52.8 deletion 2395 VLDL,LDL NA NA Farese et al 
of nucleotide 7359 (1992) 
Apo B54.8: C~T at 2485 VLDL,LDL 1.27 Heterozygotes Wagner et al 
nucleotide 7665 (1991) 
Apo B55: C~T at 2492 VLDL,LDL NA NA Farese et al 
nucleotide 7692 (1992) 
Apo B61: deletion of 2784 VLDL,LDL NA Compound Pullinger et al 
nucleotides 8525~ heterozygote (1992) 
8561 
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Apo B67: deletion of 3040 VLDL,LDL l.09 Heterozygote with Welty et 01 
nucleotide 9327 high HDL levels (1991) 
Apo B75: deletion of 3386 VLDL,LDL l.24 Heterozygotes Krul et 01 
nucleotide 10366 (1992) 
Apo B83: C~A at 3749 VLDL,LDL 1.34 Heterozygote Farese et 01 
nucleotide 11458 (1991) 
Apo B86: deletion of 3896 VLDL, LDL NA Compound Linton et 01 
nucleotide 11840 heterozygote (1990) 
Apo B87: deletion of 3978 VLDL,LDL l.60 Asymptomatic Tennyson et 01 
nucleotide 12032 homozygotes (1990) 
Apo B89: deletion of 4039 VLDL,LDL l.91 Compound Krul et 01 
nucleotide 12309 heterozygote (1989) 
a Not Available 
26 
1989; Parhofer et ai, 1990). Shorter variants which lack the receptor binding domain do not 
react with the LDL receptor (Young et ai, 1987b). It is therefore hard to ascertain why these 
variants are associated with such low levels ofLDL cholesterol since there appears to be no 
clearance pathway. Impaired secretion or alternatively extracellular degradation or rapid 
clearance of the lipoprotein particles containing the abnormal apo B has been suggested 
(Collins et ai, 1988). 
The class of lipoprotein formed with these shorter variants and hence the density distribution 
varies according to size. The smallest of these truncated apo B species, apo B-25 (1085 
amino acids, Huang et ai, 1989) was not detected in the lipoprotein fraction of plasma 
suggesting that this protein is shorter than the critical length required for lipoprotein 
formation. This was also the case for apo-B 29 (1305 amino acids, Collins et ai, 1988). 
Young et al (1991) recently described an apo B-31 species which was detectable within the 
HDL and lipoprotein-deplete fraction (d> 1.21 g/mL) of plasma. The density distribution of 
apo B-31 suggested that this molecule, which contains the amino-terminal 1425 amino acids, 
was adequate to form an abnormal small dense lipoprotein particle but not LDL or the larger, 
triglyceride-rich lipoproteins. In contrast the apo B-37 mutant (1728 amino acids, Young et 
ai, 1987a) was detected in VLDL as well as in LDL and HDL, implying that this molecule 
was of adequate size to form LDL and the larger triglyceride-rich lipoproteins. Truncated 
species longer than apo B-37 are all capable of forming VLDL. The length of apo B 
molecule that is required to fonn particles in the LDL density class is less clear and appears to 
lie between the apo B-31 and apo B-37 region~ 
In conclusion it seems that the longer the apo B species the more lipid is bound and the more 
buoyant the lipoprotein fonned. This is consistent with the finding that apo B-IOO has lipid 
binding regions throughout its length. The exact regions required for the formation of the 
apo B containing VLDL and LDL particles is becoming clearer but still requires further 
definition. A number of questions however still remain relating to the synthesis, secretion and 
catabolism of these truncated apo B species. 
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2.9 Expression of truncated variants in cell culture 
Characterisation of truncated forms of apo B has provided important information on the 
functional domains of apo B. However the metabolic pathway of the lipoprotein particles 
formed from the truncated variants has remained elusive. Focus has now turned to the 
expression of truncated apo B proteins in cell culture in an attempt to further characterise the 
lipoproteins made and to elucidate the basis of their low concentrations. 
Blackhart et al (1990) have designed an in vitro expression system for apo B. An apo B 
minigene constructed from cDNA and genomic clones and inserted into a vector carrying the 
cyclomegalovirus promoter was designed and expressed in a rat hepatoma cell line McA-
RH7777. This cell line was chosen over simian and human liver cell lines because of its 
maximal expression and secretion capabilities. The McA-RH7777 cells act as primary rat 
hepatocytes and produce apo B-containing VLDL particles (Tanabe et ai, 1989). This is an 
advantage over human liver hepatoma cell lines such as HepG2 in which the majority of apo 
B-containing lipoproteins that are produced are LDL-like (Bostrom et ai, 1988). Originally 
both human apo B forms (apo B-I00 and apo B-48) were shown to be expressed and 
secreted as lipoprotein particles using this system. 
The same group of investigators (Yao et ai, 1991) have since expressed the truncated apo B 
proteins apo B-18, B-23, B-28, B-31, B-37, B-48, and B-53. All of the variants were 
secreted from the transfected cells. The secretion rates were normal except for the apo B-18 
and apo B-23 variants which were secreted at a much slower rate than normal. Both variants 
were found associated with very little lipid compared to the larger truncated variants in which 
the longer the apo B the more lipid-rich and more buoyant the particle. Results from this 
study suggest that secretion rates do not account for the low concentration of truncated apo 
B seen in human subjects to date. This study did indicate that the ability of apo B to assemble 
lipids into lipoprotein particles increased as the length of apo B increased. This was 
reinforced by work by Spring et al (1992) in which carboxy-terminally truncated apo B 
variants of increasing length were associated with increasing lipoprotein core circumference. 
28 
Graham et al (1991) have expressed the truncated apo B species apo B-9, B-13, B-17, B-23, 
B-26 and B-39 in HepG2 cells. All were secreted except for apo B-9. Only apo B-39 was 
found exclusively in the lipoprotein density fraction (d<I.25). Apo B-17, B-23 and B-26 
were found in both the lipoprotein and infranatant (d>1.25) fractions whereas apo B-13 was 
only in the infranatant fraction suggesting no association with lipid. Herscovitz et al (1991) 
have expressed the amino-terminal 17% of apo B in a murine cell line. Characterisation of the 
expressed apo B-17 showed it was capable of binding some lipid suggesting that the 
amino-terminus may contribute to the formation of the triglyceride-rich lipoproteins. The 
secretion of these very short truncated variants is in contrast with the in vivo situation where 
the naturally occurring variants apo B-25 and apo B-29 (Huang et ai, 1989; Collins et ai, 
1988) were undetectable in patient plasma, suggesting these variants were not being secreted 
from the liver. 
Expression of apo B in cell culture has wide application in the study of truncated apo B 
variants. As well as studying the naturally occurring variants any region of the apo B gene 
can be mutated to produce truncated apo B variants of varying length. As well as studying 
the metabolism of the truncated apo B species, the in vitro expression system allows the 
identification of important functional domains in the large apo B protein. 
2.10 Summary 
The two forms of apo B playa crucial role in lipid metabolism. Much progress has been 
made in recent years in understanding this important lipid-carrying protein. Apo B-1 00 is an 
extremely large protein synthesised in the liver and is crucial for the assembly of the 
triglyceride-rich VLDL which carry endogenous triglyceride to peripheral tissues. Apo B-I00 
is the major protein component of the cholesterol-rich LDL and is responsible for the 
receptor-mediated uptake ofLDL by the liver and extrahepatic tissues. Apo B-48, a product 
of the apo B-1 00 gene, is synthesised in the intestine and integral to the assembly of the 
triglyceride-rich chylomicrons which carry dietary triglyceride to peripheral tissues. 
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Important regions in the structure of apo B, such as the receptor-binding region and possible 
lipid binding regions, have been identified. Many different mutations in the apo B gene 
associated with abnormal cholesterol levels and disease have been identified, some of which 
have pointed to important functional domains on this large protein. 
Familial hypobetalipoproteinaemia is a disease associated with abnormally low levels ofLDL 
cholesterol and apo B. Hypobetalipoproteinaemia is caused by different mutations in the apo 
B gene which prevent translation of the full length protein (4536 amino acids). Despite the 
rarity of these truncated forms of apo B, they have been a source of valuable information on 
the structure-function relationships of apo B and lipid metabolism. 
CHAPTER 3 MATERIALS AND METHODS 
3.1 Biochemicals 
Specialist biochemicals and materials were obtained from the following companies: 
American Type Culture Collection, Rockville, MD., USA 
Amersham International, Amersham, England. 
Bio-Rad Laboratories Pty, Ltd., Richmond, CA., USA 
Boehringer Mannheim, Mannheim, Germany. 
Calbiochem, La Jolla, CA., USA 
Dupont, Boston, MA., USA 
Falcon, Lincoln Park, NJ., USA 
Fissons, Loughborough, England. 
FMC Bioproducts, Rockland, ME., USA 
GibcolBRL, Gaithersberg, MD., USA 
Kodak, Rochester, NY., USA 
New England Biolabs Inc., Beverly, MA., USA 
New England Nuclear, North Ryde, NSW., Australia. 
Nunc, Roskilde, Denmark. 
Perkin Elmer Cetus, Norwalk, CT., USA 
Pharmacia Fine Chemicals, Uppsala, Sweden. 
Promega Corporation, Maddison, WI., USA 
Schleicher and Schuell, Dassel, Germany. 
Sigma Chemical Co., St Louis, MO., USA 
United States Biochemicals, Cleveland, OH., USA 
Whatman International Ltd., Maidstone, England. 
Unless otherwise stated in the text all other biochemicals were of analar grade and obtained 
from British Drug Houses Chemicals, Poole, England. 
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Water used in all solutions and reactions was deionised and filtered (0.2J..lm filter) by the Milli-
Q water purification system. Water used for molecular biology techniques was also sterilised 
by autoclaving. 
3.2 Equipment 
Major items of equipment used were: 
Centrifuges 
Beckman L8-70 ultracentrifuge 
Sorval RC5C . 
Centra-M microfuge 
Spectrophotometer 
PU 8740 scanning spectrophotometer 
Oligonucleotide synthesiser 
391 DNA synthesiser 
PCRmachine 
DNA thennal cycler 
Electroluter 
Model UEA 
Vacuum dryer 
SpeedVac concentrator 
Beckman Instruments Inc., 
Palo Alto, CA., USA 
Dupont, Boston, MA., USA 
International Equipment Company, 
Needham Hts., MA.,USA 
Pye Unicam, Cambridge, England 
Applied Biosystems Pty. Ltd., Victoria, 
Australia 
Perkin-Elmer Cetus, Norwalk, CT., 
USA 
International Biotechnologies Incorporated, 
CN., USA 
Savant Instruments Inc., Fanningdale, 
NY., USA 
Incubators 
G 24 Environmental incubator shaker 
Sanyo MIR 160 
Fraction collection system 
Fraction collector: 2210 Super Rae. 
Peristaltic pump: 2232 Microperpex S. 
U. V. detector: 2238 Uvicord S II. 
Chart recorder: 2210 2-channel recorder. 
Concentrating cells 
Model 12 
Water purification system 
MilliQTM 
New Brunswick Scientific, Co., Inc., 
Edison, NJ., USA 
Sanyo Electric Co., Ltd., Japan 
Pharmacia LKB Biotechnology, 
Uppsala, Sweden 
Amicon, Beverly, MA., U.S.A. 
Millipore Corporation, 
Bedford, MA., USA 
3.3 Human subjects and selection criteria 
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The individual involved in this study was found to have low LDL cholesterol during a routine 
check at the diabetes outpatient clinic at Princess Margaret Hospital, Christchurch in 1989. A 
repeat blood sample in 1990 showed an LDL cholesterol level (31 mg/dL) well below the 
lower limit of the normal range (105 mg/dL) as determined by a local population study (Janus 
et ai, 1981). This individual was selected for further investigation along with four other 
patients who had LDL levels below 105 mg/dL. Neither the subject or the other four patients 
showed any clinical signs of fat malabsorption however it was noted that one of the patients 
was in hospital for liver function tests at the time his hypobetalipoproteinaemia was identified. 
Investigation of the subject's family was very limited as both of his parents were deceased and 
he had no siblings or offspring. Blood samples were however, obtained from his first cousins. 
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Samples were also obtained from normolipidaemic controls at various times during the course 
of this study. 
3.4 Plasma preparation 
Blood (20-80 mL) was collected into sterile tubes containing EDTA (l.5 mg/mL). Plasma 
was separated immediately by centrifugation at 3000 rpm for 10 minutes at room temperature. 
Isolated plasma was then mixed with the following inhibitors as used by Young et al (1987b): 
100 kallikrein units/mL aprotinin (Boehringer Mannheim), 1 mM TLCK (Boehringer 
Mannheim), 1 mM TPCK (Boehringer Mannheim), 1 mM PPACK (Calbiochem), 2 mM 
PMSF (Sigma) and 175 mg/mL sodium azide (Fissons). 
Small aliquots of plasma (50J.lL) were frozen at -80°C for measurement of vitamins A and E 
(appendix 7.1) and immunoblot analysis. Remaining plasma was kept at 4°C and used for the 
measurement of plasma apolipoproteins, lipoprotein isolation and the measurement of 
lipoprotein lipids (appendices 7.2, 7.3 and 7.5). Buffy coat was aspirated from the red cells 
and stored at -80°C until required for isolation of genomic DNA. 
3.5 Lipoprotein isolation from plasma 
Analytical lipoprotein isolations were performed at the Lipid Clinic, Princess Margaret 
Hospital using density gradient ultracentrifugation as described in appendix 7.3. 
Initial isolation of the apo B-32 lipoproteins was performed by density gradient 
ultracentrifugation in a Beckman LS-70 ultracentrifuge using a Beckman Ti 60 rotor 
according to the method of Havel et al (1955). Density solutions were as described in 
appendix 7.4. Isolation of lipoproteins commenced as soon as the blood was taken. 
Approximately 25mLs of plasma was adjusted to a density of 1.075 as described in appendix 
7.4, added to a polyallomer centrifuge tube, and overlaid with a l.075 density solution so that 
the tubes were filled when capped. VLDL and LDL (d<l.075) were isolated by 
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ultracentrifugation at 40 000 rpm at 20°C for 18 hrs. The infranatant was adjusted to a 
density of 1.291 then overlaid with a 1.291 density solution and ultracentrifugation repeated. 
After each ultracentrifugation the supernatant lipoproteins were aspirated and stored in the 
dark under nitrogen at 4°C. 
3.6 Isolation of apo B-32 lipoproteins by heparin-Sepharose 
chromatography 
Apo B-32 containing lipoproteins were fractionated from the 1.075-1.291 fraction isolated in 
section 3.5 by heparin-Sepharose chromatography using a method similar to that of Owen et 
al (1987). Heparin-Sepharose (preswollen and stored in 50mM TrisIHCI (pH 7.4), 1M NaCI, 
0.1 % sodium azide) was kindly provided by Dr Maurice Owen. 
The 1.075-1.291 fraction (2mL) was dialysed for 18 hrs at 4°C in 50mM TrisIHCI (pH 7.4), 
10mM sodium citrate before being loaded onto a 6mL heparin-Sepharose column equilibrated 
with the same buffer. Chromatography with the equilibration buffer was continued until all 
unbound lipoproteins were eluted. Bound lipoproteins were then eluted with a salt gradient 
to 0.5MNaCI (in equilibration buffer). Fractions (1.5 mL) were collected with the aid ofa 
fraction collector (flow rate = 20mLlhr). Fractions containing peaks (unbound and bound) 
were pooled, concentrated to 2mL and screened for their lipoprotein composition by SDS 
PAGE and immunoblotting with polyclonal anti-apo B, anti-apo Al and anti-apo E antibodies 
(see sections 3.10 and 3.11). The unbound and bound lipoprotein peaks along with control 
lipoprotein fractions were subjected to particle size analysis via electron microscopy as 
described in appendix 7.7. 
3.7 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed on plasma and the isolated apo B-32 as described 
in appendix 7.8. Following electrophoresis, gels were either protein stained or the proteins 
transferred to nitrocellulose (Schliecher and Schuell) by pressure blotting. This involved the 
placement ofa strip of nitrocellulose followed by 3 pieces of What man 3MM blotting paper 
(all previously soaked in water) on the gel. On top of this was placed approximately 20 
sheets of paper towels and a 500g weight and transfer allowed to proceed for 15 minutes. 
The nitrocellulose was then subjected to immunoblotting as described in section 3.11. 
35 
Alternatively, proteins separated by 1 % agarose electrophoresis were electrophoresed in the 
second dimension by SDS PAGE (section 3.10). For this, lanes were cut from the agarose gel 
using a scalpel blade and ruler, and placed on the top of the SDS PAGE gel as described in 
appendix 7.9) 
3.8 Composition analysis of lipoproteins 
3.8.1 Cholesterol and triglyceride detenninations 
Total cholesterol and triglyceride determinations on plasma and lipoprotein fractions were 
performed at the Princess Margaret Lipid Clinic using the Boehringer enzymatic assays (see 
appendix 7.5). Total cholesterol and triglyceride determinations on the isolated apo B-32 
lipoproteins were performed manually using the same assays. 
For triglycerides, 20~ of lipoprotein was mixed with ImL of Test-Combination Triglyceride 
GPO-P AP reagent and the reaction incubated at room temperature for 15 minutes. Twenty 
ilL of a 2mg/mL triglyceride solution was mixed with 1 mL of reagent and incubated under 
the same conditions. The absorbance of the sample and standard at 500nm was measured 
against a reagent blank. The concentration (C) of triglyceride in the sample was then 
calculated from the following equation: 
C (mg/mL) = 2 x A sample 
A standard 
For cholesterol, 20llL of lipoprotein was mixed with 1mL of Monotest Cholesterol CHOD-
reagent and the reaction incubated at room temperature for 15 minutes. Twenty ilL of a 2 
mg/mL cholesterol solution was mixed with 1 mL and incubated under the same conditions. 
The absorbance of the sample and standard at 500nm was measured against a reagent blank. 
The concentration (C) of cholesterol in the sample was then calculated from the following 
equation: 
C (mg/mL) = 2 x A sample 
Astandard 
3.8.2 Phospholipid detenninations 
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Phospholipid concentrations in lipoprotein fractions were detennined using the Test-
Combination Phospholipids enzymatic assay (Boehringer Mannheim) based on the method of 
Takayama et al (1977). This method measures the release of choline from phospholipids by 
the action of the phospholipase D enzyme. Lipoprotein samples were dialysed against 50mM 
TrislHCI (pH 7.4), 10mM sodium citrate before analysis. Twenty ilL of sample was mixed 
with 1 mL of phospholipid reagent (1000 unitsIL phospholipase D, 1400 unitsIL choline 
oxidase, 800 unitsIL peroxidase (all from Sigma) and 8mM 4-aminophenazone in 50mM 
TrisIHCI (pH 8.0), 20mM phenol) and incubated at 42°C for 30 minutes. The standard was a 
0.9mg/mL solution of choline iodide (Sigma) which is equivalent to 3mg/mL phospholipid. 
Twenty IlL of standard was mixed with 1 mL of phospholipid reagent and incubated under the 
same conditions. The absorbance of both the sample and standard were measured against a 
reagent blank and the concentration of phospholipid calculated from the following equation: 
C (mg/mL) = 3 x A sample 
A standard 
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3.8.3 Total protein detenninations 
The total protein in the lipoprotein fractions was determined using the Bio-Rad protein assay 
based on the method of Bradford (1976). Ten J.lL of sample was diluted with lOJ.lL of water 
and mixed with 1 mL ofBio-Rad dye (previously diluted with 4 volumes of water and filtered 
through Whatman IMM paper) and the absorbance of the sample at 595nm measured. A 
standard curve using bovine serum albumin (Img/mL) as the reference protein was established 
over a protein concentration range of 50J.lg/mL to 1 mg/mL. The protein ,- )ncentration of the 
sample was read from the standard curve and multiplied by the sample dilution factor in order 
to give a final protein concentration (mglmL). 
3.8.4 Percentage composition calculation 
Percentage chemical composition was calculated by dividing each individual chemical 
component (mg/mL) by the sum of all four chemical components. For example: 
% Cholesterol = C (cholesterol) x 100 % 
----~------~--------------------------
~ C (cholesterol, triglyceride, phospholipid, protein) 
Where C = concentration (mglmL) 
3.9 Precipitation of apo B-containing lipoproteins 
Apo B-containing particles (VLDL and LDL) were precipitated from the plasma of 
hypobetalipoproteinaemic patients with each of three different reagents commonly used to 
prepare HDL. Samples from patients with plasma containing apo B-31, apo B-46 apo B-61, 
apo B-67, and apo B-83 were kindly provided by Dr Stephen Young of the Gladstone 
Foundation Laboratories, San Francisco, CA., USA. Normal plasma was used as a control 
throughout the experiment. 
38 
After addition of each reagent the mixture was immediately vortexed and then left at room 
temperature for 15 minutes. The precipitant was sedimented by centrifugation at 2000rpm for 
20 minutes. After centrifugation the supernatant was transferred into fresh tubes. The 
precipitant was then redissolved in 1 mL of 1: 1:8 (v/v/v) water:tetramethyl urea: 10mM 
TrislHCI (pH 8.0), 8M urea. An equivalent amount of plasma, supernatant, and redissolved 
precipitant was analysed for the presence of the truncated apo B species by western blot 
analysis using a polyclonal anti-apo B antiserum (section 3.11). 
3.9.1 Precipitation with sodium phosphotungstate/magnesium 
VLDL and LDL were precipitated from plasma with a sodium phosphotungstic 
acid/magnesium chloride reagent using a modification of the method of Grove (1979). The 
precipitation reagent (ImL of 2M MgCl2 and 5mL of 45gIL phosphotungstic acid, 160mM 
NaOH (pH 7.4)) was freshly prepared and 30J,LL added to 250J,LL of plasma at room 
temperature. 
3.9.2 Precipitation with polyethylene glycol 
VLDL and LDL were precipitated from plasma with polyethylene glycol (PEG) 6000 
following the method of Warnick et al (1979). Two hundred J,LL of an aqueous solution of 
PEG solution (240gIL PEG 6000) was added to 200J,lL of plasma. 
3.9.3 Precipitation with heparin/manganese 
VLDL and LDL were precipitated from plasma with a heparin/manganese reagent according 
to the method of Bullock et al (1980). To 500J,LL of plasma was added 25J,lL of heparin 
(7500 unitsIL in 150mM NaCI, Fissons) and 25J,LL of2.02M manganous chloride. 
3.9.4 Precipitation with dextran sulphate 
Precipitation of VLDL and LDL with dextran sulphate was according to a modified method 
of Finley et al (1978). To 500~L of sample was added 25~L of a 20g/L 
solution of dextran sulphate 500 (Pharmacia) and 25~L of 2M MgCl2 solution. 
3.10 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
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Proteins in plasma and lipoprotein fractions were separated by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS PAGE) using a modification of the method of 
Laemmli (1970). Linear gradient gels (3-6% and 3-15%) were made as described in 
appendix 7.9 and poured into the Mini-Protean II mini-gel system (Bio-Rad). Gel dimensions 
were 1 00mrnx60mmxO.75mrn. Thicker 3-6% gels (1.5mrn) were used for imrnunoblotting 
for easier handling. Stacking gels (3%) were poured on top of each gradient gel (see 
appendix 7.9). Samples were incubated for 3 minutes at 100°C in sample buffer (2% (w/v) 
SDS, 10% (w/v) sucrose, 5% ~-mercaptoethanol, 0.001% (w/v) bromophenol blue, in 20mL 
of tank buffer) before loading. 
Electrophoresis was at a constant voltage of 180 V until the dye band had migrated to the end 
of the gel. The 3-6% gels were run for a further 20-30 minutes before electrophoresis was 
terminated. Gels were either stained with warmed Coomassie blue protein stain (0.5g 
Coomassie brilliant blue-R250 dissolved in 300mL of water, 67mL of acetic acid and 300mL 
of ethanol) and destained in the same solution without Coomassie or subjected to 
immmunobiotting. 
3.11 Immunoblotting 
Proteins were transferred to nitrocellulose (Schliecher and Schuell) by electrophoresis using 
the Mini Trans Blot system (Bio-Rad). Briefly, the gel was placed on top of a gel holder on 
which was stacked a fibre pad followed by 1 sheet of Whatman 17MM blotting paper 
40 
previously soaked in tank buffer (appendix 7.9) without the SDS and containing 5% 
methanol. On top of the gel was placed the nitrocellulose followed by a further sheet of 
17MM Whatman and another fibre pad (also previously soaked). This was then placed in the 
Mini Trans Blot electrophoresis chamber with the gel side nearest to the cathode plate. The 
chamber was filled with the above buffer and electrophoresis commenced at 100V for 1 hour. 
Immunodetection was as described by Michaelis et al (1990). Excess protein-binding sites on 
the nitrocellulose were blocked with 3% non-fat powdered milk in 50mM TrislHCI (pH 7.9), 
150mM NaCI, 0.05% Tween 20 (solution A) for at least 30 minutes at room temperature. 
The membrane was incubated with 10J,.lg of a rabbit antiserum to human LDL apo B-1 00 
(supplied by James Yeo, Steroid Unit, Christchurch Hospital) in 30mL of fresh solution A at 
room temperature for approximately 18 hours. After washing with solution A (3x5 minute 
washes) the membrane was incubated with a 1: 5000 dilution of goat anti-rabbit alkaline 
phosphatase conjugated antibody (Sigma) for 2 hrs at room temperature. After washing as 
before, the immunoblots were developed by adding 60J,.lL of Nitro Blue Tetrazolium (Sigma) 
and 30J,.lL of 5-bromo-4-chloro-3-indolyl phosphate (Sigma) in 25mL of 100mM TrislHCI 
(pH 9.5), 100mM NaCl, 5mM magnesium acetate. 
At times, blots were incubated with a rabbit anti-human apo Al antibody (Calbiochem) or a 
rabbit anti-human apo E antibody kindly provided by Dr Stephen Young of the Gladstone 
Foundation Laboratories, San Francisco, CA, USA. 
A series of immunoblots was performed where the membranes were incubated with three 
previously characterised monoclonal antibodies to apo B, MB3 which binds between amino 
acids 994 and 1084, 2D8 which binds between amino acids 1403 and 1480 and MB44 which 
binds between amino acids 2488 and 2658 (pease et ai, 1990). These antibodies were kindly 
provided by Dr Stephen Young. The second antibody was a 1 :5000 dilution of goat-anti 
mouse alkaline phosphatase conjugated antibody (Sigma). 
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In some cases, blots were incubated with a 1 :SOOO dilution of goat anti-rabbit or goat anti-
mouse peroxidase conjugated antibody for 1 hr at room temperature and the blots developed 
with ECL western blot detection reagents (Amersham). 
3.12 Molecular weight estimation of the abnormal apo B species 
Apolipoproteins in the patient's HDL were separated alongside protein markers (SDS-6H 
High Molecular Weight Kit, Sigma) on a 3-1S% gradient gel by SDS PAGE (described in 
3.10) and the proteins stained with Coomassie blue. A graph was established by plotting 
molecular weight against electrophoretic mobility for each of the protein markers. 
Electrophoretic mobility was calculated from the distance migrated by the protein band from 
the top of the gel (em), divided by the total distance from the top of the gel to the dye front 
(cm). The molecular weight of the abnormal apo B was read from this graph by plotting the 
electrophoretic mobility. 
3.13 Preparation of genomic DNA 
Genomic DNA was prepared using a modification of the method of Kunkel et al (1977). 
Buffy coat (3mL) was thawed at room temperature and transferred to a SOmL Nunc tube to 
which was added 47mL of Triton Lysis Buffer (0.32M sucrose, 10mM TrisIHCI (pH 7.S), 
SmM MgCI2, 1% Triton X-IOO). The tubes were stored on ice for 30 minutes and 
centrifuged at room temperature for 10 minutes at 2500 rpm. The supernatant was discarded 
down to 8mL and Triton Lysis Buffer again added to a volume of 50mL. The tube was 
centrifuged as before, all of the supernatant was discarded and the pellet resuspended in 2mL 
ofSTE (10mM TrisIHCI (pH 7.4), 10mMNaCl, 10mMEDTA). The resuspended pellet was 
transferred to a IOmL tube with a ImL wash of STE. SDS (350J,lL of 10% (w/v» and 
proteinase K (150J,lL of 10mglmL, Boehringer Mannheim) were added and the tube incubated 
overnight at 37°C. The next morning 700J,lL of6M sodium perchlorate was added and the 
incubation continued for a further 2 hrs. 
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Genomic DNA was extracted from the incubation mixture with an equal volume of 
phenoVchloroform. Two mL of both phenol saturated with 0.1 M TrislHCI (pH 8.0) and 
chloroform:isoamyl alcohol 24: 1 (v/v) was added and the tube mixed by inversion before 
being centrifuged at 3000rpm for 2 minutes to separate the phases. The upper aqueous phase 
containing the DNA was removed to a fresh tube and a repeat phenoVchloroform extraction 
performed followed by a 4mL chloroform:isoamyl alcohol 24: 1 (v/v) extraction. DNA was 
then precipitated from the upper aqueous phase by addition of one tenth the volume of 3M 
sodium acetate (pH 4.7) and 2-4 volumes of ice-cold ethanol. The precipitated DNA was 
removed with a sterile needle to a 1.5mL eppendorftube where it was washed in 70% ethanol 
before being air-dried for 30 minutes. The genomic DNA was resuspended at 4°C overnight 
in TE (IOmM TrisIHCI (pH 8.0), ImM EDTA). The concentration (C) of DNA was 
determined by measuring the OD260 value of a 1 in 200 dilution against the reagent blank and 
calculation from the following equation: 
C (~g/mL) = OD260 sample x 50 x 200 
Where 50 = C (~glmL) of DNA at an OD260 value of 1 
and 200 = dilution factor 
3.14 Amplification of an apo B gene fragment by the polymerase chain 
reaction 
A 759 bp portion of the apo B gene (encompassing apo B cDNA nucleotides 4369-5127, 
coding for apo B-I00 amino acids 1388-1639) was amplified via the polymerase chain 
reaction (PCR) from the patient and a control. Genomic DNA (I ~g) was added to a 1 OO~L 
PCR reaction which contained: Ampli-Taq DNA polymerase buffer (50mM KCI, 10mM 
Tris/HCI (pH 8.3), 1.5mM MgCI2, 0.001% (w/v) gelatin), 0.2mM dNTP's (Perkin Elmer 
Cetus), l~M each of oligonucleotide primers B31-1 and B31-2 and 2.5 units Ampli-Taq DNA 
polymerase (Perkin Elmer Cetus). The primers, B31-1 
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(5'ACAAGAATACGTTCACACTATCATGTGATG'3) and 31-2 
(5'GCACCtGcAGACTACACTTCAAGTTGGTCG3') were those designed by Young et al 
(1990). Two base mismatches (lower case letters) had been included in B3 1-2 to create a 
Pst! site. Both oligonucleotides were synthesised on an Applied Biosystems 391 DNA 
Synthesizer. PCR involved amplification for 30 cycles on a DNA thermal cycler (Perkin-
Elmer Cetus). Each cycle involved a denaturation step for 1 minute at 96°C, annealing for 1 
minute at 60°C and extension for 1 minute at 74°C with a final extension of 3 minutes. The 
same apo B gene fragment was also amplified from an apo B-31 expression vector (Yao et ai, 
1991) kindly supplied by Dr Stephen Young, using PCR conditions as described above with 
0.1 ~g of the plasmid DNA as a template. 
Products amplified by PCR were analysed by agarose gel electrophoresis alongside DNA 
molecular weight markers (q,XI74 RF DNAlHaeIII, GibcolBRL) at 100V for 1 hour in a 3% 
Nu-sieve (FMC Bioproducts), 1% agarose (GibcoIBRL) gel in 0.5x TBE buffer (45mM 
Tris/Borate (pH 8.0), ImM EDTA) containing 0.5~g/mL ethidium bromide. PCR products 
were visualised over UV light and gels photographed through an orange filter using Polaroid 
667 film. The amount of DNA generated by each reaction was estimated by the intensity of 
the bands over UV light in relation to a known concentration of the molecular weight 
markers. 
3.15 Electroelution ofPCR DNA 
PCR amplified DNA was purified and prepared for sequencing by electroelution in a 
commercial electroeluter (International Biotechnologies Incorporated, Conneticut, USA) in 
accordance with the manufacturers instructions. PCR product (200~L) was electrophoresed 
on a 3% Nu-sieve, 1% agarose gel as in section 3.14. The 759 bp apo B fragment band was 
visualised over UV light and quickly exised from the gel using a sterile scalpel blade. The 
exised band was placed in the electro elution chamber previously filled with 0.5x TBE and 
DNA electrophoresed from the gel into an adjacent V-shaped channel containing a high salt 
solution (7.5M ammonium acetate, 0.01% (w/v) bromophenol blue). Electrophoresis 
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continued at lOOV until gel slices were free of DNA, as determined with a hand-held UV light 
(approximately 30 minutes). The salt solution was then collected from the V-shaped chamber 
with a ImL syringe and the DNA precipitated with 2 volumes of ethanol at -20°C for 1 hour. 
After a wash with 70% ethanol the DNA pellet was left to air-dry before being redissolved in 
75JlL ofTE. Recovery ofPCR DNA from electro elution was checked by electrophoresis on 
a 3% Nu-sieve, 1% agarose gel. 
3.16 Sequencing of peR amplified DNA 
PCR amplified DNA was directly sequenced using the method of Higuchi et al (l988b) and 
the Sequenase Version 2.0 sequencing reagents (United states Biochemical Corporation). 
3.16.1 Sequencing reactions 
For each DNA template there were four sequencing reactions, one for each of the four' 
dideoxy nucleotides (ddGTP, ddATP, ddTTP, ddCTP). All steps were performed on ice and 
reactions mixed by gentle pipetting so as to avoid air bubbles .. 
A "premix" of 5x buffer (200mM TrisIHCI (pH 7.5), 100mM MgCI2, 250mM NaCl: 0.37JlL 
per reaction), Sequenase 2.0 enzyme (0.15 ~ per reaction) and O.lM DTT (Q.22JlL per 
reaction) was prepared in an 0.5mL eppendorftube. Dideoxy nucleotide termination mixes 
(ddGTP, ddATP, ddTTP and ddCTP each containing 80mM ofdeoxy nucleotide, 8mM of 
dideoxy nucleotide and 50mM NaCl) were aliquoted into 0.5mL eppendorftubes to give 
2.5~ ofdideoxy nucleotide per reaction and premix added (0.75JlL per reaction). The 
dideoxy nucleotidel"premix" solution (3~ per reaction) was then aliquoted to the wells of a 
Nunclon microtitre plate and the wells labelled G, A, T, C. 
The template/primer pair mix was prepared by adding 3~ ofa IJlM solution of32P-end 
labelled primer (appendix 7.10) to 8JlL of electroelution purified PCR DNA (0.15-0.6 pmols). 
The primer used to sequence PCR DNA was the B31-3 primer (5'TCAAAAGGTTTACTA'3) 
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which hybridises to the normal apo B-1 00 allele at the B-31 position. The template /primer 
mix was denatured by heating to 95°C for 5 minutes and annealing allowed by incubation on 
ice for 5-10 minutes. This was followed by centrifugation for 10 seconds in a microfuge to 
spin down any condensate. 
To each dideoxy reaction was added 2.5J.lL of the template/primer mix and the reactions 
incubated for 15 minutes at 37°C to allow extension. Sequencing reactions were terminated 
by the addition of 4J.lL of "stop" solution (95% (v/v) formamide, 20mM EDT A, 0.05% (w/v) 
bromophenol blue, 0.05% (v/v) xylene cyanol). The sequencing reactions were then 
denatured by heating for 5 minutes at 95°C and kept on ice while 2J.lL of each reaction was 
loaded onto the sequencing gel. 
3.16.2 Sequencing gel 
Sequencing was performed in a 6% polyacrylamide denaturing gel using the Bio-Rad Sequi-
Gen nucleic acid apparatus (21x40 cm) with wedge spacers. A sealing gel consisting of 15mL 
acrylamide (6% (w/v) acrylamide in Ix TBE and 1M urea), 260J.lL of 10% (w/v) ammonium 
persulphate and 75J.lL ofTEMED was poured and left to set for 5-10 minutes. The resolving 
gel consisting of 40mL acrylamide, 400J.lL of 10% (w/v) ammonium persulphate and 8J.lL of 
TEMED was then poured and the straight edge ofa 0.2Smm sharks tooth comb applied to the 
top of the gel which was allowed to polymerise for 1 hour. 
Gels were pre-run in 1 x TBE buffer for 30 minutes at 2000 V before loading. Sequencing 
reactions were electrophoresed at SOW until the xylene cyanol dye band had migrated to the 
end of the gel (approximately 2 hours). Sequencing gels were fixed in 10% acetic acid, 10% 
methanol, backed onto Whatman 3MM paper, vacuum dried and exposed to X-ray film 
(Kodak X-Omat) for either 24 hours at -20°C or 48 hours at room temperature. 
3.17 Cloning of the apo B PCR fragment into the pUC19 plasmid 
Electroeluted PCR product as generated in section 3. IS was cloned into the pUC 19 plasmid 
(Yanisch-Perron et ai, 1985) shown in figure 3.1. 
3.17.1 Digestion ofPCR and pUC19 DNA 
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Purified PCR fragment (O.SJ..I.g) was subjected to double digestion with 1 unit each of the PstI 
and Xbal restriction enzymes (Boehringer Mannheim) in buffer (50mM TrisIHCI (pH 7.S), 
IOmM MgCI2, IOOmM NaCl, ImM dithioerythritol) in a 20J..l.L reaction. The PstI enzyme 
was allowed to digest for 1· hr at 37°C before the Xbal enzyme was added and the incubation 
continued for a further two hours. Restriction enzymes were heat denatured after digestion 
by a 10 minute incubation at 80°C. 
Plasmid pUCI9 DNA (I'J..I.g, Boehringer Mannheim) was double digested with PstI and Xbal 
in a similar 20 J..t.L reaction. Digestion efficiency was evaluated by agarose electrophoresis in 
1% agarose gels (1% agarose in O.Sx TBE buffer containing O.SJ..I.g/mL ethidium bromide) at 
IOOV for 1 hr. 
3.17.2 Ligation of digested DNA and transfonnation into E. coli 
Fifty ng ofPstIlXbaI digested pUCI9 was ligated to 150ng ofPstIlXbal digested apo B PCR 
fragment in ligase buffer (2S0mM TrisIHCI (pH 7.6), SOmM MgCI2, 5mM ATP, SmM 
dithiothreitol, 25% (w/v) PEG 8000) with 1 unit ofT4 DNA ligase (GibcoIBRL) for 16 hours 
at 16°C. The ligation reaction (2J..1.L) was transformed into E. coli DH5a. cells (Gibco BRL) 
according to the manufacturer's transformation procedure (appendix 7.12). The cells were 
then pelleted by spinning in a microcentrifuge for 1 minute, resuspended in 200J..l.L ofLB 
media (appendix 7.13) and plated on LB agar containing 1 25J..1.g/mL ampicillin (appendix 
7.13) previously spread with 50J..l.L of20mg/mL Xgal and IOOJ..t.L of IOOJ..l.M IPTG. Plates 
were placed in a 37°C incubator and cells allowed to grow for 18-24 hours. 
Sca I 2177 
Ssp I 2501 
pUC 19 
(2686 bp) 
AlwN 11217 
Figure 3.1 pUC19 plasmid circle map. 
3.18. Identification of cloned DNA and Southern blot analysis 
EcoR I 
Sac I 
Kpn I 
Xmal 
Sma I 
8amH I 
Xba I 
Sail 
Hinc II 
Acc I 
8spM I 
Pst I 
Sph I 
Hind III 
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The polycloning site of pUC 19 resides within the E. coli lac Z gene which codes for a 
fragment of ~-galactosidase (Yanisch-Perron et ai, 1985) In the presence ofIPTG and X-gal 
this enzyme makes colonies blue. Insertion of DNA into the polycloning site disrupts the lac 
Z gene therefore clones transformed with plasmids containing DNA inserts remain white 
giving an effective selection for recombinant clones. 
Nine white and 1 blue colony were chosen for plasmid DNA preparation. One half of each 
colony was restreaked onto a LB/Amp master plate and the other half inoculated into I.SmL 
ofLB/Amp media and incubated for 18 hours at 37°C in a shaking incubator. "Mini-preps" 
(appendix 7.14) of plasmid DNA were prepared from eac~_ cultured colony. To determine the 
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presence of the 759 bp apo B insert, each mini-prep DNA (0.5~g) was digested with the Pst! 
and Xbal restriction enzymes using the same conditions as described in 3. 17. 1. The digest 
(1 O~L) was electrophoresed on a 1 % agarose gel and visualised over UV light. 
The DNA on the above gel was transferred to two filters using a combination of the original 
techniques of Southern (1975) and the sequential blotting technique of Grosveld et al (1981). 
The gel was treated with 200mL volumes of the following solutions: 0.25N HCl for 25 
minutes with one change of solution followed by 0.5N NaOH, 1.5M NaCI for 40 minutes with 
one change of solution and finally, 0.5 M TrislHCI (pH 7.0), 3M NaCI for 60 minutes with 
one change of solution. The gel was placed on top offour pieces of What man 3MM which 
was placed on a sponge in a reservoir of stock 20x SSC (0.3M sodium citratelNaOH (pH 
7.0), 3M NaCI). A Nylon filter (Hybond-N, Amersham) presoaked in 2x SSC was placed on 
top of the gel followed by four pieces of What man 3MM presoaked in 2x sst, approximately 
20 sheets ofHygenex Handitowels and a 500g weight. DNA was allowed to transfer for 15 
. minutes when the filter was replaced and transfer continued for a further 15 minutes. The 
blotted filters were rinsed in 2x SSC and allowed to air-dry at room temperature. 
The membranes were prehybridised for 4 hours in 6x SSC, 1 % SDS and 100J.,lg/mL herring 
salmon sperm DNA (preboiled for 10 minutes, Boehringer Mannheim) at 30°C. The 
membranes were then probed overnight with two 32P-end labelled oligonucleotide probes 
labelled as described in appendix 7.10. One membrane was probed with an allele-specific 
probe for the normal apo B-100 allele, B32-1 (5'AAGAAACAGCATTTG'3) the other with 
an allele-specific probe for the mutant apo B-32 allele, B32-2 (5'CAAATGCTATTTCTT'3). 
The labelled probe was added directly to the prehybridising solution and left to hybridise 
overnight at 30°C. Hybridisation and subsequent wash conditions for this and other 
hybridisations during this study were based on the calculation of melting temperatures of each 
oligonucleotide probe. Melting temperatures (Tm) were derived from the following equation 
formulated by Itakura et al (1984): 
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Tm = NQ A + T residues x 2°C + NQ G + C residues x 4°C 
The following morning the hybrid ising solution was disposed of and the membranes washed 
with 2x SSC and 0.1 % SDS for 3 washes at 30°C, 34°C and 36°C respectively. The 
membrane probed with the B 32-1 probe was given an extra wash at 38°C. The two 
membranes were then sealed in a plastic bag and autoradiographed at -80°C for 1 hour using 
Kodak X-Omat XARS film. The film was developed in the automatic developer at the 
Christchurch Hospital X-ray Department. 
3.19 Sequencing of cloned DNA 
The apo B PCR fragment cloned into pUC 19 was sequenced according to the protocol 
described in 3.16. The primer used was a universal sequencing primer Messing et al (1983) 
supplied in the Sequenase kit which anneals to pUC 19 40 bp before the polylinker (see figure 
3. 1 ). A mutant and a non-mutant clone as identified in 3.18 were sequenced with the plasmid 
DNA being linearised before sequencing by restriction digestion with the Pst! enzyme. 
3.20 Dot blot analysis 
3.20.1 Preparation of DNA 
PCR amplified DNA (100J,JL, see section 3.14) from the subject, a control and an expression 
vector carrying the apo B-31 allele was phenoVchloroform extracted and ethanol precipitated 
as described in section 3.13. The DNA was resuspended in 100J..l.L of water and the DNA 
then denatured by incubation for 10 minutes in 0.25M NaOH at room temperature. DNA was 
neutralised by the addition of sse to O.2Sx. 
3.20.2 Transfer of DNA to a Nylon filter 
One quarter of each of the three denatured samples (approximately 1 J..I.g ) was applied to 4 
wells of a Bio dot apparatus (Bio-Rad Laboratories) containing a Nylon membrane (Hybond-
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N, Arnersham) assembled according to the manufacturer's instructions. The samples were left 
for 30 minutes at room temperature before a vacuum was applied for 20 seconds. After 
dismantling the apparatus the membrane was left to air dry. 
3.20.3 Hybridisation of oligonucleotide probes 
The membrane was prehybridised as in 3. 18 then cut into horizontal strips and each set of the 
three DNA samples probed with the following probes: 
B31-3 (S'TCAAAAGGTTTACTA'3) which hybridises to the normal apo B-I00 allele at the 
B-31 position 
B31-4 (S'CTCAAAAGTTT ACT A'3) which hybridises to the mutant apo B-31 allele 
B32-1 (S'AAGAAACAGCATTTG'3) which hybridises to the normal apo B-I00 allele at the 
B-32 position 
B32-2 (S'CAAATGCTATTTCTT'3) which hybridises to the mutant apo B-32 allele 
The probes were end labelled with y_32p as in appendix 7.10 then added directly into the 
prehybridising solution and left to hybridise overnight at 30°C. The next morning the 
hybridising solution was disposed of and the membranes washed as in 3. 18 at the same 
temperatures with the membrane probed with B32-1 given an extra wash at 38°C. The four 
membranes were then sealed in a plastic bag and autoradiographed at -80°C for 1 hour using 
Kodak X-Omat film. 
3.21 Production of an apo B-32 expression vector 
A vector (pB32) designed to express the apo B-32 protein was constructed from the apo B-
42 expression vector (pB42) described by Blackhart et al (1990). The pB42 vector was 
kindly provided by Dr Zemin Yao of the Gladstone Foundation Laboratories, San Francisco, 
CA, USA. The pB42 vector (see figure 3.2) was originally constructed from pCMV4 
(Andersson et ai, 1989) an expression vector which utilises the cytomegalovirus promoter-
enhancer sequences and the human growth hormone transcription termination and 
f1 
ori 
apo B eDNA 
(20-5848) 
pB42 
10.5 Kb 
Ampr 
Figure 3.2 pB42 plasmid circle map. 
polyadenylation signals. The pB32 expression vector was constructed by introducing the 
C~T mutation at nucleotide 4557. The nucleotide numbering used in this plasmid was 
different to that originally used to report the apo B-32 mutation (McCormick et al. 1992) 
where the mutation was reported at nucleotide 4548. 
3.21.1 Mutagenesis method 
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Mutagenesis was performed on pB42 using the unique site elimination (USE) method of Deng 
and Nickoloff (1992) with slight modification. This method eliminates the need for cloning as 
mutagenesis is performed directly in the expression vector. USE mutagenesis employs two 
primers, one carrying the desired mutation, another containing a mutation which eliminates a 
unique non-essential restriction site. Both primers are annealed to the circular single stranded 
plasmid (produced by heat denaturation) and a new strand containing both primers is 
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synthesised. The resultant DNA is then transformed into a negative mismatch repair E. coli 
strain. This increases the chance of the mutant strand cosegregating from the wild type 
during the first round of DNA replication. Transformants are selected by growth in an 
appropriate antibiotic and plasmid DNA prepared and treated with the enzyme which 
recognises the unique restriction site. The mix of digested and undigested DNA is then 
retransformed into an appropriate E. coli host Plasmids with a mutation in this site are 
resistant to digestion and remain circular. Circular DNA is selected for since linearized DNA 
transform bacteria very inefficiently. The frequency at which the undigested circular DNA 
also contains the other desired mutation is reported to be about 80%. 
3.21.2. The mutagenic primers 
Two 21-mer oligonucleotides (Hpa I and B 32, figure 3.3) were synthesised on a 
Applied Biosystems 391 DNA synthesiser both of which had a single base mismatch 
(underlined) at the central position. 
Hpa I 5' TGGAGCAGTTQACTCCAGAAC '3 
B 32 5' CAAAAAGAAAIAGCATTTGTT '3 
Figure 3.3 Prim en for USE mutagenesis 
The Hpa I primer was designed to eliminate the unique HJW: restriction site which occurs at 
nucleotide position 1616 in the apo B cDNA. Because this was in a coding region care was 
taken so that the mismatch did not change the amino acid being coded for. The B 32 primer 
was designed to introduce the desired mutation as described above. 
Before mutagenesis, both oligonucleotides were phosphorylated by treatment with T 4 
Polynucleotide kinase (GibcoIBRL). Primers (100pmol) were incubated with 5 units ofT4 
polynucleotide kinase in 50mM TrisIHCI (pH 7.5), 10mM MgCI2, 5mM dithiothreitol in a 
20~L reaction at 37°C for 30 minutes. The kinase was then inactivated by heating to 70°C 
for 10 minutes. 
3.21.3. The mutagenesis reaction 
Mutagenesis of pB42 was perfonned as follows: 
S3 
A 20~L reaction containing the B 32 and Hpa I primers (2Spmol each) and pB42 (O.lj.lg) in 
20mM TrislHCI (pH 7.S), 10mM MgCl, SOmM NaCl was heated to 100°C for 3 minutes. 
Primers were annealed by immediately placing tubes in an ice bath. DNA synthesis was 
perfonned by the addition of3~ of lOmM TrisIHCI (pH 7.S), SmM each dNTP's, 10mM 
ATP and 20mM DTT; S~L of H20; IJ,lL ofT4 DNA polymerase (13 units, Promega) and 
I~L ofT4 DNA ligase (10 units, Promega). The reaction was incubated at 37°C for 90 
minutes and then stopped by heating to 80°C for 10 minutes. Some of the mutagenesis 
reaction (10J,lL) was transfonned into the E. coli host strain BMH 71-18 mut S as in appendix 
7.12. After recovery a further SmL ofLB containing ampicillin (l2S~g/mL) was added and 
the cells incubated for 18 hours at 37°C. Plasmid DNA was prepared from the SmL culture 
as in appendix 7.14 and O.SJ,lg digested with the HpaI enzyme (3.S units, Boehringer, 
Mannheim) in 33mM Tris acetate (pH 7.9), 10mM magnesium acetate, 66mM potassium 
acetate, O.SmM DTT for 16 hours at 37°C. Digests were heat denatured for 10 minutes at 
80°C then electrophoresed at 75V for 90 minutes on a 0.7% agarose gel. The gel was stained 
in 0.5~g/mL ethidium bromide and visualised over UV to determine the amount of uncut and 
cut plasmid DNA. The HpaI digest was retransfonned into the E. coli strain DH5a. and the 
transfonned cells plated onto LB plates containing 125J,lg/mL ampicillin and incubated at 37° 
C overnight. Plasmid DNA was prepared from 10 colonies and the DNA again digested with 
HpaI. Plasmid DNA resistant to HpaI digestion was sequenced along with the wild type 
pB42 vector to verify the presence of the B-32 mutation. 
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3.21.4. Sequencing of the apo B-32 expression vector 
Both the pB32 and original pB42 expression vectors were sequenced with the Sequenase 
version 2.0 kit (United States Biochemical Corporation) using the protocol provided with the 
kit. Mini-prep DNA (SJlg from each of S pB32 mini-preps) were alkali denatured by 
incubation in 0.2M NaOH and 0.2mM EDT A at 37°C for 30 minutes. Denatured DNA was 
then precipitated with 0.1 volumes of 3M sodium acetate (pH 4.7) and 3 volumes of ice-cold 
ethanol at -80°C for 20 minutes. Denatured DNA was redissolved in 7JlL of water and 
annealing reactions set up by the addition of 2JlL of annealing buffer (200mM TrislHCI (pH 
7.S), 100mM MgCI2, 2S0mM NaCl) and IJlL ofa 2mM solution of the sequencing primer 
B31-3 described in 3.16.1. The annealing reaction was heated to 6SoC for 2 minutes and the 
reaction allowed to cool at room temperature for 30 minutes. At this stage 2.SJlL of each of 
the four dideoxynucleotides termination mixes (ddGTP, ddATP, ddTTP, ddCTP, see section 
3.16. I) were aliquoted into eppendorf tubes and incubated at 37°C 
The annealing reaction was then placed on ice and the following added: I IlL ofMn buffer 
(United States Biochemicals), I IlL O.IM OTT, 21lL 1 in IS dilution of dGTP labelling mix 
(7.SmM each of dGTP, dCTP, dTTP), O.SIlL [a._35S]-dATP (SJlCi, Amersham), 2JlL 
Sequenase Version 2.0 enzyme diluted 1 in 8 with dilution buffer (10mM TrisIHCI (pH 7.S), 
SmM OTT, O.S mg/mL BSA). 
The above labelling reaction was incubated for 3-S minutes at room temperature and 3.SJlL 
then placed into each of the dideoxynucleotide solutions. The reactions were then placed at 
37°C for S minutes to allow termination and 41lL of stop solution (9S% v/v formamide, 
20mM EDTA, O.OS% w/v bromophenol blue and O.OS% (v/v) xylene cyanol) added. Tubes 
were kept on ice until loading when they were heated to 90°C for S minutes. Each reaction (2 
IlL) was loaded on a 6% denaturing gel and electrophoresed as described in section 3.16.2. 
Gels were run until the bromophenol blue dye band was near the bottom of the gel 
(approximately I.S hours). Sequencing gels were backed onto Whatman 3MM paper, 
vacuum dried and exposed to X-ray film (Kodak X-Omat) for 24 hours at room temperature. 
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Only the C and T dinucleotide reactions were loaded for the sequencing of the mini prep DNA 
described above. After identification of clones with the B-32 mutation, mini prep DNA from 
these clones was transformed into E. coli DH5a. and plasmid DNA prepared as described in 
appendix 7.15. This DNA, along with similarly prepared DNA from the pB42 vector, was 
sequenced as described above with all four dinucleotide reactions being loaded. 
3.22. Expression of apo B-32 and apo B-42 in cell culture 
The pB32 expression vector along with the original pB42 vector were expressed in a 
rat hepatoma cell line McA-RH7777 using the protocol ofYao et al (1991). All cell culture 
work was performed with sterile solutions (either autoclaved or filter sterilised through a 0.2J.,l 
filter) under sterile conditions. 
3.22.1 Maintenance of cell line used in expression 
The rat hepatoma cell line McA-RH7777 was obtained from American Type Culture 
Collection. Cells were grown in Dulbeccco's modified Eagle's medium (DMEM) 
supplemented with 20% heat-inactivated fetal bovine serum, 25mM glucose, 100 unitslmL 
Penicillin and 100 J.,lg ImL of streptomycin (all obtained from Gibco). Medium was filter 
sterilised through a 0.22J.,l filter and stored at 4°C. Cells were grown in 15mL of medium in 
Falcon 50mL flasks in a 37°C incubator with 5% CO2, Cells were maintained by feeding 
twice a week which involved the aspiration of old medium and addition of fresh medium to 
the flasks. 
Cells were split 1 :24 weekly. Splitting was performed when the cells were 60-70% confluent 
as determined by microscopy. Cells were loosened from the flasks for splitting by the 
addition of3mL of 0.05% Trypsin, 0.53mM EDTA (Gibco BRL) and the rolling of flask for 
30 seconds. Trypsin was then aspirated before cells were placed in new medium. 
Stocks ofMcA-RH7777 cells were frozen at -BO°C in ImL aliquots in freezing medium (20% 
fetal bovine serum, 10% DMSO, in DMEM). 
3.22.2 Co-transfection of McA-RH7777 cells with the apo B expression and 
pCMVneo vectors. 
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Stable cell lines expressing apo B-32 and apo B-42 were generated by cotransfection of the 
pB32 and pB42 vectors with the pCMVneo vector (kindly provided by Dr Martin Kennedy of 
the Cytogenetics Laboratory, Christchurch Hospital). pCMVneo contains a gene coding for a 
phosphotransferase enzyme (Jimenez and Davies, 1980) which, when expressed in eukaryotic 
cells, confers resistance to the antibiotic Geneticin. Cells transfected with and expressing this 
gene continue to grow in the presence of Geneticin while untransfected cells die. 
Transfection was performed using the calcium phosphate coprecipitation and glycerol shock 
method previously described by Tanabe et al (1989). Cells trypsinised as above at 60-70% 
confluency were split 1:6 into SOrnL flasks with ISrnL of medium and allowed to reattach 
overnight at 37°C, S%C02. Expression vector DNA (Sllg ofpB32 or pB42) along with 
0.31lg pCMVneo in IOOIlL of H20 was placed in 14rnL Falcon 20S7 tubes. To each DNA 
sample was added SOOIlL of2x BES buffered saline (SOmM BES (pH 6.9S), 280mM NaCI, 
I.SmM Na2HP04, Sigma). A 0.32M CaCl2 solution was then made by diluting 631lL ofa 
2M CaCl2 solution with 3371lL of H20 and this was added dropwise to the samples while 
vortexing. The tubes were then capped tightly and left to stand at room temperature for 20-
30 minutes. The CaP04-DNA solution was then vortexed vigorously for 30 seconds and 
immediately added dropwise to the culture medium of each flask and gently mixed. After 4 
hours at 37°C, S%C02 a glycerol shock was performed on the cells. Medium was aspirated 
and 3rnL of IS% glycerol in IS0mM PBS (pH 7.4) was added to one end of the flask and 
gently rolled over the layer of cells 3-4 times. After 2 minutes the glycerol was aspirated and 
the cells quickly washed twice with lOrnLs of PBS. Fresh medium (ISrnL) was added and the 
cells incubated for 48 hours before being split into two SOrnL flasks and exposed to 
400Ilg/rnL Geneticih (G418) containing media. Cells were incubated at 37°C, S% CO2 with 
the G418 containing medium changed 2-3 times a week. After 14-21 days, colonies which 
formed were picked when the colony diameter was approximately Imm. Medium was 
57 
aspirated and 5~L of trypsin added to the top of a colony and the colony transferred to a six 
well Nunclon multidish. The cells in the colony were loosened by gentle pipetting and 2mL of 
G418-containing medium added. Cells were incubated and the medium changed as before. 
Medium was analysed for the expression of apo B when the cells became confluent. 
3.22.3 Screening for apo B expression 
Media (2mL) was aspirated from the cells and lipoproteins precipitated from the media by the 
addition of60~L ofa 20mg/mL slurry offumed silica (Sigma) in PBS. After one wash with 
PBS the lipoproteins were eluted from the silica by adding 60~L of sample buffer (section 
3.10) and heating to 100°C for 5 minutes. Thirty ~L of this was then subjected to SDS 
PAGE electrophoresis and immunoblotting as described in sections 3.10 and 3.11. 
Immunoblotting was performed with both the polyclonal anti apo B antibody described in 
section 3.11 and a monoclonal anti-apo B antibody, IDI (Pease et ai, 1990), kindly provided 
by Dr Stephen Young of the Gladstone Foundation Laboratories (San Francisco, CA, USA). 
Cells identified from resistant colonies as expressing apo B-32 and apo B-42 were trypsinised 
as in 3.22.1 and transferred to Falcon 250mL flasks in 30mL of media. Cells were grown as 
before and on reaching confluency medium from pB32 and pB42 expressing cells were 
subjected to density ultracentrifugation as described in section 3.5 so as to obtain four 
fractions: VLDL (d<1.006 g/mL), LDL (d=1.006-1.063), HDL (d=1.063-1.2I) and d>1.21. 
The lipoproteins in each fraction were precipitated and subjected to electrophoresis and 
immunoblotting as described above to determine the density distribution of the expressed B-
32 and B-42 apoproteins. 
3.22.4 Supplementation of media with oleic acid 
The media of cells expressing apo B-32 and apo B-42 was supplemented with ImM oleic acid 
for 48 hours before being subjected to density ultracentrifugation. Oleic acid dissolved in 
O.IM KOH was added to media which was then stirred for 30 minutes to allow adequate 
mixing before being filtered. 
58 
CHAPTER 4 RESULTS 
4.1 Lipoprotein and apolipoprotein concentrations in the proband and 
relatives 
Lipoprotein and apolipoprotein concentrations in non-fasting plasma samples ,from the subject 
and three genetic relatives are given in Table 4.1. The proband's LDL cholesterol and apo B 
concentrations were well below the 5th percentile limits of 105 and 45 mg/dL respectively. 
One of the proband's first cousins (subject 3) also had a low LDL cholesterol concentration 
(below 105 mg/dL) and a low apo B concentration while the other two subjects (2 and 4) had 
relatively normal lipoprotein and apolipoprotein concentrations. The proband, a diabetic, had 
no clinical symptoms or signs of fat malabsorption. The proband was also characterised as 
having high HDL and apo Al levels. 
Table 4.1 Lipoprotein and apolipoprotein concentrations in the apo B-32 subject and 
relatives 
Subject ApoB Age/Sex Triglyceride Cholesterol Apolipoproteins 
Phenotype Total LDL HDL B Al 
(mg/dL) 
1 100/32 64/M 23 143 31 90 20 191 
2a 100/100 65/M 42 248 155 51 94 139 
3a 100/100 681F 77 197 56 69 63 139 
4a 100/100 671F 54 283 151 78 95 165 
Normalb 155-317 105-215 45-125 
aSubjects 2, 3 and 4 are first cousins to subject 1, and are free of significant medical problems. 
bThe normal range for LDL cholesterol and apo B concentrations are the 5th to 95th 
percentile values as determined in two local studies (Janus et ai, 1981; Walmsley et ai, 1991). 
4.2 Lipoprotein and apolipoprotein concentrations in other unrelated 
subjects 
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Table 4.2 shows non-fasting lipoprotein and apolipoprotein concentrations from four other 
subjects identified at the Christchurch lipid disorder clinic as having low total cholesterol and 
LDL levels below 105 mg/dL. Plasma apo B concentrations were well below the normal 
range in all subjects. Subject 6 had lower apo Band LDL cholesterol levels than the proband 
described in 4.1. LDL cholesterol levels in the other three subjects (5, 7 and 8) were well 
below the 5th percentile but not as low as those measured in subjects 1 and 6. Like the 
proband, the subjects in table 4.2 had no symptoms of fat malabsorption. Based on their low 
LDL and apo B levels, subject 1 in table 1 and all subjects in table 2 were classified as having 
hypobetalipoproteinaemia. 
Table 4.2 Lipoprotein and apolipoprotein concentrations in four unrelated subjects 
Subject Age/Sex Triglycerides Cholesterol Apolipoproteins 
Total LDLa HDL B Al 
(mg/dL) 
5 331F 40 151 80 63 36 167 
6 40IM 108 94 (25) 45 15 123 
7 801M 214 114 33 38 23 117 
8 391M 41 97 39 50 23 42 
Normal 105-215 45-125 
a The LDL cholesterol levels given here were calculated using the Friedewald equation (see 
appendix 7.6). The LDL cholesterol value in brackets is a measured LDL cholesterol as are 
the values in table 4.1. 
4.3 Vitamin A and E concentrations 
Plasma vitamin A and E concentrations in the five subjects with hypobetalipoproteinaemia are 
shown in Table 4.3. Vitamin A levels were low but within the normal range except for subject 
5 whose vitamin A level was well below the normal range. Vitamin E levels were normal in 
subjects 1 and 7. Subjects 5 and 8 had vitamin E levels below the normal range. 
Table 4.3 Vitamin A and E concentrations in five hypobetalipoproteinaemic subjects 
Subject Vitamin A Vitamin E 
(llg/mL) (IlmoVL) 
1 470 24.2 
5 241 6.3 
6 702 
7 728 14.3 
8 561 10.0 
Normala 350--800 12-46 
aThe normal adult ranges for both vitamins are taken from Kaplan and Pesce (1989). 
4.4 Immunoblot analysis of an abnormal apo B 
Immunoblotting of plasma from subject 1 (figure 4.1, lane 1) showed an abnormal apo B 
band along with the normal apo B-I00 band indicating subject 1 was heterozygous for a 
truncated species of apo B. The truncated protein was found largely in the HDL fraction 
(lane 4) although a small amount was detected in the LDL and d>1.21 fractions (lanes 3 and 
5). Immunoblotting of plasma from relatives (not shown) revealed only normal apo B-I00 
bands. Further study of these individuals was therefore abandoned. 
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Immunoblot analysis of plasma from the four individuals in table 4.2 is shown in figure 4.2. 
Subjects 6 and 7 (lanes 2 and 4) initially showed apo B bands at approximately apo B-74 and 
apo B-48 positions respectively. Repeat analysis of fasting samples (lanes 3 and 5) however 
showed only apo B-1 00 bands in the subjects. Similar results were obtained with subjects 5 
and 8 (lanes 1 and 6). Thus there was no evidence of any truncated apo B variants in 
subjects 5, 6, 7 and 8. Further analysis of these individuals was abandoned because of the 
lack of substantial evidence linking their hypobetalipoproteinaemia with the apo B gene. A 
detailed linkage analysis study involving family members would be required to assess the 
association between apo B and the hypobetalipoproteinaemia in these subjects. Such a study 
is beyond the scope of this thesis. 
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~igure 4.1 Immunoblot detection of a truncated apo B in the subject's plasma and 
ipoprotein fractions. Lane I , whole plasma; lane 2, isolated VLOL; lane 3, isolated LOL; 
ane 4, isolated HDL; lane 5, lipoprotein-deplete plasma (d> 1.21 glmL). The loadings in 
Jlasma equivalents are 5, 30, 10, 30, and 30.lL. Proteins were electrophoresed on a 3- 6% 
;OS PAGE minigel and immunoblotting performed as previously described by Michaelis el a/ 
'1991) using a polyclonal anti- apo B antibody. 
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Figure 4.2 Western blot analysis of plasma from four hypobetalipoproteinaemic 
mbjects . Plasma (5)LL) was electrophoresed on a 3- 6% SOS PAGE minigel and 
.mmunoblotting described as in figure 4.1. Lane I, subject 5; lane 2, subject 6; lane 3, subject 
5 (repeat sample); lane 4, subject 7; lane 5, subject 7 (repeat sample), lane 6, subject 8. The 
:op band is apo B-1 00 while the arrows indicate the position of apo B-48. 
62 
Immunoblotting plasma of the proband with apo B-31 and apo B-37 (figure 4.3a) as standards 
showed that the truncated apo B was similar in length to apo B-3 1. The latter contains the 
1425 amino-terminal amino acids of apo B-1 00 (Young el ai, 1990). The reaction of the 
truncated apo B with three monoclonal antibodies was also similar to apo B-31 . Antibody 
MB3 (figure 4.3b), which binds to an epitope between apo B-100 amino acids 994 and 1084 
(Pease el ai, 1990), reacted with both apo B-31 and the new variant. Antibody 2D8 (figure 
4.3c), which binds to an epitope between apo B-IOO amino acids 1403 and 1480 (Pease el ai, 
1990), did not react with either apo B-3 1 or the new variant. Antibody MB44 (figure 4.3d), 
which binds to an epitope between apo B-100 amino acids 2488 and 2658 (Pease et ai, 1990), 
reacted only with apo B-1 00. 
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Figure 4.3 Immunoblots demonstrating binding of three apo 8 specific monoclonal 
antibodies to apo 8-100, apo 8-37, apo 8-32 and apo 8-31 . A., B, C and Dare 
immunoblots using a polyclonal anli-8 antiserum and monoclonal antibodies MB3, 2D8 and 
MB44 respectively. Lanes 1- 4 are the same in each immunoblot. Lane I, I ilL plasma from 
a normal control; lane 2,0.3 ilL HDL from a patient with apo B-37; lane 3, 3 ~IL plasma from 
the apo 8 -32 subject; lane 4, 2 ~lL plasma from a patient with apo B-31 . The apo B-31 and 
apo B-37 samples along with the three monoclonal antibodies were generously provided by 
Dr Stephen Young of the Gladstone Foundation Laboratories CA., USA. Immunoblots were 
performed as in figure 4.1. 
3 4 
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4.5 Determination of molecular weight 
The molecular weight of the truncated apo-B was estimated from SOS-PAGE of HDL 
alongside protein markers (figure 4.4). On this basis, a molecular weight of 165 000 was 
estimated and the abnormal apo B designated apo 8-32 using the nomenclature suggested by 
Kane el at (1980) . 
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Figure 4.4 Size estimation of the truncated apo B species. 
HDL from the subject was electrophoresed on a 3- 15% SOS-PAGE mini-gel alongside 
protein markers. Lane I, 3 ~lL protein markers (SOS-6H High Molecular Weight Kit, Sigma, 
USA); lane 2, 20 ~lL patient HDL (equivalent to 40 ilL plasma). Protein bands were detected 
by staining with Coomassie blue R-250. 
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4.6 Two-dimensional analysis of apo B-32 lipoproteins from plasma 
Analysis of the apo B-32 particles by electrophoresis on 1% agarose (figure 4.5b) showed no 
abnormal band with protein staining (I) or Western blot analysis (2). The low LDL (or ~ 
lipoprotein fraction) in the plasma from the patient was apparent from the reduced intensity of 
staining in both the lipid stain (not shown) and Western blot compared to control plasma 
(figures 4.5a and b, 2) . However, further analysis of the electrophoresed proteins in the 
second dimension followed by immunoblotting revealed the apo 8-32 protein (indicated by 
the arrow) in patient plasma (figure 4.5b, 3). Only apo B-100 (indicated by the arrow) was 
present in control plasma (figure 4. Sa, 3). The B-32 band appeared slightly anodal to the apo 
B-IOO band in the ~ lipoprotein position indicating the apo B-32 lipoproteins were of pre-~ 
electrophoretic mobility similar to that of the VLDL lipoproteins. 
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Figure 4.5 Two-dimensional analysis of apo 8-32 lipoproteins from plasma. Plasma (3 
ilL) from a normal control (A) and the apo B-32 subject (B) were electrophoresed in 1% 
agarose to separate the various lipoprotein classes and the resultant gel either stained with 
Coomassie blue (1) or immunoblotted with a polyclonal anti apo B antibody (2). The protein 
component of the separated lipoproteins was then electrophoresed in the second dimension 
(3) by SDS PAGE in a 3-10% gel and western blotted as in figure 4.1. The arrows indicate 
the position of the apo B-100 (figure 4.5a) and apo B-32 proteins (figure 4.5b). 
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4.7 Isolation of apo B-32 lipoproteins 
Affinity chromatography of isolated HDL on heparin-Sepharose (figure 4.6) separated the apo 
B-32 containing lipoproteins from HDL lipoproteins. Analysis of the breakthrough peak (A) 
by SDS PAGE showed that the HDL was not retarded by the heparin column. Furthermore 
the apo B-32 protein was not present in this peak indicating that the apo B-32 lipoproteins 
were bound to the column. A small broad peak (B), which was absent in a control HDL 
sample, was eluted off the heparin column at approximately O.IM NaCI. SDS PAGE analysis 
of the O.IM NaCI eluted peak showed the presence of apo B-32. This peak also contained 
some apo E and Al (confirmed by Western blot analysis). 
The possibility of contamination of the apo B-32 lipoproteins with HDL containing apo E was 
investigated by 1% agarose gel electrophoresis of the isolated apo B-32 followed by 
immunoblotting with anti apo B, anti-apo A 1 and anti-apo E antibodies. Two bands of pre-J3 
mobility which reacted with the anti apo B and Al antibodies were evident (Figure 4.7a, 
lanes 2 and 3). The lack of bands in the J3 and a positions on these blots indicated that the 
isolated apo B-32 was free of any significant contamination from LDL or HDL lipoproteins. 
The more cathodal of the two apo B-32 lipoprotein bands reacted with the apo E antibody 
(lane 4). Immunoblotting with the 2D8 monoclonal antibody whose epitope lies beyond the 
1449 amino acids ofapo B-32 showed a signal indicating some contamination from LDL apo 
B degradation. Further two-dimensional analysis of the isolated apo B-32 (figure 4.7b) 
showed only very slight contamination from LDL apo 8 breakdown. The isolated apo 8-32 
fraction shown above was subjected to chemical composition and particle size analysis. 
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Figure 4.6 Heparin-Sepharose elution profile of patient HDL (d=1.075-1.291 glmL) and electrophoresis of eluted fractions. HDL 
(2mL) was applied to the column and the unbound fraction (A) eluted in 50mM TrisIHCI (pH 7.4), 10mrn sodium citrate. The bound fraction (B) 
was eluted with a 0.5M NaCI gradient. The apoprotein composition of the eluted peaks was determined by SDS PAGE electrophoresis on a 3-
15% gel (shown in inset). Lane N, HDL from normal subject; lane P, HDL from apo B-32 patient; lane A, peak A (unbound fraction) ; lane B, 
peak B (bound fraction) . 
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Figure 4.7a Agarose gel electrophoresis and Western blotting of isolated apo 8-32 
lipoproteins. Lane 1 is a 3.IL plasma control incubated with both a polyclonal anti-apo B 
antibody and an anti-apo A 1 antibody to identifY the position of the various lipoprotein 
classes. Lanes 2- 5 are loaded with approximately 3~g of isolated apo B-32. Lane 2 was 
incubated with a polyclonal anti-apo B antibody; lane 3, an anti-apo A 1 antibody; lane 4, an 
anti-apo E antibody; lane 5, a monoclonal anti-apo B antibody which binds to an epitope 
beyond apo 8-32. 
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b Two-dimensional analysis of isolated apo 8-32 lipoproteins. Isolated apo B-
32 lipoproteins (approximately 3.lg) was electrophoresed in 1% agarose (1) then taken into 
the second dimension by SOS PAGE in a 3- 10% mini-gel (2). 80th gels were western 
blotted and probed with an anti-apo 8 antibody. The arrow indicates the apo 8-32 protein. 
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4.8 Chemical composition of apo B-32 lipoproteins 
The chemical composition of isolated apo B-32 particles is compared with normal lipoprotein 
classes in table 4.4. Cholesterol, triglyceride, phospholipid and protein analysis of normal 
VLDL, LDL and HDL showed their composition to be comparable to literature values. The 
chemical composition of the isolated apo B-32 lipoproteins was most similar to HDL 
lipoproteins since protein was high (40%) and triglycerides low (7.0%). 
Table 4.4 Percentage chemical composition of apo B-32 lipoproteins 
Lipoprotein TyPe Cholesterol Triglyceride Phospholipid Protein 
VLDL 19.4 (21.6) 50.S (49.9) 16.9 (1S.6) 12.9 (7.7) 
LDL 50.5 (47.0) 10.5 (11.2) 22.6 (22.1) 16.4 (20.9) 
HDL 24.0 (17.9) 4.S (S.O) 26.0 (22.7) 42.0 (51.9) 
B-32 19.0 7.0 24.0 40.0 
Numbers in brackets indicate reported values (Chapman, 1986) 
4.9 Particle size analysis of apo B-32 lipoproteins 
Electron microscopy of normal control lipoproteins gave particle sizes within reported normal 
ranges. Electron microscopy of isolated apo B-32 lipoproteins showed an average particle 
size intermediate between HDL and LDL with a tendency to HDL. 
Analysis of particle size distribution by measuring particle area (Figures 4.8a and b) showed a 
much wider distribution of particle sizes in the apo B-32 patients HDL than normal HDL. 
The range of particle sizes in the normal HDL (figure 4.Sa) was narrower than the range for 
patient HDL (figure 4.Sb), where greater variation was observed. 
69 
Table 4.5 Average particle size of apo 8 -32 lipoproteins 
Lipoprotein Type Average Particle Size3 (nm) 
VLDL 45 .3 (30-80) 
LDL 21.0 (18-25) 
HDL 10.7 (5-12) 
B 32 13.3 
a The diameter of 50 free standing particles were measured manually or by the MIA image 
analysis program. Numbers in brackets indicate reported ranges amongst normal lipoprotein 
types (Gotto el aI, 1986). Electron micrographs at 170000 X magnification are shown for 
each lipoprotein fraction . 
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Figure 4.8a Lipoprotein particle size distribution in normal HOL. Areas of lipoprotein 
particles were measured by electron microscopy of negatively stained HDL using the MIA 
image analysis program. These areas were plotted on a histogram to show the number of 
particles in the area range 25- \ 000 nm (particle diameter 6- 36nm). 
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b Lipoprotein particle size distribution in patient HOL. Areas of lipoprotein 
particles were measured by electron microscopy of negatively stained HDL using the MIA 
image analysis program. These areas were plotted on a histogram to show the number of 
particles in the area range 25- \ 000 nm (particle diameter 6- 36nm). 
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4.10 Precipitation of apo B-containing lipoproteins 
Treatment with four different precipitation reagents gave complete precipitation of apo B-1 00 
but only partial precipitation of apo B-32 as indicated by the presence of apo B-32 in all four 
supernatants after precipitation treatment (figure 4.9a). Both apo B-100 and some apo B-32 
were recovered in redissolved pellets (figure 4.9b) except in the pellet from heparin 
/manganese treatment which showed poor recovery ofapo B-I00. This was largely due to 
the insolubility of this pellet even after repeated heating. 
Other truncated apo B variants treated with heparin manganese or dextran sulphate showed 
differing propensities to precipitate depending on the size of the particular variant (figures 
4.10 a and b). The shortest variant (apo B-31) was largely unprecipitated while apo B-46 and 
apo B-61 were mainly precipitated by both reagents. Apo B-67 and apo B-83 appeared to be 
completely precipitated as was apo B-1 00 by both reagents. All the precipitated apoproteins 
were recovered in the redissolved pellets. 
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Figure 4.9 a Western blot of supernatant after precipitation of lipoproteins from 
patient plasma. Lane I, 5 ilL unprecipitated plasma; lanes 2- 5, plasma supernatant after 
precipitation with sodium phosphotungstate, polyethylene glycol, heparin manganese and 
dextran sulphate respectively. Loadings are equivalent to 5~ll plasma. 
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b Western blot of redissolved precipitants after precipitation of lipoproteins 
from patient plasma. Lane 1, 51lL unprecipitated plasma; lanes 2- 5, redissolved precipitants 
after precipitation with sodium phosphotungstate, polyethylene glycol, heparin manganese and 
dextran sulphate respectively. Loadings are equivalent to 5~Ll plasma. 
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Figure 4.10 a Western blot of supernatants after heparin manganese precipitation of 
lipoproteins from subjects with truncated apo B variants. Lane I, apo 8-31 ; lane 2, apo 
8-46; lane 3, apo 8-61; lane 4, apo 8-67; lane 5, apo 8 -83 . Loadings are equivalent to 5 ~lL 
of plasma. 
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b Western blot of supernatants after dextran suiphateIMgCI2 precipitation 
of lipoproteins from subjects with truncated apo B variants. Lane I, apo 8-31 ; lane 2, 
apo 8-46; lane 3, apo 8-61 ; lane 4, apo 8 -67; lane 5, apo 8-83 . Loadings are equivalent to 5 
~L of plasma. 
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4.11 peR amplification of an apo B gene fragment 
Based on the molecular weight estimation of the abnormal apo B, a fragment of the apo B 
gene (apo B cDNA nucleotides 4369-5127) was selected and amplified using peR. Analysis 
of the peR reaction on agarose electrophoresis (figure 4.11) showed a single band of about 
759 bp in the patient DNA. The same band was evident in a control DNA sample (not 
shown). 
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Figure 4.11 Agarose gel electrophoresis of peR amplified DNA encoding a 759 bp 
fragment of apo B eDNA. Lane I, peR amplified DNA from the apo B-32 subject; lane 2, I 
kb DNA molecular weight markers. 
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4.12 DNA sequencing of the apo B peR fragment 
Direct DNA sequencing was performed on the 759 bp apo B gene PCR product from the 
subject and a normal control. Sequencing revealed a single C---+ T transition of nucleotide 
4548 of the coding sequence (figure 4.12). This mutation changes the CAG codon for 
glutamine 1450 to an in-frame stop codon (TAG). As a result, a truncated apo B species (apo 
B-32) is generated which is predicted to contain the amino-terminal 1449 amino acids of apo 
B-100. Apo B-32 has a calculated molecular weight of 164160. 
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Figure 4.12 DNA sequencing gels showing the mutation responsible for apo B-32. The 
relevant region of the apo B gene in a normal control (A) and the apo B-32 subject (B) was 
enzymatically amplified and subjected to direct DNA sequencing. Both a C and T (marked by 
an asterisk) can be seen at apo B DNA nucleotide 4548 in the subject's DNA. In the 
abnormal allele, a C---+ T transition converts a codon for glutamine (CAG) into a premature 
stop codon (TAG). 
4.13 Cloning of the PCR product and Southern blot analysis 
The PCR amplified apo B gene fragment shown in figure 4.11 was cloned into the pUC 19 
plasmid. Figure 4.13 shows the presence of both the apo B insert (750 bp) and pUC 19 (2.7 
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kb) after PstUXbaI digestion in 9 positive clones (lanes 2-10) identified by the disruption of [3-
glucosidase activity. A negative (blue colony) clone contained only the pUCI9 plasmid (lane 
II). The same agarose gel was blotted and probed with allele specific probes for the wild 
type and mutant alleles. The resultant Southern blot is also shown in figure 4.13 . Six out of 
the nine clones carried the mutant B-32 allele, while three carried the normal apo B-1 00 allele. 
Two of each were sequenced to confirm this finding. The sequence ofa negative clone (A) 
carrying the normal allele and a positive clone (B) containing the mutant apo B-32 allele is 
shown in figure 4. 14. 
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Figure 4.13 Agarose gel electrophoresis of the cloned apo B PCR fragment in the 
pUC19 vector. Lane I, <j>X1741HaeIII DNA molecular weight markers; lanes 2- 10, 
PstUXbaI digested DNA from 9 white colony clones; lane II, PstUXbaI digested from a blue 
colony clone containing pUC 19 only. Below is an autoradiograph of the same clones 
analysed by allele specific hybridisation to B32-1 (1), a probe with the normal sequence at the 
B-32 position and B32-2 (2), a probe with the mutant C--+ T transition at the B-32 position. 
Six out of the nine clones carried the mutant apo B-32 allele. 
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Figure 4.14 DNA sequencing gels of the cloned apo B peR fragment. Panel A shows the 
sequence of a nonnal clone with the nonnal CAG codon while panel B shows the sequence 
of a mutant clone carrying the mutant TAG stop codon. 
4.14 Allele specific probing 
In order to confinn the DNA sequence, PCR amplified DNA from the subject and controls 
was hybridized to allele-specific probes (figure 4. 15). The results showed that the subject's 
DNA hybridized to both the nonnal apo 8-32-1 probe and the mutant apo 8 -32-2 probe 
confinning that he was heterozygous for the apo 8-32 mutation. The amplified DNA was 
also probed with allele-specific oligonucleotide probes for the nonnal and mutant apo 8-3 I 
sequences (probes 8-31 -3 and 8-31 -4).This confirmed the specificity of these probes for the 
mutant sequences. 
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Figure 4.15 Binding of allele-specific oligonucleotide probes for the apo B-31 and apo 
B-32 mutations to amplified DNA. B31, B32 and N are DNA amplified from an apo B-31 
expression vector, the apo B-32 subject and a normal control respectively. Probes 8 31-3 
and B 31 -4 are allele-specific oligonucleotides for the apo B-3 I normal and apo 8 -31 mutant 
sequences. Probes 8 32- 1 and 8 32-2 are allele-specific oligonucleotides for the apo 8-32 
normal and apo 8-32 mutant sequences. 
4.15 Production of an apo 8-32 expression vector 
Figure 4.16 shows the HpaI digests of the pB42 plasmid DNA of seven clones from the 8-32 
mutagenesis reaction. Five of the seven clones showed uncut plasmid DNA while DNA from 
two clones (lanes 2 and 4) appeared to have been digested by HpaI as indicated by the 
presence of a single band of around 11 kb . 
The same uncut plasmid DNA from five clones was sequenced to check for the presence of 
the C~ T transitions in the B-32 mutation. Figure 4.17 represents sequencing data showing 
only the C and T dinucleotides. Three out of five uncut p842 plasmids from 8-32 
mutagenesis had the 8-32 mutation. Sequencing of a further five plasmids showed four more 
mutants indicating an efficiency of the USE mutagenesis method of around 60-80%. The 
mutant plasmid was designated pB32. Figure 4.18 shows the full sequence of the pB32 
plasmid alongside the original pB42 vector on which mutagenesis was performed . 
... 13kb 
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Figure 4.16 Agarose gel electrophoresis of pB42 DNA after USE mutagenesis to 
introduce the B-32 mutation. Lanes 1-7, DNA from seven clones after 16 hr digestion with 
Hpar; lane 8, I kb DNA molecular weight markers. Five of the seven clones appear to posses 
uncut DNA while the pB42 DNA from two clones (lanes 2 and 4) appears linear. 
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Figure 4.17 Sequencing gels (C and T lanes only) of clones yielding uncut DNA after 
mutagenesis. The arrow indicates the base at which the C-tT transition occurs in the B-32 
mutation. Three out of the five clones possessed the B-32 mutation. N indicates a clone with 
the normal sequence at the B-32 position. M indicates a mutant clone with the B-32 
mutation. 
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Figure 4.18 DNA sequencing gel of the mutant pB32 apo B expression vector. The 
sequence of the original pB42 expression vector on which B·32 mutagenesis was performed is 
also shown. The arrows indicate the posi tion of the C to T transition which occurs in pB32. 
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4.16 Western blot analysis of expressed lipoproteins 
4.16.1 Identification ofMcA-RH7777 cell line clones expressing apo B-32 and 
apo B-42 
A rat hepatoma cell line McA-RH7777 was transfected with the pB32 and pB42 apo B 
expression vectors. The media from the cells was analysed by Western blotting to identify 
those clones expressing the human apo B-32 and apo B-42 proteins. Figure 4.19a shows a 
Western blot of the media from three pB32 transfected (lanes 2--4) and four pB42 transfected 
cell lines (lanes 5-8). The blot was incubated with a polyclonal anti-human apo B antibody 
which also reacts with the endogenous rat apo B. Both the rat apo B-IOO and B-48 proteins 
are present as well as some breakdown products from rat apo B-IOO. The expressed apo B-
32 from the cell line in lane 2 is the same size as the apo B-32 in the plasma of the apo B-32 
subject (lane 1). The expressed apo B42 (lanes 5 and 7) was also of the correct size. Probing 
of the same blot with the monoclonal anti-human apo B antibody 101 (figure 4.19b), which 
does not cross react with rat apo B, confirmed the identity of the expressed human apo B 
proteins. The growth of the cell lines shown in lanes 2 and 5 were scaled up and the media 
subjected to density distribution analysis to determine the density of the expressed apo B-32 
and apo B-42 lipoproteins. 
4.l6.2 Density distribution of the expressed apo B-32 and apo B-42 lipoproteins 
Lipoproteins were fractionated from the media of both an apo B-32 expressing and apo B-42 
expressing cell line by density ultracentrifugation to obtain the four fractions, VLOL 
(d<1.006), LOL (d=1.006-1.063), HDL (d=1.063-1.2I) and d>1.21. Western blot analysis 
of these fractions (figures 4.20a and 4.20b) showed the expressed apo B-32 to be exclusively 
in the d>1.21 fraction while the apo B-42 was found in both the HDL and d>1.21 fraction, the 
majority being in the d> 1.21 fraction. 
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Figure 4.19a Western blot analysis of McA-RH7777 cell media with a polyclonal anti-
apo B antibody. Lipoproteins in I mL of media from pB32 and pB42 transfected cells were 
absorbed with fumed silica then subjected to SDS PAGE and immunoblotting. Lane I is a 
plasma sample from the subject with the apo B-32 variant; lanes 2-4, media from three pB3 2 
transfected cell clones; lanes 5-8, media from four pB42 transfected cell clones. The blot was 
incubated with a polyclonal anti-human apo B antibody which also reacts with the 
endogenous rat apo B- 1 00 and apo B-48. 
b Western blot analysis of McA-RH7777 cell media with a monoclonal anti-
apo B antibody. The same blot described in figure 4.19a was incubated with the monoclonal 
anti-apo B antibody ID I which reacts with human apo B only. 
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Figure 4.20a Density distribution of expressed apo 8-32. The various lipoprotein classes 
were fractioned rrom the media of an apo 8-32 expressing cell line by density 
ultracentrifugation. Lipoproteins were absorbed with fumed silica and subjected to SDS 
PAGE and immunoblot analysis. Lane I, whole media; lane 2, VLDL (d< I .006); lane 3, LDL 
(d=1.006-1.063); lane 4, HDL (d=1.063- 1.2 I); lane 5, d>1.21. The blot was incubated with 
the monoclonal anti-human apo 8 antibody 101 which only reacts with human apo B. 
b Density distribution of expressed apo 8-42. The various lipoprotein classes 
were rractioned from the media of an apo 8-42 expressing cell line by density 
ultracentrifugation. Lipoproteins were absorbed with fumed silica and subjected to SDS 
PAGE and immunoblot analysis. Lane I, whole media; lane 2, VLDL (d<1.006); lane 3, LDL 
(d=1.006- 1.063); lane 4, HDL (d=1.063- 1.21); lane 5, d>1.21. The blot was incubated with 
the monoclonal anti-human apo 8 antibody ID 1. 
4.16.3 The effect of oleic acid supplementation on density distribution of 
expressed lipoproteins 
Supplementation of the media with I mM oleic acid did not have any effect on the density 
distribution of the apo 8-32 protein which remained in the d> 1.21 fraction (not shown). It 
did however increase the proportion of apo 8 -42 in the HDL compared to the d> 1.21 
fraction. Figure 4.21a shows the density distribution ofapo 8-42 before (I) and after (2) 
supplementation of the media with I mM oleic acid. The density distribut ion of the 
endogenous rat apo 8 - 100 was also altered after supplementation with oleic acid. Figures 
4.21b shows the density distribution of the rat apo 8 -100 before (I) and after (2) 
supplementation with oleic acid in a cell line expressing apo 8-32. In both this and the apo 8 -
42 expressing cell line (not shown) the proportion of rat apo 8-100 in the VLDL compared to 
the LDL fraction was increased by oleic acid supplementation. 
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Figure 4.21a The effect of oleic acid supplementation on the density distribution of 
expressed apo B-42. The various lipoprotein classes were fractioned by density 
ultracentrifugation from the media of an apo B-42 expressing cell line before (I) and after (2) 
supplementation of the media with I mM oleic acid . Lipoproteins were absorbed with fumed 
silica and subjected to SDS PAGE and immunoblot analysis. Lane I , whole media; lane 2, 
VLDL (d< l.006); lane3, LDL (d= l.006- 1.063); lane 4, HDL (d= 1.063- 1.21); lane 5, 
d> 1.21 . The blots were incubated with the monoclonal anti-human apo B antibody I D I . 
b The effect of oleic acid supplementation on the density distribution of rat 
apo B-I00. The various lipoprotein classes were fractioned by density ultracentrifugation 
from the media of an apo B-32 expressing cell line before (I) and after (2) supplementation of 
the media with I mM oleic acid. Lipoproteins were absorbed with fumed si lica and subjected 
to SDS PAGE and immunoblot analysis. Lane I, whole media; lane 2, VLDL (d<1.006); lane 
3, LDL (d= 1.006- 1.063); lane 4, HDL (d= 1.063- 1.21); lane 5, d> 1.21. The blots were 
incubated with a polyclonal anti-human apo B antibody which reacts with endogenous rat apo 
B-IOO. 
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CHAPTER 5 DISCUSSION 
5.1 Reiteration of aims 
The initial aim of this thesis was to focus on subjects with low LDL cholesterol levels in order 
to investigate any linkage between the hypobetalipoproteinaemia and the apo B gene. Five 
subjects that had low LDL cholesterol and apo B levels were initially identified. From these it 
was demonstrated that one of the cases of hypo bet alipoproteinaemi a was due to a defect in 
the apo B gene. This was established when inununoblot analysis of the subject's plasma 
revealed a truncated species of apo B approximately one third the normal length of apo B-
100. The focus was then on characterisation of the defective protein and the exact defect 
causing the truncation. Once this was established the role of the defective apo B (apo B-32) 
in the formation of lipoproteins was investigated by characterisation of the lipoproteins 
formed with the apo B-32 variant. 
This type of investigation was directed towards providing more information about the 
structural properties of the large apo B protein since naturally occurring variants of apo B 
(and other proteins) have in the past provided important structural information. Although a 
number of truncated apo B variants have now been reported, information is lacking on the 
type of lipoproteins formed with each variant and their metabolism. It was expected that 
characterisation of the apo 8-32 lipoproteins would give more insight as to the possible 
metabolism of lipoproteins made with shorter variants ofapo B. 
5.2 Subjects studied 
The subject on which this thesis was based was originally investigated because he had very 
low levels of plasma apo Band LDL cholesterol (20 and 31mgldL respectively). These 
concentrations of apo Band LDL cholesterol were similar to those seen in heterozygous 
hypobetalipoproteinaemia patients (Farese et ai, 1992). The LDL cholesterol and apo B 
levels in the only available relatives to the subject were relatively normal hence the familial 
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nature of the hypobetalipoproteinaemia in this case could not be demonstrated. This was not 
surprising since the number of relatives was small and the relationship distant. There were no 
clinical signs of fat malabsorption in the subject and serum levels of the fat-soluble vitamins 
were normal. It was noted that the subject had a high HDL cholesterol level in association 
with a high level of apo AI. High HDL levels have previously been reported in 
hypobetalipoproteinaemia heterozygotes (Young et ai, 1989; Young et ai, 1990; Welty et al 
1991). The mechanism behind this association has not been established. 
The other four subjects studied all had low total and LDL cholesterol levels indicative of 
heterozygous hypobetalipoproteinaemia. Although no clinical signs of fat malabsorption were 
observed in these individuals, their low vitamin A and E status in some cases suggested 
impaired intestinal absorption of the fat soluble vitamins. Western blot analysis of these 
patients however did not reveal any truncated apo B. Other possibilities for the cause of the 
hypobetalipoproteinaemia observed in these subjects include: 
1. A truncated apo B of less than 30% the amino-terminal length of apo B-1 00 which would 
not be observed in plasma since apo B-29 and smaller variants are not secreted into plasma 
(Collins et ai, 1988; Huang et ai, 1989). 
2. A defect in a non-coding region of the apo B gene controlling expression which reduces 
the amount of full length apo B-100. 
3. The hypobetalipoproteinaemia is not linked to the apo B gene and may be due to a defect 
in another protein involved in the lipoprotein metabolism pathway. There have been reports 
of hypobetalipoproteinaemia within families where the low cholesterol levels have not 
co segregated with polymorphic markers on the apo B gene (Hobbs et ai, 1989; Fazio et ai, 
1991). 
4. The hypobetalipoproteinaemia is from a non genetic cause such as liver malfunction. This 
was certainly a possibility for one of the subjects who was in hospital for liver function tests at 
the time his hypobetalipoproteinaemia was diagnosed. 
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Detailed family studies would have to be performed on these individuals and family members 
in order to investigate the above possibilities. 
5.3 Identification and characterisation of apo B-32 
During this study a new truncated apo B species (apo B-32) in an individual with 
heterozygous hypobetalipoproteinaemia was identified. The truncated apo B was initially 
detected by immunoblot analysis of whole plasma which showed an abnormal apo B of 
slightly higher molecular weight than apo B-31. The molecular weight estimate of 165 kDa 
corresponded to the truncated apo B being about 3 1.9% the length of normal apo B-1 00 
hence the truncated apo B was named apo B-32. 
5.3.1 Reaction with three monoclonal anti-apo B antibodies 
The apo B-32 protein was characterised further using monoclonal antibodies which bind to 
different epitopes of the apo B-I00 protein. The reaction ofapo B-32 with the MB3 antibody 
and not the MB44 antibody demonstrated that the amino-terminus and not the carboxy-
terminus was intact. Immunoblot analysis also showed that the 208 antibody, which is 
thought to bind around apo B-I00 amino acids 1403 to 1480 (Pease et aI, 1990), failed to 
react with apo B-32. The apo B-31 variant (Young et aI, 1990) did not bind to 208 either, 
suggesting that the binding epitope for 208 was beyond amino acid 1425 ofapo B-100. Thus 
the lack of 208 reaction with apo B-32 suggests that the binding epitope for 208 is on the 
carboxy-terminal side of amino acid 1449 ofapo B-100. The apo B-32 protein has therefore 
been useful in more narrowly defining the binding epitope for the 208 monoclonal anti apo-B 
antibody. 
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5.3.2 Density distribution. 
Lipoprotein fractionation from plasma showed the apo B-32 protein to be largely in the HDL 
fraction (d=1.063-1.21 g/mL). Since apo B-I00 is only present in the more buoyant VLDL 
and LDL fractions this suggested that an abnormally dense particle was being made. A small 
amount of the apo B-32 protein was also detected in both the LDL (d=1.006-1.063) and 
d> 1.21 fractions. The density distribution of apo B-32 is unique since it is the shortest known 
apo B molecule to be found in the LDL density range. The presence of apo B-32 in LDL was 
checked by double ultracentrifugation of the d= 1. 006-1. 063 fraction to reduce the possibility 
that the apo B-32 detected on Western blotting ofLDL did not originate from contaminating 
HDL. 
5.3.3 Lipid binding properties 
Together with the information provided by the apo B-31 variant (1425 amino acids, Young et 
ai, 1990), the finding of apo B-32 amongst the lipoprotein fractions suggests that an amino-
terminal sequence of approximately 1425 amino acids provides the critical length ofapo B 
required for the formation and secretion of apo B-containing lipoproteins. In contrast, the 
apo B-29 species found by Collins et al (1988) was not found in plasma suggesting that the 
apo B-29 protein is shorter than the critical length required for lipoprotein formation. 
Alternatively it was suggested that the absence of apo B-29 from plasma may have been due 
to either impaired secretion or rapid clearance of any lipoprotein particle formed. The finding 
of apo B-32 on a lipoprotein particle adds weight to the fact that the amino-terminus of apo B 
may be important in the formation of lipoprotein particles. A study by Herscovitz et al (1991) 
suggests that even the amino-terminal 17% of apo B is important for the formation of 
lipoproteins. A major structural feature of the amino-terminus of apo B is the high content of 
cysteine residues which are associated with a high degree of cross linkage. It may be that this 
structural feature is important in the formation and/or stabilisation of lipoprotein particles. It 
is likely however that other regions of apo B such as the mid-region or the carboxy-terminal 
region identified by Xiong et al (1991) are important in lipoprotein formation also. 
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5.3.4 Role in the fonnation ofLDL 
Since apo B-31 (1425 amino acids) was not detected in LDL, apo B-32 (1449 amino acids) 
is the shortest known apo B molecule capable of forming particles in the LDL density range. 
Although it is hard to visualise why the addition of an extra 24 amino acids of apo B allows 
the formation of these particles, it is possible that the region around amino acid 1449 is 
critical for the formation of a lipid binding domain. Yang et al (1989a) have analysed the 
structure of apo B-1 00 by tryptic digestion and subsequent separation of trypsin-releasable 
and trypsin-nonreleasable peptides. Amino acid 1449 is at the end of a large trypsin-
releasable peptide which does not appear to be directly associated with lipid. However this 
trypsin-releasable peptide follows a trypsin-nonreleasable peptide which is thought to be lipid 
associated. In view of the findings of this study it seems possible that the extra amino acids 
are required to give the appropriate conformation for lipid binding and lipoprotein particle 
formation. Thus apo B-31 which terminates immediately after this putative lipid associated 
peptide, may be unable to form LDL even though apo B-32 , which contains only a further 24 
amino acids forms at least some LDL. 
Recent work by Xiong et al (1991) suggests that it is a region in the carboxy-terminus that is 
important for the formation ofLDL. Expression of a carboxy-terminal region of apo B-I00 in 
transgenic mice and the finding of the expressed protein exclusively in the LDL density 
fraction suggested that this region of apo B (amino acids 2878-3925) must be important for 
LDL formation. However there was no evidence that the expressed apo B protein was. 
forming its own discreet particles which leaves the possibility that it could have been 
associating with pre-existing mouse LDL. 
In summary, it seems the apo B-32 protein has defined an important lipid binding region of 
the apo B molecule. Hopefully, the critical length ofapo B required for the formation ofLDL 
particles will be further defined by studies of the lipoproteins in other patients with different 
mutations in this region. 
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5.3.5 Heparin binding characteristics of apo B-32: comparisons with apo E 
The apo B-32 protein does bind heparin as demonstrated by its isolation by heparin-Sepharose 
chromatography. It was also demonstrated that the apo B-32 protein has a greater affinity for 
heparin than does the apo E protein. The apo E-containing HDL particles in the apo B-32 
subject were only just retarded by the heparin column whereas the apo B-32 containing 
lipoproteins were eluted by N aCI at a concentration of O. 1 M using a N aCl gradient. The apo 
E protein has two heparin binding sites, only one of which reacts with heparin when the apo E 
is associated with lipid (Weisgraber and Rail, 1987). The apo B-32 protein contains three of 
the seven heparin binding sites in apo B-100 predicted by Weisgraber and Rail (1987). The 
difference in heparin affinity between apo B-32 and apo E is probably due to the two extra 
binding sites in apo B-32. This study indicates that the first three predicted heparin binding 
sites from the amino-tenninus in apo B-1 00 are active in binding heparin. 
5.4 The apo B-32 mutation 
DNA sequencing showed that the mutation involved was a C----+ T transition in exon 26 at apo 
B cDNA nucleotide 4548. This mutation was confinned when PCR amplified DNA from the 
subject was shown to hybridise to an allele-specific oligonucleotide (B32-2) containing the 
C----+T transition. This·mutation introduces a stop codon which causes premature termination 
ofrnRNA translation and the generation ofa truncated apo B protein. Apo B-32 is predicted 
to be 1449 amino acids in length, with a calculated molecular weight of 164 160. This 
corresponds with the molecular weight estimate of apo B-32 derived from SDS-PAGE. 
The latest review on apo B gene mutations by Farese et al (1992) records 21 mutations, 
including the apo B-32 mutation, that result in truncated apo B proteins. The majority of 
these mutations (12) are deletions of one or more nucleotides leading to an out of frame stop 
codon. The nine remaining mutations are due to single base changes to stop co dons, the 
majority of which are C----+T transitions at CGA codons. There are 12 CGA codons in the apo 
B rnRNA, 5 of which have been associated with C----+ T transitions causing truncated apo B 
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variants. The C~ T transition that occurs in the apo B-32 mutant occurs at a CAG codon as 
does the mutation in the apo B-50 variant (Hardman et ai, 1991). There are many more CAG 
than CGA codons in the apo B mRNA, 121 in total. This suggests that the CGA codon is far 
more susceptible to mutation than the CAG codon. In humans 35% of single base 
substitutions in coding sequences which cause genetic disorders are due to C~T or G~A 
transitions within CpG dinucleotides (Cooper and Youssofian, 1988). It has been 
demonstrated that the cytosine in CpG diI~.Jcleotides is methylated at the 5'position and that 
this modification makes the cytosine very susceptible to deamination to form a thymidine 
hence explaining the high frequency ofC~T transitions in CGA codons (Cooper and 
Y oussofian, 1988). The remaining 7 CGA and 119 CAG co dons still provide ample 
opportunity for single base mutations to form stop co dons within the coding sequence of the 
apo B gene. In time more of these mutations causing truncated apo B variants should be 
discovered. 
5.5 Characterisation of apo B-32 lipoproteins 
Apart from the apo B-37 lipoproteins characterised by Young et al (1987a) the majority of 
lipoproteins formed from truncated apo B variants have only been characterised on their size 
and density. Information about the electrophoretic mobility and chemical composition of 
these lipoproteins is lacking. In addition there has been no investigation of the precipitation 
characteristics of these lipoproteins to date. 
5.5.1 Density distribution 
As discussed in section 5.3.2 the majority of the apo B-32 lipoproteins had a density similar to 
that of normal HDL (d=1.063-1.21). The presence ofapo B-32 in the LDL (d=1.006-.-1.063) 
and d>1.21 fraction indicated that the apo B-32 lipoproteins had a wide density distribution. 
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5.5.2 Electrophoretic mobility 
Agarose gel electrophoresis of the apo B-32 lipoproteins in plasma showed the particles to 
have a pre-~ mobility similar to that of normal VLDL. This is in keeping with the lipoproteins 
made with the similar sized apo B-31 and apo B-37 variants (Young et ai, 1987a; Young et al 
,1990). The apo B-32 lipoproteins isolated by heparin-Sepharose chromatography had the 
same pre-~ mobility. 
5 .5.3 Particle size 
The average particle size of the apo B-32 lipoproteins isolated from HDL were approximately 
2.3 nm bigger than that of the normal HDL particles. Young et al (1987a) found the apo B-37 
lipoproteins to be 3.5 nm bigger than normal HDL particles. Results from non-denaturing gel 
electrophoresis of the apo B-31, B-37 and B-46 variants (Young et al, 1990) demonstrated 
that the bigger the truncated apo B variant, the bigger the lipoprotein particles formed with 
the variant. The presence of a larger than normal lipoprotein particle in the patients HDL, 
although at low concentration, would be expected to increase the particle size heterogeneity 
ofHDL. This was confirmed by the abnormally wide distribution of particle sizes seen in the 
HDL of the apo B-32 subject compared with a normal HDL sample. 
5.5.4 Chemical composition 
The chemical composition of the apo B-32 lipoproteins was similar to normal HDL being high 
in protein and phospholipids and low in triglyceride and cholesterol. The apo B-32 
lipoproteins did however contain slightly more lipid and less protein than normal HDL. The 
low lipid to protein ratio of the apo B-32 particles would explain their presence in such a high 
density class. The composition of apo B-32 particles was similar to that of the apo B-37 
particles characterised by Young et ai, (1987a) which also had a chemical composition similar 
to that ofHDL. 
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The low lipid to protein ratio of the apo B-32 particles would also explain the lack of full 
precipitation by the apo B-32 particles when treated with the polyanionlcation reagents which 
normally precipitate apo B containing particles. The propensity of a lipoprotein particle to 
precipitate is governed by its lipid to protein ratio (Burstein and Scholnick, 1973). Particles 
with low lipid to protein ratios, such as HDL particles, are not precipitated by the 
polyanionlcation reagents. That is, the greater the lipid to protein ratio the greater the 
propensity of the lipoprotein particle to precipitate. This was demonstrated by the 
precipitation of plasma lipoproteins from plasma samples of subjects with apo B variants of 
varying length. Generally, those apo B variants nearer to full size such as apo B-67 and apo 
B-83 behaved as apo B-1 00 in that they were fully precipitated by the polyanionlcation 
reagents. Shorter variants such as apo B-31 and apo B-32 were only partially precipitated. 
The apo B-46 variant was almost completely precipitated. This variant was found in the more 
buoyant LDL and VLDL fractions in plasma (Young et ai, 1989) suggesting that it binds 
more lipid than the apo B-31 and apo B-32 variants which were found in the denser HDL and 
d> 1.21 g/mL plasma fractions. It seems that the amino-terminal half of apo B binds enough 
lipid to form particles capable of being partially precipitated by the reagents used to 
precipitate the normal apo B-1 00 containing LDL and VLDL particles. In general as the apo 
B molecules increase in length, the propensity of the lipoproteins formed from these 
molecules to precipitate increases, suggesting that with increasing length of apo B lipid 
binding capacity is increased. This is in keeping with results from studies that show that the 
apo B-1 00 has lipid binding regions throughout its structure (Yang et ai, 1989a). 
5.5.5 Apolipoprotein composition 
The apo B-32 lipoproteins seemed to contain a small amount of the Al and E apolipoproteins 
identified by SDS PAGE and subsequent staining of the isolated apo B-32 preparation with 
Coomassie blue. This result was confirmed by Western blot analysis with both the apo Al 
and E antibodies. Agarose gel electrophoresis and western blotting with the apo Al and E 
antibodies confirmed that the presence of the A I and E apolipoproteins was not a 
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consequence of contaminating HDL. Small amounts of the Al and E apolipoproteins were 
also present on the apo B-37 lipoproteins characterised by Young et ai, (1 987a). Both the Al 
and E apoproteins are readily exchanged between lipoprotein particles in circulation. Whether 
the apo Al and apo E are secreted on the apo B-32 lipoproteins or whether they are added 
once in circulation is not known. 
5.6 Metabolism of apo B-32 and other truncated apo B lipoproteins 
Apo B-32 was found in very low concentrations in plasma. This was first evident on protein 
staining of the subject's HDL fraction and was subsequently apparent during isolation of apo 
B-32 lipoproteins from plasma, and protein concentration analysis. The extremely low 
concentration of apo B-32 is in keeping with observations made on other truncated variants 
(Young et ai, 1990). The basis for the low plasma levels of truncated apo B variants has not 
yet been fully investigated. Expression of truncated variants in cell culture has shown the 
secretion rates of these variants to be normal (Yao et ai, 1991). This suggests that either the 
synthesis or catabolism of lipoproteins made with the truncated apo B is abnormal. 
It has been well documented that the near full length truncated apo B variants, which have the 
LDL receptor binding region, compete with apo B-1 00 for the LDL receptor and are 
catabolised by this pathway (Gabelliet ai, 1989; Parhofer et ai, 1990; Parhofer et ai, 1992). 
As yet no one has identified any catabolic pathway for lipoproteins made from the shorter apo 
B variants without LDL receptor binding characteristics. It has been demonstrated that 
shorter variants do not compete with apo B-lOO for the LDL receptor (Young et ai, 1987b). 
Either the lipoproteins made with the truncated apo B species remain in plasma or are 
catabolised by an alternate pathway. Our characterisation of the apo B-32 particles has 
shown the presence of both A 1 and E apolipoproteins on the particles. The remnant 
clearance pathway, which metabolises chylomicron and VLDL remnants by the reaction of 
apo E with its receptor, may therefore be a possible pathway for the metabolism of apo B-32 
lipoproteins. The HDL clearance pathway, which involves metabolism of plasma HDL by 
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interaction of apo Al with the HDL receptor on liver cells, is also a possible clearance 
pathway for apo B-32 lipoproteins. This study did not directly address the question of apo B-
32 lipoprotein metabolism but it is hoped that a further study as outlined in chapter 6 will 
provide more information. 
5.7 Expression of apo B-32 in cell culture 
After introduction ofthe apo B-32 mutation into an apo B expression vector (pB42), the 
resultant vector (pB32) was used to transfect a rat hepatoma cell line McA-RH7777. This 
particular cell line has been used previously in studies expressing truncated apo B variants. It 
was originally chosen over the human hepatoma cell line HepG2 because McA-RH7777 cells 
have a greater capacity to secrete triglyceride-rich VLDL particles (Tanabe et ai, 1989). 
HepG2 cells secrete particles that are LDL-like in density, size and composition (Bostrom et 
ai, 1988). Consequently it was thought that a wider range of particles could be made from 
various lengths of apo B in McA-RH7777 cells since the apo B-1 00 containing lipoproteins 
secreted by these cells seemed more akin to those in rat and human circulation. 
The apo B-32 protein expressed by the McA-RH7777 cells was identical in size to that found 
in plasma, indicating that the protein had been processed correctly by the cell line. Apo B-32 
has four of the apo B-100 glycosylation sites (Yang et ai, 1989a), all of which are utilised. If 
the glycosylation of apo B-32 in McA-RH7777 cells had been impaired, a difference in the 
molecular weight between expressed apo B-32 and plasma apo B-32 would have been 
observed. The expressed apo B-42 protein was also of the correct size. The reaction of apo 
B-32 and apo B-42 proteins with the monoclonal anti-human apo B antibody IDl, which 
binds to an epitope between apo B-100 amino acids 474 and 539 (Pease et ai, 1990), 
confirmed the identity of both proteins. 
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5.7.l Density distribution of the expressed apo B-32 and apo B-42 
The density distributions ofapo B-32 and apo B-42 did not parallel that seen in the circulation 
of subjects with the same or similar length apo B species. Wherea,s apo B-32 was found 
mainly in the HDL of the apo B-32 subject, the apo B-32 when expressed in McA-RH7777 
remained largely in the d> 1.21 fraction. Similarly, although an apo B-40 variant was found 
mainly in the VLDL and LDL fractions, when expressed in McA-RH7777 cells, the larger apo 
B-42 protein was found mostly in the denser HDL fraction. The fact that both apo B species 
exhibited their own characteristic density suggested that each was forming their own 
char~cteristic lipoprotein particle rather than associating with any pre-existing lipoprotein in 
the media. Since apo B-32 was in the d> 1.21 fraction and apo B-42 in the HDL it was 
apparent that the apo B-42 protein bound significantly more lipid than apo B-32. Expression 
of apo B-32 and apo B-42 and subsequent density distribution studies revealed that as the 
length of apo B increased, the density of the lipoproteins formed decreases. This is in 
agreement with the results from other expression studies (Yao et ai, 1991; Graham et ai, 
1991; Spring et ai, 1992). That is, the longer the variant the more buoyant the lipoprotein 
made with the variant. 
It is apparent from this and other studies that the lipoprotein particles assembled and secreted 
from ,cultured McA-RH7777 cells are denser than those found in the circulation of affected 
individuals. Yao et al (1991) expressed a range of truncated apo B species of varying length 
in McA-RH7777 cells including the naturally occurring apo B-37 variant. Although found in 
the VLDL, LDL and HDL of the affected subject, apo B-37 when expressed in McA-RH7777 
cells was only found in the HDL and d> 1.21 fraction. Even the endogenous rat apo B-48 was 
found in the HDL density range in this study. In summary it was not possible to reproduce 
the density distribution of apo B-32 seen in plasma by expression studies to confirm the 
importance of apo B-32 in forming particles in the LDL density range. This was largely due 
to the fact that the rat hepatoma cell line used in this study was not very efficient at 
assembling buoyant lipoproteins from shorter forms of apo B. The reason for this is unclear. 
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5.7.2 Effect of oleic acid supplementation 
Since initially, a significant proportion of the apo B-42 protein was located in the d>1.21 
fraction, it was suspected that the cells may have been deficient in fatty acids. The lack of 
endogenous rat apo B-1 00 in the VLDL fraction also suggested an impairment in the 
secretion of the more triglyceride-rich particles. Supplementation of the media with 1 mM 
oleic acid did significantly increased the amount of rat apo B-1 00 appearing in VLDL. The 
increase in the lipid content of the cell after supplementation was apparent by the presence of 
large lipid droplets in the cytoplasm ofMcA-RH7777 cells. Oleic acid supplementation also 
increased the proportion of apo B-42 in the HDL fraction leaving only a small amount of apo 
B-42 associated with the d> 1.21 fraction. Similar results were obtained by White et al (1992) 
in McA-RH7777 cells expressing apo B-36 and apo B-48. A shift to a lower density range 
was shown by both expressed proteins, after supplementation of the media with 0.8mM 
oleate. Supplementation with oleic acid had no effect on the density distribution of apo B-32 
which remained in the d>1.21 fraction. This is not surprising given that the apo B-32 
lipoproteins characterised in this thesis were triglyceride-poor. That is, it would be expected 
that supplementation with oleic acid would only have an effect on apo B lipoproteins 
containing significant amounts of triglyceride. 
5.8 Conclusions 
A new truncated apo B variant was identified during this investigation. The defect causing 
the new variant was found to be a C~ T transition changing the CAG codon coding for amino 
acid 1450 to a stop codon. At the time of discovery ofapo B-32 there were seven reported 
mutations in the apo B gene causing truncations of various lengths ofapo B. However, an 
increased focus on individuals with low cholesterol and apo B, the majority of which exhibit 
no clinical symptoms, has led investigators to identify a number of mutations causing 
truncated apo B variants over the past 2-3 years. These mutations are therefore more 
common than was first believed. 
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Some of the reported truncated variants have enhanced our knowledge on the structure of 
the large apo B-lOO protein, mainly in terms of lipid-binding and LDL receptor binding 
characteristics. Apo B-32 has joined the ranks of these informative variants by identifying an 
important lipid binding region as well as confirming three of the proposed heparin binding 
sites in apo B-1 00. 
The lipoprotein particles formed with apo B-32 differ from those formed with normal apo B-
100. Apo B-32 cannot support the formation of the triglyceride-rich VLDL particles and 
forms particles which are like HDL in their density, size and composition. The apo B-32 
lipoproteins possess other surface apolipoproteins (apo Al and apo E) which provides the 
possibility that these particles may be metabolised through an apo A 1 or apo E mediated 
pathway, since the apo B-32 protein does not possess the LDL receptor binding region. 
Expression studies of apo B-32 in the rat hepatoma cell line McA-RH7777 showed that the 
apo B-32 protein was secreted on a denser class of lipoprotein than those characterised from 
human circulation. This study, along with similar studies by other investigators, has 
established that the lipoproteins made from truncated apo B variants in cell culture are 
different from those found in circulation. Thus the expression system used in this study is not 
an ideal system for reproducing the subtle differences in lipoprotein density that occurs in the 
circulating lipoproteins of subjects with truncated apo B variants. 
The results obtained from this work, as is often the case in scientific investigation, raise 
questions which call for further investigation. These questions are outlined in chapter 6. 
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CHAPTER 6 FUTURE WORK 
This thesis has focused on hypobetalipoproteinaemia due to truncated apo B variants. Cases 
of hypobetalipoproteinaemia have been reported that lack any link with the apo B gene 
(Hobbs et al, 1989; Fazio et al, 1991). Four subjects were identified during the course of this 
investigation all of whom had no evidence of a truncated apo B in their plasma. Truncated 
apo B variants <30% the length ofapo B-100 are not secreted into plasma. Since it would be 
an extremely large undertaking to sequence the region of the large apo B gene coding for the 
amino-terminal 30% of apo B, a link between the hypobetalipoproteinaemia seen in these 
individuals and the apo B gene would first have to be established. Boerwinkle et al (1989) 
have established a linkage analysis study of apo B using peR of a hypervariable region of the 
apo B gene comprising at least 12 different alleles. This could be applied to the above 
subjects and their family members to establish if the apo B gene is involved in any of the 
remaining as yet uncharacterised hypobetalipoproteinaemic cases. 
Throughout this study it has been assumed that the apo B-32 lipoproteins in the circulation of 
the subject were of hepatic origin. A recent paper by Krul et al (1992) demonstrated that 
truncated variants less than apo B-48 were present in intestinal tissue. The intestine secretes 
apo B-48 in the form of the large triglyceride-rich chylomicron lipoproteins. Whether shorter 
variants of apo B like apo B-32 are secreted in the form of lipoproteins from the intestine 
remains to be investigated. 
An area that needs to be actively investigated is the association between truncated apo B 
variants and the low LDL cholesterol levels they confer. One mechanism for this association 
has been identified in the lipoproteins made with near full-length variants which are more 
rapidly cleared from plasma than apo B-1 00 containing LDL due to having a greater affinity 
for the LDL receptor. The metabolism of the lipoproteins made from truncated apo B 
variants lacking the LDL-receptor binding region is unknown. It would be expected that 
these lipoproteins would remain in plasma and therefore supplement LDL cholesterol levels. 
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This is clearly not the case since subjects with these variants all have very low cholesterol 
levels. The presence of other apolipoproteins on the surface of these lipoproteins may be the 
clue to their metabolism by alternative pathways. We propose to investigate this by 
determining the plasma halflives of radio labelled apo B-32 lipoproteins versus radiolabelled 
LDL particles in rabbits. 
Finally, since the cell line used in the expression studies secreted lipoproteins different to 
those seen in circulation, it would be of interest to investigate the characteristics of apo B-3 2 
lipoproteins in other cell lines. These could include the human liver cell line HepG2 and the 
murine cell line used by Herscovitz et al (1991) to secrete the amino-terminal 17% of apo B. 
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CHAPTER 7 APPENDICES 
7.1 Vitamin A and E measurements 
Plasma vitamins A and E were measured by the Free Radical Research group at the 
Christchurch Clinical School. Measurements were based on the HPLC method of Driskell et 
al (1982). Vitamins were extracted from 200llL of plasma with 100llL ethanol, in which was 
dissolved an internal retinol acetate standard, followed by 400llL hexane extraction. Three 
hundred ilL of supernatant was then dried down and redissolved in 200llL methanol. After 
filtering through glass wool the sample was loaded onto a Pye Unicam 4100 HPLC pre-
equilibrated in 93 % methanol, 7% water. A five micron C-18 Brownlee column (lOx 
0.46cm) was used with a 7 micron C-18 guard column (1.5 x 0.32). Pump parameters were: 
Flow rate = 2.5mL/minute 
Pressure limit = 400 bars 
Run Time = 10 minutes 
Concentrations of vitamin A and E were calculated in relation to the retinol acetate standard 
using the Pye Unicam 6000 integration system. 
7.2 Apolipoprotein determinations 
The concentration of apo B and apo Al in plasma was measured using an immunoturbometric 
assay Walmsley et al (1991). Plasma samples were diluted twenty one fold in 150mM PBS 
(pH 7.4). For apo B, 30llL of diluted sample and 10J..I.L of distilled H20 was preincubated 
with 200J..I.L of PBS containing 5% (w/v) Polyethylene Glycol 6000 (PEG) and 0.2% (w/v) 
Tween 20 for 120 seconds. Antiserum (20IlL ofa five fold dilution of Anti-h-lipoprotein B 
antiserum, Boehringer Mannheim) was added and the absorbance change at 340 nm measured 
after 10 minutes. The apo B concentration was then calculated by comparing the absorbance 
change of the sample with that of six standards (Boehringer apolipoprotien calibration serum) 
using the Cobas-Bio log/logit data evaluation for non-linear standard curves. 
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For apo AI, SJ.1L of diluted sample was mixed with 3SJ.1L of distilled H20 and preincubated 
with 200J.1L of PBS containing PEG and Tween 20 for 120 seconds. Antisera (20J.1L of a five 
fold dilution of Anti-human-lipoprotein Al antiserum, Boehringer Mannheim) was added and 
the absorbance change at 340 nm measured after 10 minutes. The apo Al concentration was 
calculated by comparing the absorbance change of the sample with that of six standards 
(Boehringer apolipoprotein calibration serum) using the Cobas-Bio log/logit data evaluation 
for non-linear standard curves. 
7.3 Lipoprotein isolations 
Lipoproteins were isolated from plasma by density ultracentrifugation in a Kontron TGA-65 
ultracentrifuge using a Kontron TFT 45.6 rotor and the method of Havel et al (1955). 
Four mL of plasma was overlayed with 1 mL ofd=1.006 g/mL density solution (see appendix 
7.4) and the VLDL (d<1.006) isolated by ultracentrifugation at 37 000 rpm at 15°C for 17 
hours. Subsequently LDL (d=1.006-1.063 g/mL) and HDL (d=1.063-1.21 g/mL) were 
isolated by centrifugation as above. The supernatant lipoproteins were separated by tube 
slicing and stored at 4°C while 4mL of the remaining~ infranatant was overlayed with ImL of 
the desired density solution and recentrifuged. 
7.4 Density solutions 
Density solutions were prepared and density adjustments made to plasma as described by 
Wardell (1986). A 1.346 g/mL solution (38.25g NaCI and 88.4g KBr made up to 2S0mL in 
H20 with the pH adjusted to 7.0-7.5 with 1M NaOH) was diluted with a 1.006 g/mL 
solution (20.7g NaCI and 0.2g disodium EDTA in 2L H20 pH adjusted to 7.0-7.5 with 1M 
NaOH) to gain the appropriate density according to the following formula: 
(A X 1.006) + (B X 1.346) = (A + B)X 
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where A is the volume of 1.006 glmL solution, B is the volume of 1.346 glml solution and X 
the desired density of the mixture. 
The density of plasma samples and infranatants was adjusted by the addition of solid KBr 
according to the following formula: 
X= Vj(d f -dJ 
1- Vd f 
where X was the amount (g) of solid KBr to be added, Vj is the initial volume (mL) of the 
solution to be adjusted, df was the final density (glmL) desired, and d j was the initial density 
(g/mL), and Vi was the partial specific volume (cm3/g) ofKBr (taken as 0.3 for d=1.075 and 
0.31 for d=1.291). 
7.5 Cholesterol and triglyceride determinations 
7.5.1 Cholesterol detennination 
Total cholesterol in plasma and lipoprotein fractions were determined on a Cobas Bio 
Centrifugal analyser using an enzymatic colorimetric assay (Monotest Cholesterol CHOD-
PAP, Boehringer Mannheim). This method is based on that ofSiedel et al (1983) and 
measures both esterified and free cholesterol using the following series of reactions: 
chol.st.rol 
cholesterol esters + H20 _.st_.~ ___ ... ) cholesterol + RCOOH 
chol,st,rol 
oritJa. cholesterol + 02 ---'-='---+) cholest-4-en-3-one + H20 2 
2H20 2 + 4-aminophenazone + phenol JMrox/dQ8.) quinoneimine + 4H20 
RCOOH = free fatty acids 
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The first reaction involves the conversion of cholesterol esters to free cholesterol. The 
following reactions involve the production of a quinoneimine dye, a red coloured dye which 
absorbs light at 500 nm. The intensity of colour produced is directly proportional to the 
concentration of cholesterol in the sample 
7.5.2 Triglyceride detennination 
Total triglycerides in plasma and lipoprotein fractions were determined on a Cobas Bio 
Centrifugal analyser using an enzymatic colorimetric assay (Triglycerides GPO-PAP, 
Boehringer Mannheim). This assay is based on a modification of the method ofWahlefeld 
(1974) and involves the following series of reactions: 
triglycerides + 3H20 II
p
as.) glycerol + 3RCOOH 
glycerol 
glycerol + ATP _ki_·nas_.---+) glycerol-3-phosphate + ADP 
glycerophosphat. 
glycerol-3-phosphate + 02 --'==·d;;.:;as:..:.... -----+) dihydroxyacetone phosphate + H20 2 
H202 + 4-aminophenazone + 4-chlorophenol ~roxIdas.) 2H20 + HCI + 4-(p-benzoquinone-
mono-amino )-phenazone 
The glycerol portion of the triglyceride molecule is determined through a series of reactions 
which lead to the formation of a quinoneimine dye which absorbs light at 500 nm. The 
intensity of colour is directly proportional to the amount of triglyceride in the sample. 
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7.6 Calculation of LDL cholesterol 
Where LDL cholesterol was not measured from the LDL isolated by ultracentrifugation, the 
Friedwald equation (Friedewald et ai, 1972) was used to calculate LDL cholesterol as 
follows: 
LDL Chol = Total Chol - HDL Chol - TrigstS 
7.7 Determination of particle size by electron microscopy 
Electron microscopy of isolated lipoprotein fractions was kindly performed by Mr Tony Day. 
Samples of lipoprotein solutions at protein concentrations of 0.1-0.4 mg/mL were applied to 
carbon coated grids and negatively stained with 1% phosphotungstic acid adjusted to pH 7.0. 
Samples were then viewed under a Phillips eM 12 electron microscope. The diameters of 
50 random particles were measured manually from electron micrographs. 
7.8 Agarose gel electrophoresis 
Agarose gel electrophoresis in 1% agarose (pH 8.6) was performed as described by Peach 
(1991). A glass mould was formed by clamping 2 glass plates (11x21cm) separated by a 
1.0mrn thick U-frame. To one of the plates was attached a sheet of Gel bond (FMC 
Bioproducts), with the hydrophobic side next to the glass plate, although this was omitted 
when electrophoresis was to be taken into the second dimension via SDS PAGE. A 1 % 
agarose (LSAILSM 50:50~Litex) in electrophoresis buffer (3SmmollL TrisIHCI (pHS.6), 
46mmollL sodium barbitone, 16mrnollL diethylbarbituric acid) was boiled to dissolve the 
agarose and cooled to 60°C before pouring into the glass mould. After cooling, the mould 
was dismantled and a 2cm strip of the gel blotted with Whatman IMM paper. A plastic strip 
with slotted wells was then placed on the blotted strip and samples loaded (10J.lL maximum 
loading). A sample of human plasma (3J.lL) containing bromophenol blue was always loaded 
to determine the length of electrophoresis. After samples had diffused into the gel the well 
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strip was peeled off and the gel positioned on a cooling plate. Lint wicks were used to bring 
the gel in contact with the tank buffer and the gel electrophoresed at 250V for SO minutes. 
Gels to be stained for protein were fixed in a 4: 1 (v/v) saturated solution of picric acid:glacial 
acetic acid for 10 minutes then pressed under Whatman 3MM paper and paper towels for 10 
minutes. Gels were stained with Coomassie blue then destained as in section 3.10. 
Alternatively gels were pressure blotted for immunoblotting (see section 3.7) or the lanes cut 
out for 2-dimensional electrophoresis (see appendix 7.9). 
7.9 Gels for SDS PAGE 
The following stock solutions were used to make gels for SOS PAGE. 
Acrylamide: 60% (w/v) acrylamide, 1.6% (w/v) bis-acrylamide was dissolved in water, 
filtered through glass wool and stored in the dark at room temperature 
Running gel buffer: 2M Tris pH 8.8 
Stacking gel buffer: 0.5M Tris pH 6.8 
Tank buffer: 0.025M Tris, 0.192M glycine, 0.1 % (w/v) SOS (pH 8.3) 
Polymerisation agents: NNNN-tetramethylethylenediamine (TEMEO) 
10 % (w/v) ammonium persulphate (freshly prepared) 
Gradient gels 3-6% and 3-1S% were prepared by placing solutions into two identical glass 
chambers one of which was stirred and had an outlet to the Bio-Rad mini gel glass mould. A 
10mL solution of6% (or lS%) acrylamide was prepared by mixing 1mL (2.SmL) acrylamide 
stock, 2.0 mL running gel buffer, 50J,tL 20% (w/v) SOS, 6.9 mL (S.4 mL) water, 0.8g sucrose 
and lSj..lL TEMEO. At the same time a 10mL solution of3% acrylamide was prepared by 
mixing 0.5 mL acrylamide stock, 2.0 mL running gel buffer, 50j..lL 20% (w/v) SOS, 7.4 mL 
water and lSj..lL TEMEO. Fifty j..lL of ammonium persulphate solution was then added to the 
6% (IS%) solution and the 3% solution and both solutions poured into the glass chambers the 
6 (IS%) solution being added to the stirred chamber. The gradient was immediately poured 
into the glass mould by way of a peristaltic pump connected to the stirred chamber. Water 
was placed over the top of the gradient gel to ensue a flat surface on polymerisation. 
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After polymerisation of the running gel (30 minutes) a SmL stacking gel was prepared by 
mixing 0.2SmL acrylamide stock, 1.2SmL stacking gel buffer, 2S~L 20% (w/v) SDS, 3.4 mL 
water, lO~L TEMED and 30~L ammonium persulphate. This was immediately poured on 
top of the glass mould and a plastic comb was then applied to form 10 wells. After 
polymerisation of the stacking gel (20 minutes) the gel mould was assembled into the Bio-Rad 
tank system and the upper and lower chambers filled with tank buffer. When SDS PAGE was 
performed in the second dimension after 1 % agarose electrophoresis, the stacking gel was 
poured approximately one third of the usual height and the agarose gel strip placed on top of 
this. More stacking gel was then placed around the sides and top of the strip. 
7.10 32p end-labelling of oligonucleotide primers 
Primers were end-labelled with [y_32p]_ATP (New England Nuclear) using the T4 
polynucleotide kinase enzyme (GibcoIBRL) and the method of Sambrook et al (1989). One 
~L of 10~M primer was placed in a O.SmL eppendorftube along with l~L of kinase buffer 
(SO rnM TrisIHCI (pH 7.5), 10rnM MgCI2, 5rnM dithiothreitol), 3~L of [y-P32]-ATP (2.S 
~Ci), 4~L of H20 and 1~ ofT4 polynucleotide kinase and the reaction placed at 37°C for 
30 minutes. The reaction was diluted to 100~L with 90~1 of water and labelled primer then 
separated from unincorporated [y-P32]-ATP in a Sephadex G-50 spin column (appendix 
7.11). The labelled primer was collected in a O.SmL eppendorfplaced inside a 10mL tube. 
An estimate oflabelling efficiency was gained by measuring the number of counts in both the 
labelled primer in the eluant and the unincorporated [y-P32]-ATP left in the column with a 
giegercounter. Labelled primer was vacuum dried in a speed-vac and reconstituted in 1 O~L 
of water to give a l~ solution of labelled primer. 
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7.11 Sephadex G50 spin columns 
Sephadex GSO spin columns were constructed according to Sambrook et al (1989) and used 
to purify labelled primers and PCR products. A one mL syringe was plugged with siliconised 
glass wool and filled with Sephadex GSO (Pharmacia) and placed inside a 10mL plastic tube. 
The column was washed with two 200llL washes of distilled water by centrifugation at 2000 
rpm for S minutes and the water eluant discarded. Labelled primer or PCR product (1 00 ilL) 
was added to the column and the column centrifuged as before with the eluant collected. 
7.12 Transformation procedure 
Competent cells (E coli DHSa., Gibco BRL) were taken from the -80°C freezer and thawed 
on ice. Fifty ilL of cells were used for each transformation. Cells were placed into prechilled 
Falcon 20S9 tubes and ligation reaction (approximately 40ng DNA) added. pUC19 DNA (1 
ng) was used as a control transformation. DNA was pipetted gently into the cells and the 
tubes mixed by gentle tapping. Tubes were incubated on ice for 30 minutes before receiving a 
heat shock for 20 seconds at 37°C. LB (0.95mL) was added to the transformation and cells 
were allowed to recover by incubation at 37°C in a shaking incubator for 1 hour. 
7.13 Media used for bacterial culture 
The following medium and agar plates were used to maintain growth of bacteria used in this 
study: 
LB medium (per litre): 
109 Bacto/tryptone 
Sg Bacto/yeast/extract 
SgNaCI 
Autoclave and cool before adding the appropriate antibiotic if required. 
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LB/agar plates containing antibiotic (per litre): 
15g of agar (Davis-Germantown) was added to 1 litre ofLB medium and autoclaved. After 
cooling to 55°C ampicillin (125Jlg/mL) was added and the medium poured into 85mm 
Nunclon petri dishes (30-35mL per dish). The agar was left to harden and the plates then 
stored at 4°C for up to one month until required. 
7.14 Alkaline lysis mini-prep 
Plasmid DNA was prepared from overnight cultures using the alkaline lysis mini-prep of 
Sambrook et al (1989). Culture was placed into an 1.5 mL eppendorf tube and cells pelleted 
from the culture by centrifugation in a microfuge for 30 seconds. Media was removed by 
aspiration and the cells resuspended in 1001lL of lysis buffer (25mM TrislHCl (pH 8.0), 10 
mM EDT A, 50mM glucose) and left for five minutes at room temperature. Two hundred JlL 
of freshly prepared 0.2 M NaOHfl % SDS (w/v) was added and the tube mixed by inversion 
and stored on ice for five minutes. Ice cold potassium acetate solution (150JlL of 5M) was 
then added and the tube mixed thoroughly by inversion and stored on ice for at least five 
minutes. Cell debris was pelleted by centrifugation in a microfuge at 4°C for 5 minutes and 
the supernatant transferred to a fresh tube. An equal volume of 1: 1 Tris-saturated 
phenoVchloroform:isoamyl alcohol (24: 1 v/v) was added to the supernatant, vortexed for 1 
minute and centrifuged for 2 minutes in a microfuge. The supernatant was transferred to a 
fresh tube and DNA precipitated with 2 volumes of ethanol on ice for at least two minutes. 
DNA was pelleted by centrifugation for 5 minutes at 4°C and the ethanol removed by 
aspirated. The DNA pellet was washed with ImL of 70% ethanol by vortexing and the DNA 
repelleted by centrifugation and left to air dry. The pellet was then redissolved in 50JlL of TE 
and 20Jlg/mL RNAase A (Boehringer Mannheim) added and incubated at 37°C for 15 
minutes to digest RNA. 
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7.15 Large scale alkaline lysis 
Plasmid DNA was prepared from overnight cells using the method of Sambrook et at (1989). 
A single colony was inoculated into 200mL ofLB/Amp media and the culture grown 
overnight in a 37°C shaking incubator. The culture was transferred to a 200mL Sorval 
centrifuge bottle and cells pelleted by centrifugation at 4000 rpm for 10 minutes at 4°C. The 
cell pellet was resuspended in 10mL of lysis butTer (appendix 7.14) and incubated for 5 
minutes at room temperature. Twenty mL ofO.2M NaOHll% SDS was then added and 
mixed by swirling followed by 10mL of ice cold 5M potassium acetate which was mixed 
thoroughly and left on ice for 5-10 minutes. The lysed mixture was transferred to 50mL 
Sorval tubes and the cell debris was pelleted by centrifugation at 10 000 rpm for 20 minutes at 
4°C. The supernatant was strained through sterile gauze into fresh tubes and an equal volume 
of isopropanol added and the tubes left on ice to precipitate the DNA. Precipitated DNA was 
pelleted by centrifugation at 10 000 rpm for 10 minutes at 4°C. After the pellet had been 
resuspended in 2mL of TE an equal volume of 5M LiC} was added and the tubes left on ice 
for at least 10 minutes to precipitate RNA. Precipitated RNA was pelleted by centrifugation 
at 10 000 rpm for 10 minutes at 4°C and a further isopropanol precipitation step performed as 
before. The DNA pellet was resuspended in 0.8mL ofTE and transferred to a 1.5 mL 
eppendorf tube where 41lL of 10mg/mL RNAase A was added and the tube incubated for 15 
minutes at 37°C. DNA was then precipitated with 0.5mL of 20% PEG/2.5M NaCl on ice for 
ten minutes and pelleted by a 5 minute spin in a microfuge. The PEG supernatant was 
removed and the pellet respun in the microfuge and all the remaining PEG removed. A 
phenoVchloroform extraction was performed and the DNA precipitated with 30llL of 3M 
sodium acetate (pH 7.4) and ImL of ethanol for 30 minutes at -20°C. DNA to be used for 
transfection was given two extra phenoVchloroform and an extra chloroform extraction before 
precipitation. DNA was pelleted by a 5 minute spin in a microfuge, washed in 70 % ethanol 
and dried under vacuum for 10 minutes. DNA was resuspended in 0.5mL of H20. 
CHAPTER 8 REFERENCES 
Alexander, C. A., Hamilton, R. L., and Havel, R. 1. (1976) Subcellular localisation ofB 
apoprotein of plasma lipoproteins in rat liver. J. Cell BioI. 69:241-263 
III 
Andersen, G. E., Brokhattingen, K, and Lous, P. (1979) Familial hypobetalipoproteinemia in 
9 children diagnosed as the result of cord blood screeninig for hypobetalipoproteinemia in 10 
000 Danish newborns. Arch. Dis. Child. 54:691-694. 
Andersson S., Davis D. L., Dahlback, H., Jornvall, H., and Russall, D. W. (1989) Cloning, 
struc.ture, and expression of the mitochondrial cytochrome P-450 Sterol 26-hydroxylase, a 
bile acid biosynthetic enzyme. J. Bioi. Chem. 264:8222-8229. 
Attie, A. D., Pittman, R. C., and Steinberg, D. (1982) Hepatic catabolism of low density 
lipoprotein: mechanism~ and metabolic consequences. Hepatology 2:269-281. 
Bamberger, M. 1., and Lanes, M. D. (1988) Assembly of very low density lipoproteins in the 
hepatocyte. J. Bioi. Chem. 263: 11868-11878. 
Berg, K, Powell, L. M., Wallis, S. C., Pease, R., Knott, T. J., and Scott, 1. (1986) Genetic 
linkage between the antigenic group (Ag) variation and the apolipoprotein B gene: assignment 
of the Ag locus. Proc. Natl. Acad. Sci. 83:7367-7370 
Berger, G. M. B., Brown, G., Henderson, H. E., and Bonnici, F. (1983) Apolipoprotein B 
detected in the plasma of a patient with homozygous hypobetaiipoproteinemia: implications 
for aetiology. J. Med Genet. 20:189-195 
Biesiegel, u., Weber, W., Ihrke, G., Herz, J., and Stanley, K K (1989) The LDL-receptor-
related protein, LRP, is an apolipoprotein E binding protein. Nature 341: 162-164. 
Biesegel, u., Weber, W., and Bengtsson-Olivecrona, G. (1991) Lipoprotein lipase enhances 
the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc. Natl. 
Acad. Sci. 88:8342-8346. 
112 
Blackhart, B. D., Ludwig, E. M., Pierotti, V. R, Caiati, L., Onasch, M. A, Wallis, S. C., 
Powell, L., Pease, R, Knott, T. 1., Chu, M-L., Mahley, R W., Scott, 1., McCarthy, B. 1., and 
Levy-Wilson, B. (1986) Structure of the human apolipoprotein B gene. 1. Bioi. Chem. 
262: 15364-15367. 
Blackhart, B. D., Yao, Z., and McCarthy, B. 1. (1990) An expression system for human 
apoiipoprotein BlOO in a rat hepatoma cell line. 1. Bioi. Chem. 265:8358-8360. 
Boerwinkle, E., Xiong, W., Fourest, E., and Chan, L. (1989) Rapid typing oftandemly 
repeated hypervariable loci by the polymerase chain reaction: application to the apolipoprotein 
B 3' hypervariable region. Proc. Natl. Acad Sci 86:212-216. 
Borchardt, R A, and Davis, R A (1987) Intrahepatic assembly of very low density 
lipoproteins. 1. Bioi. Chem. 262: 16394-16402. 
Bostrom, K., Boren, 1., Wettesten, M., Sjoberg, A, Bondjers, G., Wiklund, 0., Carlsson, P., 
and Olofsson, S. O. (1988) Studies on the assembly ofapo B-I00- containing lipoproteins in 
hepG2 cells. 1. Biol.Chem. 263':4434-4442. 
Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-
254. 
Breckenridge, W. C., Little, 1. A, Aiaupovic, P., Wang, C. S., Kuksis, A, Kakis, G., 
Lindgren, F., and Gardiner, G. (1982) Lipoprotein abnormalities associated with a familial 
deficiency of hepatic lipase. Atherosclerosis 45: 161-179. 
Breslow, 1. L. (1988) Apolipoprotein genetic variation and human disease. Physiol. Rev. 
68:85-132. 
Breslow, 1. (1989) Genetic basis of lipoprotein disorders. 1. Clin. Invest. 84:373-380. 
Brown, M. S., and Goldstein, 1. L. (1986) A receptor mediated pathway for cholesterol 
homeostasis. Science 232:34-47. 
Brunzell, 1. D. (1989) Familial lipoprotein lipase deficiency and other causes of the 
chylomicronemia syn,~rome. In: The metabolic basis a/inherited disease (Scriver, C. R., 
Beaudet, A L., Sly, W. S., and Valle, D. eds.), sixth edition ppI165-1180. McGraw Hill 
Inc., New York. 
Bullock, D. G., Carter, T. 1. N., and Hughes, S. V. (1980) Applicability of various quality-
control sera to assay of high-density lipoprotein cholesterol. Clin. Chern. 26:903-907. 
Burstein, M., and Scholnick, H. R (1973) Lipoprotein-polyanion-metal interactions. 
Advances in Lipid Research 11:67-108. 
113 
Cardin, A D., Witt, K. R, Chao, 1., Margolius, H. S., Donaldson, V. H., and Jackson, R L. 
(1984) Degradation of apolipoprotein B-1 00 of human plasma low density lipoproteins by 
tissue and plasma kallikreins. 1. Bioi. Chern. 259:8522-8528. 
Carlson, L. A, Holmquist, L., and Nilsson-Ehle, P. (1986) Deficiency of hepatic lipase 
activity in post-heparin plasma in familial hyperalphatriglyceridemia. Acta. Med Scand 
219:435-447. 
Chapman, M. 1. (1986) Comparative analysis ofmamrnalian plasma lipoproteins. Methods in 
enzymology 128:70-143. 
Chen, S. H., Habib, G., Yang, C. Y., Gu, Z. W., Lee, B. R., Weng, S. A., Siberman, S. R., 
Cai, S. 1., Deslypere, 1. P., Rosseneu, M., Gotto, A. M. Jr., Li, W. H., and Chan, L. (1987) 
Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop 
codon. Science 238:363-366. 
Chen, G. C., Hardman, D. A, Hamilton, R L., Mendel, C. M., Schilling, 1. W., Zhu, S., Lau, 
K., Wong, 1. S., and Kane, 1. P. (1989) Distribution of lipid-binding regions in human 
apolipoprotein B-I00. Biochemistry 28:2477-2484 
114 
Cladaras, C., Hadzopoulou-Cladaras, M., Nolte, R. T., Atkinson, D., and Zannis, V. 1. (1986) 
The complete sequence and structural analysis of human apolipoprotein 8-100: relationship 
between apo 8-100 and apo 8-48 forms. £MBO 1. 5;3495-3507. 
Collins, D. R, Knott, T. J., Pease, R J., Powell, L. M., Wallis, S. c., Robertson, S., 
Pullinger, C. R, Milne, R W., Marcel, Y. L., Humphries, S. E., Talmud, P. J., Lloyd, J. K., 
Millar, N. E., Muller, D., and Scott, J. (1988) Truncated variants ofapolipoprotein B cause 
hypobetalipoproteinaemia. Nucleic Acids Res. 16:8361-8375. 
Cooper, D. N., and Youssoufian, H. (1988) The CpG dinucleotide and human genetic disease. 
Hum. Genet. 78: 151-155 
Das, H. K., Leff, T., and Breslow, J. L. (1988) Cell type-specific expression of the human apo 
B gene is controlled by two cis-acting regulatory regions. J. Bioi. Chem. 263: 11452-11458. 
Davis, M. S., Wallis, S. c., Driscoll, D. M., Wynne, J. K., Williams, G. W., Powell, L. M., 
and Scott, J. (1989) Sequence requirements for apolipoiprotein 8 RNA editing in transfected 
rat hepatoma cells. J. Bioi. Chem. 264:13395-13398. 
De Loof, H., Rosseneu, M., Yang, C. Y., Li, W. H., Gotto, A. M. Jr., and Chan, L. (1987) 
Human apolipoprotein B: Analysis ofintemal repeats and homology with other 
apolipoproteins. J. Lipid Res. 28: 1455-1465. 
Deng, W. P., and Nickoloff, 1. A. (1992) Site-directed mutagenesis of virtually any plasmid by 
eliminating a unique site. Anal. Biochem. 200:81-88. 
Driskell W. J., Neese 1. W., Bryant C. C., and Bashor M. M. (1982) Measurement of vitamin 
A and vitamin E in human serum by high-performance liquid chromatography. J. Chromat. 
231 :439-444. 
Farese, R. V. Jr., Garg, A., Pierotti, V. R, Vega, G. L., Young, S. G., and Grundy, S. M. 
(1991) A truncated species of apolipoprotein B, apo 8-83, associated with 
hypobetalipoproteinemia. Clin. Res. 276A:39 
115 
Farese, R V. Jr., Linton, M. F., and Young, S. G. (1992) Apolipoprotein B gene mutations 
affecting cholesterol levels. 1. Intern. Med. 231 :643-652. 
Fazio, S., Sidoli, A, Vivenzio, A, Maietta, A, Giampaoli, S., Menotti, A, Antonini, R, 
Urbinati, G., Baralle, E. F., and Ricci, G. (1991) A form of familial hypobetalipoproteinaemia 
not due to a mutation in the apolipoprotein B gene. 1. Intern. Med. 229:41-47. 
Finley, P. R, Schifman, R B., Williams, R 1., and Lichti, D. A. (1978) Cholesterol in high-
density lipoprotein: use ofMg2+tDextran sulphate in its enzymatic measurement. Clin. Chem .. 
24:931-933. 
Fojo, S. S., and Brewer, H. B. (1992) Hypertriglyceridaemia due to genetic defects in 
lipoprotein lipase and apolipoprotein C-II. 1. Intern. Med. 231 :669-677. 
Friedewald, W. T., Levy, R I., and Fredrickson, D. S. (1972) Estimation of the concentration 
of low-density lipoprotein cholesterol in plasma, without use of the preparative 
ultracentrifuge. Clin. Chem. 18:499-502. 
Gabelli, C. (1992) The lipoprotein metabolism ofapolipoprotein B mutants. Curro Opin. 
Lipidol.3:208-214. 
Gabelli, C., Baggio, G., Bilato, C., Martini, S., Previato, L., Marcel, Y., Corsini, A., and 
Crepaldi, G. (1989) Identification of a new apo B variant associated with 
hypobetalipoproteinemia. Circulation (Suppl. 11) 80:II-276. 
Glaumann, H., Bergstrand, A., and Ericsson, J. L. (1975) Studies on the synthesis and 
intracellular transport of lipoprotein particles in rat liver. 1. Cell Bioi. 64:356-377. 
Glueck, C. 1., Gartside, P. S., Mellies, M. 1., and Steiner, P. M. (1977) Familial 
hypobetalipoproteinemia: studies in 13 kindreds. Trans. Assoc. Am. Physicians 90: 184-203. 
Gotto, A. M. Jr., Pownall, H. 1., and Havel, R 1. (1986) Introduction to the plasma 
lipoproteins. Methods in enzymology 128:3-41. 
116 
Graham, D. L., Knott, T. 1., Jones, T. C., Pease, R 1., Pullinger, C. R, and Scott, 1. (l991) 
Carboxyl-terminal truncation of apolipoprotein B results in gradual loss of the ability to form 
buoyant lipoproteins in cultured human and rat liver cell lines. Biochemistry 30:5616-5621. 
Grosveld, F. G., Hans-Henrik, M. D., de Boer, E., and Flavell, R. A (1981) Isolation of~­
globin-related genes from a human cosmid library. Gene 13:227-237. 
Grove, T. H. (1979) Effect of reagent pH on determination of high-density lipoprotein 
cholesterol by precipitation with sodium phosphotungstate-magnesium. Clin. Chem. 25:560-
564. 
Hardman, D. A, Pullinger, C. R, Hamilton, R L., Kane, 1. P., and Malloy, M. 1. (1991) 
Molecular and metabolic basis for the metabolic disorder normotriglyceridemic 
abetalipoproteinemia. J Clin. Invest. 88: 1722-1729. 
Havel, R 1., and Kane, 1. P. (l989a) Introduction: structure and metabolism of plasma . 
lipoproteins. In: The metabolic basis of inherited disease (Scriver, C. R, Beaudet, A L., Sly, 
W. S., and Valle, D. eds.), sixth edition ppI129-1138. McGraw Hill Inc., New York. 
Havel, R. 1., and Kane, 1. P. (l989b) Disorders of the biogenesis and secretion of lipoproteins 
containing the B apolipoproteins. In: The metabolic basis of inherited disease (Scriver, C. R, 
Beaudet, A L., Sly, W. S., and Valle, D. eds.), sixth edition ppl139-1164. McGraw Hill Inc., 
New York. 
Havel, R 1., Eder, H. A., and Bragdon, 1. H. (1955) The distribution and chemical 
composition of ultra centrifugally separated lipoproteins in human serum. J. Clin. Invest. 
34: 1345-1353. 
Herscovitz, H., Hadzopoulou-Cladaras, M., Walsh, M. T., Cladaras, C., Zannis, V. I., and 
Small, D. M. (1991) Expression, secretion, and lipid-binding characterisation of the N-
terminal 17% of apolipoprotein B. Proc. Natl. Acad Sci. 88:7313-7317. 
Higgins, 1. A., and Fieldsend, 1. K (1987) Phosphatidylcholine synthesis for incorporation 
into membranes or for secretion as plasma lipoproteins by Golgi membranes of rat liver. 1. 
Lipid Res. 28:268-278 
117 
Higuchi, K, Hospattankar, A. V., Law, S. W., Meglin, N., Cortright, J and Brewer, H B. Jr. 
(1988a) Human apolipoprotein B (apo B) mRNA: identification of two distinct apo B 
mRNAs, an mRNA with the apo B-I00 sequence and an apo B mRNA containing a 
premature in-frame translational stop codon, in both liver and intestine. Proc. Natl. A cad. Sci. 
85: 1772-1776. 
Higuchi, R, von Beroldingen, C. H, Sensabaugh, G. F., and Erlich, H A. (1988b) DNA 
typing from single hairs. Nature 332:543-546 
Hirose, N., Blankenship, D. T., Krivanek, M. A., Jackson, R L., and Cardin, A. D. (1987) 
Isolation and characterisation of four heparin-binding cyanogen bromide peptides of human 
plasma apolipoprotein B. Biochemistry 26: 5505-5512. 
Hobbs, H H., Leitersdorf, E., Leffert, c. C., Cryer, D. R, Brown, M. S., and Goldstein, 1. L. 
(1989) Evidence for a dominant gene that suppresses hypercholesterolemia in a family with 
defective low density lipopotein receptors. 1. Clin. Invest. 84:656-664. 
Huang, L. S., and Breslow, 1. L. (1987) A unique AT-rich hypervariable mini satellite 3' to the 
apo B gene defines a high information restriction fragment length polymorphism. 1. BioI. 
Chern. 262:8952-8955. 
Huang, L. S., Miller, D. A., Bruns, G. A. P., and Breslow, 1. L. (1986) Mapping of the human 
apo B gene to chromosome 2p and demonstration of a two-allele restriction fragment length 
polymorphisim. Proc. Acad. Natl. Sci. 83:644-648. 
Huang, L. S., Ripps, M. E., Korman, S. H., Decklebaum, R 1., and Breslow, 1. L. (1989) 
Hypobetalipoproteinaemia due to an apolipoprotein B gene exon 21 deletion derived by Alu-
Alu recombination. 1. BioI. Chern. 264: 11394-11400. 
118 
Huang, L. S., Kayden, H., Sokol, R. 1., and Breslow, 1. L. (1991) Apo B gene nonsense and 
splicing mutations in a compound heterozygote for familial hypobetalipoproteinemia. 1. Lipid 
Res. 32:1341-1348. 
Innerarity, T. L., Weisgraber, K. L., Arnold, K. S., Mahley, R. W., Krauss, R. M., Vega, G. 
L., and Grundy, S. M. (1987) Familial defective apolipoprotein B-100: low density 
lipoproteins with abnormal receptor binding. Proc. Natl. Acad. Sci. 84:6919-6923. 
Innerarity, T. L., Mahley, R. W., Weisgraber, K. H., Bersot, T. P., Krauss, R. M., Vega, G. 
L., Grundy, S. M., Friedl, W., Davignon, J., and McCarthy, B. 1. (1990) Familial defective 
apolipoprotein B-1 00: A mutation of apolipoprotein B that causes hypercholesterolemia 1. 
Lipid. Res 31:1337-1349. 
Itakura, K., Ross, 1. 1., and Wallace, R. B. (1984) Synthesis and use of synthetic 
oligonucleotides. Annu. Rev. Biochem. 53:323-356 
Janus, E. D., Suckling, P. A. and Wardell, M. R. (1981) Blood lipid levels in Christchurch 
blood donors. NZ Med J. 94:114-115. 
Jimenez, A, and Davies, 1. (1980) Expression ofa transposable antibiotic resistance element 
in Saccharomyces. Nature 287:869-871. 
Jones, A L., Hradek, G. T., Hornick, C., Renaud, G., Windler, E. E. T., and Havel, R. 1. 
(1984) Uptake and processing of remnants ofchylomicrons and very low density lipoproteins 
by rat liver. 1 Lipid Res. 25: 1151-1158. 
Kahn 1. A, and Glueck, C. 1. (1978) Familial hypobetalipoproteinemia: absence of 
atherosclerosis in a postmortem study. 1. Am. Med Assoc. 240:47-48. 
Kane, 1. P., Hardman, D. A, and Paulus, H. E. (1980) Heterogeneity ofapolipoprotein B: 
isolation ofa new species from human chylomicrons. Proc. Natl. Acad Sci. 77:2465-2469. 
119 
Kaplan, L. A, and Pesce, A 1. (1989) Analyte reference chart. In: Clinical chemistry. 
Theory, analysis and correlation (Kaplan, L. A, and Pesce, A 1. eds.), second edition. inside 
back cover. C. V. Mosby Company, St Louis. 
Kesaniemi, Y A, Witzum, 1. L., and Steinbrecher, U. P. (1983) Receptor-mediated 
catabolism of low density lipoprotein in man: Quantitation using glucosylated low density 
lipoprotein. J. Clin. Invest. 71 :950-959. 
Knott, T. 1., Rail, S. C. Jr., Innerarity, T. L., Jacobson, S. F., Urdea, M. S., Levy-Wilson, B., 
Powell, L. M., Pease, R 1., Eddy, R, Nakai, H., Byers, M., Priestly, L. M., Robertson, E., 
Rail, L. B., Betsholtz, C., Shows, T. B., Mahley, R B., and Scott, 1. (1985) Human 
apolipoprotein B: structure of carboxyl-terminal domains, sites of expression, and 
chromosomal location. Science 230:37-43. 
Knott, T. 1., Pease, R 1., Powell, L. M., Wallis, S. C., Rail, S. C. Jr., Innerarity, T. L., . 
Blackhart, B., Taylor, W. H., Marcel, Y, Milne, R, Johnson, D., Fuller, M., Lusis, A I., 
McCarthy, B. 1., Mahley, R W., Levy-Wilson, B. and Scott, ). (1986) Complete protein 
sequence and identification of structural domains of human apolipoprotein B. Nature 323: 
734-738. 
Kowal, R C., Herz, 1., Goldstein, 1. L., Esser, V., and Brown, M. S. (1989) Low density 
lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from 
apoprotein E-enriched lipoproteins. Proc. Natl. Acad Sci. 86:5810-5814. 
Krul, E. S., Kinoshita, M., Talmud, P., Humphries, S. E., Turner, S., Goldberg, A C., Cook, 
K., Boerwinkle, E., and Schonfeld, G. (1989) Two distinct truncated apolipoprotein B species 
in a kindred with hypobetalipoproteinemia. Arteriosclerosis 9:856-868. 
Krul, E. S., Parhofer, K. G., Barrett, P. H. R, Wagner, R D., and Schonfeld, G. (1992) Apo 
B-75, a truncation of apolipoprotein B associated with familial hypobetalipoproteimemia: 
genetic and kinetic studies. J. Lipid Res. 33:1037-1050. 
120 
Krul, E. S., Tang, 1., Kettler, T. S., Clouse, R E., and Schonfeld, G. (1992) Lengths of 
truncated forms of apolipoprotein B (apo B) determine their intestinal production. Biochem. 
Biophys. Res. Commun. 189:1069-1076. 
Kunkel, L. M., Smith, K. D., Boyer, S. H., Borgaonkar, D. S., Wachtel, S. S., Miller, O. l, 
Breg, W. R, Jones, H. W. Jr., and Rary, 1. M. (1977) Analysis of human Y-chromosome-
specific reiterated DNA in chromosome variants. Proc. Natl. Acad. Sci. 74:1245-1249. 
Lackner, K. 1., Monge, 1. C., Gregg, R E., Hoeg, 1. M., Triche, T. 1., Law, S. W., and 
Brewer, H. B. Jr. (1986) Analysis of the apolipoprotein B gene and messenger ribonucleic 
acid in abetalipoproteinemia. 1. Clin. Invest. 78: 1707-17 . 
Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227:680-685. 
Laskarzewski, P. M., Khoury, P., Morrison, 1. A., Kelly, K, Mellies, M. 1., and Glueck, C. 1. 
(1982) Prevalence of familial hyper- and hypolipoproteinemias: the Princeton School District 
Family Study. Metab. Clin. Exp. 31 :558-577. 
Law, S. W., Lee, N., Monge, 1. C., Brewer, H. B. Jr., Sakaguchi, A. Y., and Naylor, S. L. 
(1985) Human apo B gene resides in the p23~pter region of chromosome 2. Biochem. 
Biophys. Res. Commun. 131:1003-1012. 
Law, S. W., Grant, S. M., Higuchi, K, Hospattankar, A., Lackner, K, Lee, N., and Brewer, 
H. B. Jr. (1986) Human liver apolipoprotein B-I00 cDNA: Complete nucleic acid and derived 
amino acid sequence. Proc. Natl. Acad Sci 83:8142-8146 
Levy-Wilson, B., and Fortier, C. (1989) Tissue-specific undermethylation of DNA sequences 
at the 5' end of the human apolipoprotein B gene. 1. BioI. Chem. 264:9891-9896. 
Levy-Wilson, B., Fortier," C., Blackhart, B., and McCarthy, B. 1. (1988) DNase I and 
micrococcal nuclease-hypersensitive sites in the human apolipoprotein B gene are tissue 
specific. Mol. Cell BioI. 8:71-80. 
121 
Linton, M. F., Pierotti, V. R, Hubl, S. T., and Young, S. G. (1990) An apo B gene mutation 
causing familial hypobetalipoproteinemia analyzed by examining the apo-B eDNA amplified 
from the fibroblast RNA of an affected subject. Clin. Res. 38:286A 
Ludwig, E. H, Friedl, W., and McCarthy, B. 1. (1989) High-resolution analysis ofa 
hypervariable region in the human apolipoprotein B gene. Am. 1. Genet. 45:458-464. 
Mahley, R W., and Rail, S. C. Jr. (1989) Type III hyperlipoproteinemia 
(dysbetalipoproteinemia): the role of apo E in normal and abnormal lipoprotein metabolism. 
In: The metabolic basis o/inherited disease (Scriver, C. R, Beaudet, A L., Sly, W. S., and 
Valle, D. eds.), sixth edition ppI195-1213. McGraw Hill Inc., New York. 
Malloy, M. 1. and Kane, 1. P. (1982) Hypolipidemia. Med Clin. North Am. 66,469-484. 
McCormick, S. P. A, Fellowes, A P., Walmsley, T. A, and George, P. M. (1992) 
Apolipoprotein B-32: a new truncated mutant of human apolipoprotein B capable offorming 
particles in the low density lipoprotein range. Biochim. Biophys. Acta 1138:290-296. 
Messing, 1. (1983) New M13 vectors for cloning. Methods in enzymology 101:20-78. 
Metzger, S., LefT, T., and Breslow, 1. L. (1989) Nuclear factors AF-l and CIEBP modulate 
apo B transcriptional activity in hepatic cells. Circulation 80(suppl 11):11-265. 
Michaelis, 1., Vissers, M. C. M., and Winterboum, C. C. (1990) Human neutrophil 
collagenase cleaves a I-antitrypsin. Biochem. J. 270, 809-814. 
Mills, G. L., Lane, P. A, and Weech, P. K. (1984) A guidebook to lipoprotein technique. In: 
Laboratory techniques in biochemistry and molecular biology, volume 14 (Burdon, R H., 
and van Knippenberg, P. eds.), ppI8-116. Elsevier, Amsterdam. 
Milne, R, Theolis, R. Jr., Maurice, R, Pease, R. 1., Weech, P. K., Rassart, E., Fruchart, 1. c., 
Scott, 1., and Marcel, Y. L. (1989) The use of monoclonal antibodies to localize the low 
122 
density lipoprotein receptor-binding domain ofapolipoprotein B. 1. Bioi. Chem. 264: 19754-
19760. 
Olofsson, S. 0., Bjursell, G., Bostrom, K, Carlsson, P., Elovson, J., Protter, A. A., Reuben, 
M. A., Bondjers, G. (1987) Apolipoprotein B:Structure, biosynthesis and role in the 
lipoprotein assembly process; Atherosclerosis 68: 1-17. 
Owen, M. C., Borg, J. Y., Soria, C., Soria, J., Caen, J., and Carrell., R W. (1987) Heparin 
binding defect in a new antithrombin III variant: Rouen, 47 Arg to His. Blood 69: 1275-1279. 
Palinski, W., Rosenfeld, M. E., Yla-Herttuaia, S., Gurtner, G. C., Socher, S. S., Butler, S. 
W., Parthasarathy, S., Carew, T. E., Steinberg, D., and Witzum, J. L. (1989) Low density 
lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad Sci. 86:1372-1376. 
Parhofer K G., Daugherty, A., Kinoshita, M., Schonfeld, G. (1990) Enhanced clearance from 
plasma oflow density lipoproteins containing a truncated apolipoprotein, apo B-89. 1. Lipid 
Res. 31:2001-2007. 
Parhofer, K G., Barrett, P. H. R, Bier, D. M., and Schonfeld, G. (1992) Lipoproteins 
containing the truncated apolipoprotein, apo B-89, are cleared from human plasma more 
rapidly than apo B-I00-containing lipoproteins in vivo. 1. Clin. Invest. 89:1931-1937. 
Peach, R. J. (1991) Post-translational processing of normal and variant albumins. Ph.D. 
thesis, Otago University, New Zealand 
Pease, R. 1., Milne, R. W., Jessup, W. K, Law, A., Provost, P., Fruchart, J. C., Dean, R T., 
Marcel, Y. L., and Scott, 1. (1990) Use of bacterial cloning to localise the epitopes for a series 
of monoclonal antibodies against apolipoprotein B-100. 1. Bioi. Chem. 265, 553-568. 
Powell, L. M., Wallis, S. C., Pease, R J., Edwards, Y. H., Knott, T. 1., and Scott, 1. (1987) A 
novel form of tissue-specific RNA processing produces apolipoprotein B48 in intestine. Cell 
50:831-840 
l23 
Protter, A A, Hardman, D. A, Schilling, 1. W., Miller, 1., Appleby, v., Chen, G. C., Kirsher, 
S. W., McEnroe, G., and Kane, 1. P. (1986) Isolation ofa cDNA clone containing the amino 
terminal region of human apolipoprotein B. Proc. Natl. Acad Sci. 83: 1467-1471 
Pullinger, C. R, North, 1. D., Teng, B. B., Rifici, V. A, Ronhild de Brito, A E., and Scott, 1. 
(1989) The apolipoprotein B gene is constitutively expressed in HepG2 cells: Regulation of 
secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. 1. Lipid 
Res. 30: 1065-1077 
Pullinger, P. R, Hillas, E., Hardman, D. A, Chen, G. C., Naya-Vigne, 1. M., Iwasa, 1. A, 
Hamilton, R. L., Lalouel, 1. M., Williams, R R, and Kane, 1. P. (1992) Two apolipoprotein B 
gene defects in a kindred with hypobetalipoproteinemia, one of which results in a truncated 
variant, apo B-61, in VLDL and LDL. J Lipid Res. 33:699-710. 
Rail, S. C. Jr., Weisgraber, K. H., Innerarity, T. L., Bersot, T. P., Mahley, R W., and Blum, 
C. B. (1983) Identification ofa new structural variant of human apolipoprotein E, 
E2(LYS146-+Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. 1. Clin. 
Invest. 72: 1288-1297 
Salt, H B., Wolff, O. H, Lloyd, 1. K., Fosbrooke, A S., Cameron, A H, and Hubble, D. V. 
(1960) On having no beta-lipoprotein: A syndrome comprising abetalipoproteinaemia, 
acanthocytosis and steatorrhea. Lancet 2:325-332 
Sambrook, 1., Fritsch, E. F., and Maniatis, T. (1989). In: Molecular Cloning. A laboratory 
manual (Ford, N., and Nolan, C. eds.), second edition pp1.7-1.10, pp1.25-1.28, pp1.33-1.41, 
ppl1.31-11.32, pp 11.37-11.38. Cold Spring Harbor Laboratory Press. 
Scott, 1. (1989) The molecular and cell biology ofapolipoprotein B. Mol. Bioi. Med. 6:65-80. 
Siedel, 1., Hagele, E. 0., Ziegenhorn, 1., and Wahlefeld, A W. (1983) Reagent for the 
enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin. 
Chem.29:1075-1080. 
124 
Skipski, V. P. (1972) Lipid composition oflipoproteins in normal and diseased states. In: 
Blood lipids and lipoproteins: quantitation, composition, and metabolism (Nelson, G. 1. ed.), 
pp 585-704. John Wiley and Sons Inc., New York. 
Sorci-Thomas, M., Wilson, M. D., Johnson, F. L., Williams, D. L., and Rudel, L. L. (1989) 
Studies on the expression of genes encoding apolipoproteins B 1 00 and B48 and the low 
density lipoprotein receptor in nonhuman primates: comparisons of dietary fat and cholesterol. 
1. Bioi. Chem. 264:9039-9045. 
Southern, E. M. (1975) Detection of specific sequences among DNA fragments separated by 
gel elecctrophoresis. 1. Mol. BioI. 98:503-517. 
Spring, D. 1., Chen-Liu, L. W., Chatterton, 1. E., Elovson, 1., and Schumaker, V. N. (1992) 
Lipoprotein assembly. Apolipoprotein B size determines lipoprotein core circumference. 1. 
Bioi. Chem 267: 14839-14845. 
Steinberg, D. (1991) Antioxidants and atherosclerosis: a current assesment. Circulation 
84: 1420-1425. 
Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, 1. C., and Witzum, 1. L. (1989) Beyond 
cholesterol: modifications oflow-density lipoprotein that increase its atherogenicity. N. Engl. 
1. Med. 320:915-924. 
Takayama, M., Itoh, S., Nagasaki, T., and Tanimizu, I. (1977) A new enzymatic method for 
determination of serum choline-containing phospholipids. Clinica Chimica Acta 79:93-98. 
Talmud, P. 1., Lloyd, 1. K., Muller, D. P. R., Collins, D. R., Scott, 1., and Humphries, S. 
(1988) Genetic evidence from two families that the apolipoprotein B gene is not involved in 
abetalipoproteinaemia. 1. Clin. Invest. 82: 1803-1806. 
Talmud, P., King-Underwood, L., Krul. E., Schonfeld, G., and Humphries, S. (1989) The 
molecular basis of truncated forms of apolipoprotein B in a kindred with compound 
heterozygous hypobetalipoproteinemia. 1. Lipid Res. 30: 1773-1779 
125 
Tanabe, S., Sherman, H., Smith, L., Yang, L. A, Fleming, R., and Hay, R. (1989) Biogenesis 
of plasma lipoproteins in rat hepatoma McA-RH7777: importance of diffusion-mediated 
events during cell growth. In Vitro 25: 1129-1140. 
Tennyson, G. E., Gabelli, C., Baggio, G., Bilato, C., Brewer, H. B. Jr. (1990) Molecular 
defect in the apolipoprotein B gene in a patient with hypobetalipoproteinemia and three 
distinct apo B species. Clin. Res. 38:482A 
Utermann, G., Pruin, N., and Steinmetz, A (1979) Polymorpism ofapolipoprotein E III. 
Effect ofa single polymorpic gene locus on plasma lipid levels in man. Clin. Genet. 15:63-72. 
Wagner, R. D., Krul, E. S., Tang, J., Parhofer, K. G., Garlock, K., Talmud, P., Schonfeld, G. 
(1991) Apo B-54.8, a truncated apolipoprotein found primarily in VLDL, is associated with a 
nonsense mutation in the apo B gene and hypobetalipoproteinemia. J. Lipid Res. 32: 1001-
1011. 
Wahlefeld, A W. (1974) Triglycerides. Determination after enzymatic hydrolysis. In: Methods 
of enzymatic analysis (Bergmeyer HU. ed.), pp 1831: Academic Press Inc. New York. 
Walmsley, T. A, Grant, S., and George, P. M. (1991) Effect of plasma triglyceride 
concentrations on the accuracy of immunoturbidometric assays of apolipoprotein B. Clin. 
Chem. 37, 748-753. 
Wardell, M. R. (1986) Human apolipoprotein E:structural variation and disease. Ph. D. thesis, 
Otago University, New Zealand 
Wardell, M. R., BreMan, S. 0., Janus, E. D., Fraser, R., Carrell, R. W. (1987) 
Apolipoprotein E2-Christchurch (136 Arg~Ser). A new variant of human apolipoprotein E in 
a patient with type III hyperlipoproteinemia. J. Clin. Invest. 80:483-490. 
Wardell, M. R., Rail, S. c., Brennan, S. 0., Nye, E. R., George, P. M., Janus, E. D., and 
Wiesgraber, K. H. (1990) Apolipoprotein E2-Dunedin (228Arg~Cys): an apolipoprotein E2 
variant with normal receptor binding activity. J. Lipid Res. 31 :535-543. 
126 
Warnick, G. R, Cheung, M. C., and Albers, 1. 1. (1979) Comparison of current methods for 
high-density lipoprotein cholesterol quantitation. Clin. Chem. 25:596-604. 
Weisgraber, K H., and Rall, S. C. Jr. (1987) Human apolipoprotein B-lOO heparin-binding 
sites. J. Bioi. Chem. 262: 11097-11103. 
Weisgraber, K. H., T. L. Innerarity, and R W. Mahley. (1982). Abnormal lipoprotein 
receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a 
single site. J. Bioi. Chem. 257: 2518-252l. 
Welty, F. K, Hubl, S. T., Pierotti, V. R, and Young, S. G. (1991) A truncated species of 
apolipoprotein B (B67) in a kindred with familial hypobetalipoproteinemia. J. Clin. Invest. 
87:1748-1754. 
Wetterau, 1. R, Aggerbeck, L. P., Bouma, M. E., Eisenberg, C., Munck, A, Hermier, M., 
Schmitz, 1., Gay, G., Rader, D. 1., and Gregg, R E. (1992) Absence of microsomal 
triglyceride transfer protein in individuals with abetalipoproteinaemia. Science 258:999-1001 
White, A L., Graham, D. L., LeGros, 1., Pease, R 1., and Scott, 1. (1992) Oleate-mediated 
stimulation ofapolipoprotein B secretion from rat hepatoma cells. J. Bioi. Chem. 267:15657-
15664. 
Xiong, W., Zsigmond, E., Gotto, A M. Jr., Lei, K Y., and Chan, L. (1991) Locating a low 
density lipoprotein-targeting domain of human apolipoprotein B-1 00 by expressing a minigene 
construct in transgenic mice. J Bioi. Chem. 266:20893-20898. 
Yang, C. Y., Chen, S. H., Gianturco, S. H., Bradley, W. A, Sparrow, J. T., Tanimura, M., Li, 
W. H., Sparrow, D. A, DeLoof, H., Rosseneu, M., Lee, F. S., Gu, Z. W., Gotto, A M. Jr., 
and Chan, L. (1986) Sequence, structure, receptor-binding domains and internal repeats of 
human apolipoprotein B-lOO. Nature 323:738-742. 
127 
Yang, C. Y., Gu, Z. W., Weng, S. A, Kim, T. W., Chen, S. H., Pownall, H. J., Sharp, P. M., 
Liu, S. W., Li, W. H., Gotto, A M. Jr., and Chan, L. (1989a) Structure of apolipoprotein B-
100 of human low density lipoproteins. Arteriosclerosis 9,96-108. 
Yang, C., Kim, T. W., Weng, S., Lee, 8., Yang, M., and Gotto, A M. Jr. (1989b) Isolation 
and characterisation of disulfide linkages of apolipoprotein B-1 00 in low density lipoprotien. 
Circulation 80(11):11-180 .. 
Yanisch-Perron, c., Vieira, J., and Messing, J. (1985) Improved M13 phage cloning vectors 
and host strains: Nucleotide sequences of the M13mpl8 and pUC19 vectors. Gene 33:103-
119. 
Yao, Z., Blackhart, B. D., Linton, M. F., Taylor, S. M., Young, S. G., McCarthy, B. J. 
(1991) Expression of carboxyl-terminally truncated forms of human apolipoprotein B in rat 
hepatoma cells: Evidence that the length of apolipoprotein B has a major effect on the 
bouyant density of the secreted lipoproteins. J. Bioi. Chern. 266:3300-3308. 
Young, S. G. (1990) Recent progress in understanding apolipoprotein B. Circulation 
82: 1574-1594. 
Young, S. G., Bertics, S. 1., Curtiss, L. K, Casal, D. C., and Witzum, 1. L. (1~86) 
Monoclonal antibody MB 19 detects genetic polymorphism in human apolipoprotein B. Proc. 
Natl. Acad. Sci. 83:1101-1105 
Young, S. G., Bertics, S. 1., Curtiss, L. K, and Witztum, J. L. (1987a) Characterisation of an 
abnormal species of apolipoprotein B, apolipoprotein B-3 7, associated with familial 
hypobetalipoproteinemia. J. Clin. Invest. 79: 1831-1841. 
Young, S. G., Peralta, F. P., Dubois, B. W., Curtiss, L. K, Boyles, 1. K, and Witzum, 1. L. 
(1987b) Lipoprotein B37, a naturally occurring lipoprotein containing the amino-terminal 
portion of apolipoprotein B 1 00, does not bind to the apolipoprotein B, E (low density 
lipoprotein) receptor. J. Bioi. Chern. 262:16604-1661l. 
128 
Young, S. G., Hubl, S. T., Chappell, D. A., Smith, R. S., Claiborne, F., Snyder, S. M., and 
Terdiman, 1. F. (1989) Familial hypobetalipoproteinernia associated with a mutant species of 
apolipoprotein B (B-46). N Engl. 1. Med. 320: 1604-1610. 
Young, S. G., Hubl, S. T., Smith, R. S., Snyder, S. M., and Terdiman, 1. F. (1990) Familial 
hypobetalipoproteinaernia caused by a mutation in the apolipoprotein B gene that results in a 
truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the 
portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-
rich lipoproteins. 1. Clin. Invest. 85:933-942. 
